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Abstract 
A body of epidemiological evidence suggests beneficial cardiovascular (CV) effects of 
dietary citrus flavanones. However, as systematically reviewed, there is currently only 
limited supporting evidence from randomised controlled trials (RCT); in particular, 
relatively little is known about which flavanone-derived circulating metabolites might be 
the underlying mediators of potential beneficial CV effects of flavanones. 
In an acute crossover RCT, male participants at a mild to moderate CV disease (CVD) 
risk received dietary interventions (in random order): orange juice (hesperidin dose: 320 
mg) or control, whereby both were matched for sugar and vitamin C. Markers of CVD risk 
and plasma concentrations of previously identified and novel flavanone / phenolic 
metabolites were simultaneously assessed at baseline and 5 h post dietary intervention (5 
h is the anticipated time of peak plasma concentration of flavanone metabolites). 
At 5 h post intervention, the orange juice intervention resulted in significantly elevated 
plasma concentrations of 8 flavanone metabolites (mean ± SD: 1.60 ± 1.33 μM and 0.02 ± 
0.01 μM, respectively; P < 0.0001) and 15 phenolic acid metabolites (mean ± SD: 19.59 ± 
7.46 μM and 5.69 ± 1.70 μM, respectively; P < 0.0001) compared with the control 
intervention. However, these elevated metabolite plasma concentrations did not result in 
acute improvements in digital endothelial function, central arterial stiffness, CV autonomic 
function, platelet activation, nitric oxide production and NADPH oxidase gene expression. 
In summary, relatively high plasma concentrations of metabolites (predominantly phenolic 
acids metabolites) were detected 5 h after a single dose of flavanones in men at a mild to 
moderate CVD risk. Simultaneously assessed markers of CVD risk were not beneficially 
affected and further acute RCTs with a longer time course (up to 24 h) and short-term to 
chronic (weeks up to years) RCTs are required to determine the potential beneficial CV 
effects of dietary flavanones. 
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Chapter 1. Literature review on dietary Flavanones: 
Vascular Bioactivity, Occurrence and Bioavailability 
1.1 Cardiovascular disease mortality, underlying pathology and 
risk factors 
One third of all deaths in the UK are caused by cardiovascular disease (CVD) [1] with 
coronary heart disease (CHD) and stroke being the main CVD events, and atherosclerosis 
constitutes the main underlying pathology [2, 3]. 
The early stages of atherosclerosis involve accumulation and oxidation of low density 
lipoprotein cholesterol (LDL-C) and inflammation in the vasculature, forming lesions 
known as fatty streaks (Figure 1.1) [3]. Further progression leads to atheroma, 
characterised by a core of dead cells and a fibrotic cap which narrows the vessel lumen 
(Figure 1.1) [3]. Cardiovascular (CV) events often result from plaque rupture-induced 
thrombosis, which completely occludes the artery [3, 4] (Figure 1.1). 
Figure 1.1 – Atherosclerosis timeline 
 
Figure adapted from [5] 
An increased absolute risk of CVD is associated with a range of factors including age [6], 
male gender [6, 7], elevated blood pressure (BP) [8], unfavourable blood lipid profile (i.e. 
low plasma levels of high density lipoprotein cholesterol (HDL-C) and high levels of total 
cholesterol, LDL-C and triglycerides) [9], platelet hyperactivity [10], hyperglycaemia [11], 
smoking [12], obesity [11, 13, 14], positive familial history of premature (<65 years for 
women and <60 years for men) CVD [15] and a number of diet related risk factors [16]. 
Prior to manifestation of CVD events, persistent exposure to risk factors results in 
abnormalities in clinical markers of CVD, including endothelial dysfunction [17], CV 
autonomic dysfunction [18], central arterial stiffness [19, 20] and increased platelet 
reactivity [21]. 
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Section 1.2 provides an introduction to the relationship between dietary intake patterns 
and CVD risk, followed by the potentially CV protective role of dietary flavanones, which 
are the focus of this PhD work. 
1.2 Dietary intake patterns and CVD risk 
Dietary components are modifiable risk factors that have been shown to influence the 
development of CVD [22]. Whilst most dietary guidelines recommend restrictions of foods 
rich in saturated fatty acids (SFA), there remains limited robust scientific evidence for a 
causal relationship between decreased intake of SFA and lower risk for CVD [23-25]. 
However, several reviews have indicated that replacing dietary intakes of SFA with poly- 
or mono-unsaturated fatty acids, is associated with a decreased risk of CVD [23-25] and 
that the effects of certain foods cannot be explained simply by differences in their fatty 
acid content [24]. 
Numerous studies suggest that diets rich in fruits, vegetables and plant-based food 
components [26-30], fish [31], olive oil [32], nuts [33], garlic [34] and low in sugars (i.e. 
monosaccharides)  [16], salt [35], processed meat [36] and alcohol [23] are associated 
with a reduced risk of CVD. A diet rich in fruit was recently reported to be particularly 
effective in reducing CVD mortality and morbidity having the 3rd greatest impact amongst 
modifiable risk factors; behind lowering BP or smoking cessation [37]. However, further 
research is required to examine the bioactive constituents responsible for the observed 
cardioprotective effects, to establish optimal intakes and inform future dietary guidelines. 
Flavonoids, which are bioactive constituents widely distributed in fruits, vegetables and 
plant-based foods, are the focus of this PhD project due to their high potential to 
contribute to the suggested cardioprotective benefits [38]. 
This literature review will present an introduction to the flavonoid family of phytochemicals 
and, with a focus on the sub-group of flavanones, will outline the potential effects of 
flavanones on CV health and identify research gaps that need to be addressed. 
1.3 Flavonoids; chemical structure, food sources and dietary 
intakes 
Flavonoids are a group of compounds synthesised by plants which act as antioxidants, 
provide colour to attract pollinators and defence mechanisms against harmful insects and 
microbes [39]. Flavonoids share a common structure of two phenolic rings (A and B) 
connected by a three carbon bridge (C) (Figure 1.2) [40], and the 6 traditional subclasses 
of flavonoids are flavonols, flavones, flavan-3-ols, anthocyanidins, isoflavones and 
flavanones, which differ in substituents on the C ring (Figure 1.2) [38]. 
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Figure 1.2 – Flavonoid subclasses 
 
Chemical structure of the 6 traditional flavonoid subclasses with 
their common basic structure as shown in the centre (adapted from 
[41]) 
Flavonoids are generally found as monomers or polymers in fruits, vegetables and plant 
based food products such as tea, wine and cocoa [40]. Whilst there are limited data about 
flavonoid intake in the UK, French mean flavonoid intake has been estimated as 1193 
mg/d [± 510 standard deviation (SD)] [42]. Based upon a usual diet, flavonoids reach 
plasma concentrations of nano- to low micromolar in plasma which is suggestive that their 
potential anti-atherogenic activity may be attributed to modulation of cell signalling 
pathways (through protein and/or lipid interaction), rather than via classic antioxidant 
effects [41]. 
1.4 The potential cardiovascular benefits of flavanone 
consumption 
1.4.1 Epidemiological evidence: flavanone intake and associated 
relative CVD risk reduction 
Cohort studies provide evidence to suggest that comparing the highest versus lowest 
flavanone/citrus fruit intakes, there is a lower relative risk (RR) of stroke (range: 0.29-0.84) 
[43-48] and CHD (range: 0.64-0.85) [49-52]. This broad variance of RR may be partly due 
to differences in gender, age (range 39.3 to 61.5 years), cohort size (range 1950 to 
126339 participants), number of years of follow-up (range 3.9 to 28 years), mean body 
mass index (BMI) (range 24.8 to 26.9 kg/m2) and variations of habitual intakes of 
flavanones between different nationalities (i.e. European, Japanese and US populations) 
of the cohorts (Table 1.1 & 1.2) [43-47, 49-52]. Moreover, reported intakes for both, 
flavanones and citrus fruit show considerable variance from as low as 0.4 mg/d to as 
 14 / 150 
much as 93.4 mg/d and of <1 serving per month to 1 serving per day, respectively (Table 
1.2) [43-53]. 
However, the lower relative CVD risk associated with flavanone intake has not been 
universally demonstrated (Table 1.1 & 1.2). In a study by Mursu et al., [52], increased 
flavanone intake was not associated with a reduction in stroke incidence; which was also 
the case for a cohort study by Mink et al., [49]. In agreement, the studies of Knekt et al., 
[45], Yamada et al., [47] and Cassidy et al., [53] did not report an association of lower 
relative CHD risk with increased flavanone and citrus fruit intake. Additionally, McCullough 
et al., [54] did not observe a significant inverse association between intake of flavanones 
and CVD mortality. 
While four cohort studies consistently suggested no association between lower RR of 
haemorrhagic stroke and flavanone/citrus fruit intake, the findings of total and ischemic 
stroke are inconsistent [45-48] (Table 1.1 & 1.2). A possible explanation might be that 
flavanones have a protective effect on ischaemic stroke by reducing atheroma, whereas 
for haemorrhagic stroke, which is more dependent on BP levels [48], increased flavanone 
intake may not be associated with a large reduction in hypertension [55]. 
Inconsistencies in cohort characteristics (e.g. baseline CVD risk, number of participants 
and follow-up years), data collection methods (i.e. 4 d food record or food frequency 
questionnaire including 30 up to 152 food items), and food constituent databases used to 
estimate flavanone and citrus fruit intake may account, in part at least, for discrepancies in 
the associations between increased flavanone and/or citrus fruit intake and lower RR of 
CVD [56, 57]. 
Taken together, a body of epidemiological evidence generates the hypothesis that a diet 
rich in flavanones may reduce CVD risk. However, the findings among existing cohort 
studies were not fully consistent and the methods used to estimate flavanone/citruc fruit 
intakes contain a substantial amount of error and imprecision [58]. Hence, well-designed 
human randomised controlled trials (RCTs) are required to examine whether or not a diet 
rich in flavanones is causally linked to improved CV health. 
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Table 1.1 – The relationship between flavanone intake and stroke/CHD incidence based on data from cohort studies 
 
Cohort study 
Nationality / gender / 
age
a 
/ BMI
a 
# participants / 
years of follow up Mean lower and upper intakes 
RR (95 % CI) of stroke / CHD incidence comparing upper to 
lower intakes of flavanone 
b 
Knekt et al., 
2002 [45]
 
Finnish / men and women / 
39.3 ± 15.8years / 
24.8 ± 4.1kg/m
2
 
10 054 persons/ 
28 years 
Hesperetin:1.5mg/d lower and 
20.8 mg/d upper quartiles 
Total stroke: 0.80** (0.64, 0.99) 
Ischaemic stroke: 0.74* (0.55, 1.00) 
Haemorrhagic stroke: 0.62 (0.32, 1.18) 
CHD: 0.95 (0.76, 1.19) 
Naringenin: 0.4mg/d lower and 
6.1 mg/d upper quartiles 
Total stroke: 0.79** (0.64, 0.98) 
Ischaemic stroke: 0.73** (0.54, 0.98) 
Haemorrhagic stroke: 0.56 (0.29, 1.09) 
CHD: 0.98 (0.78, 1.22) 
Mink et al., 
2007 [49]
 
US / postmenopausal 
women / 61.5 ± 4.2years, 
26.9 ± 5.0kg/m
2 
34 492 women/ 16 
years 
Quintile flavanones: 7.6mg/d 
lower and 93.7mg/d upper 
Total stroke: 0.94 (0.69, 1.27) CHD: 0.78** (0.65, 0.94) 
Mursu et al., 
2008 [52]
 
Finnish / men / 52.5 ± 
5.3years / BMI not reported 
1 950 men/ mean 
15.2 years 
Mean flavanones: 3.1mg/d Ischaemic stroke:0.89 (0.49, 1.63) n/a 
Cassidy et al 
2012., [48]
 
US women / range 30-55 
years / 25.7kg/m
2 
69 622 women/ 14 
years 
Flavanones: 18.8mg/d lower and 
44.8mg/d the upper quintiles 
Total stroke: 0.89 (0.77, 1.04) 
Ischaemic stroke: 0.81* (0.66, 0.99) 
Haemorrhagic stroke: 0.82 (0.55, 1.22) 
n/a 
McCullough et 
al., 2012 [54] 
US / men and women / 69 
± 6.1years / BMI not 
reported 
38 180 men  and 
60 289 women / 7 
years 
Flavanones: 3.5 mg/d lower and 
49.9 mg/d the upper quintiles 
CVD: 0.90 (0.80, 1.01) 
Cassidy et al., 
2013 [53] 
US women / range 25-42 
years / 24.6 ± 5.2kg/m
2
 
93 600 women/ 18 
years 
Flavanones: 6.6mg/d lower and 
71.1mg/d upper quintiles 
n/a MI: 0.91 (0.66-1.26) 
Abbreviations: BMI, body mass index; RR, relative risk; CI, confidence interval; CHD, coronary heart disease; MI, myocardial infarction
a
;
 
mean ± SD unless stated; 
b 
after 
multivariate adjustment; *P-value<0.05; ** P -value<0.01 
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Table 1.2 – The relationship between citrus fruit intake and stroke/CHD incidence based on data from cohort studies 
 
Cohort 
study 
Nationality / gender 
/ age
a 
/ BMI
a 
# participants / years of 
follow up Mean lower and upper intakes 
RR (95 %CI) of stroke / CHD incidence comparing upper to 
lower intakes of citrus fruit 
b 
Joshipura 
et al., 1999 
[44] and 
2001 [51] 
US / men and 
women/ 48.6 years / 
24.7 kg/m
2
 
75 596 women / 14 years 
and 38 683 men / 8 years 
Citrus fruits: 0.1 servings/d lower 
and 1.8 servings/d upper quintiles 
Ischaemic stroke: 0.72 (0.47, 1.11) CHD: 0.88* (0.77–1.00) 
84 251 women / 14 years 
and 42 148 men / 8 years 
Citrus fruit juices: 0 servings/d lower 
and 1 serving/d upper quintiles 
Ischaemic stroke: 0.65* (0.51, 0.84) CHD: 1.06 (0.85–1.32) 
Johnsen et 
al., 2003 
[43]
 
Danish / men and 
women / 56.1 years 
(range 51.2-63.3) / 
26±4.1 kg/m
2
 
54 506 persons / median: 
3.09 years 
Citrus fruits: 2.9 g/d lower and 100.0 
g/d upper quintiles 
Ischemic stroke: 0.63* (0.41, 0.92) n/a 
Dauchet et 
al., 2004 
[50]
 
French and Northern 
Irish / men / 54.7±2.9 
years / not reported 
8 087 / 5 years Citrus fruits: ≤0.07 fruits/d lower and 
≥0.5 fruits/d upper tertiles 
n/a CHD: 0.64* (0.41, 0.99) 
Mink et al., 
2007 [49]
 
US / 
postmenopausal 
women / 61.5±4.2 
years, 26.9±5.0 
kg/m
2 
34 492 women / 16 years Orange juices in servings/wk: <1.00 
lower and >1.00 upper tertiles 
Total stroke: 0.91 (0.75, 1.12) n/a 
Oranges in servings/wk: <1.00 lower 
and >1.00 upper tertiles 
n/a CHD: 0.96 (0.84,1.09) 
Grapefruits in servings/wk: <1.00 
lower and >1.00 upper tertiles 
n/a CHD: 0.85* (0.74, 0.98) 
Mizrahi et 
al., 2009 
[46]
 
Finnish men and 
women / 51.9 years / 
26.5 kg/m
2
 
3 932 persons /  
24 years 
Citrus fruits: men 0 g/d lower and 37-
740 g/d upper tertiles; women 0-8 g/d 
lower and 69-1040 g/d upper tertiles 
Total stroke:0.77** (0.63, 0.93) 
Ischaemic stroke: 0.79 (0.60, 1.03) 
Haemorrhagic stroke: 0.54 (0.29, 1.01) 
n/a 
Yamada et 
al., 2011 
[47] 
Japanese / men / 
54.8±12.1 years / 
22.9±2.9 kg/m
2 
10 623 persons / mean 
10.7 years 
Citrus fruits: <1/month lower and 
almost 1/day upper quintiles 
Total stroke: 0.40** (0.20, 0.81) 
Ischemic stroke: 0.28* (0.11, 0.72) 
Haemorrhagic stroke: 0.71 (0.24, 2.11) 
CHD: 0.99 (0.34, 2.80) 
Japanese / women / 
55.2±11.4 years / 
23±3.2 kg/m
2
 
Total stroke: 0.47* (0.26-0.87) 
Ischemic stroke: 0.39 (0.15, 1.00) 
Haemorrhagic stroke: 0.55 (0.24, 1.23) 
CHD: 0.67 (0.11, 4.15) 
Abbreviations: BMI, body mass index; RR, relative risk; CI, confidence interval; CHD, coronary heart disease; 
a 
mean ±SD unless stated; 
b 
after multivariate adjustment; *P-value<0.05; ** P -
value<0.01 
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1.4.2 Human randomised controlled trials examining potential effects 
of flavanones on markers of CVD risk 
Whilst in Chapter 2, RCTs have been systematically reviewed that examined the potential 
effects of flavanones on a broad range of markers of CVD risk, this chapter specifically 
focuses on RCTs with BP, endothelial function, autonomic function and platelet function 
endpoints to identify research gaps and introduce the conducted acute flavanone human 
RCT described in Chapters 3-5. 
To date, only two RCTs have examined the effects of a short-term (3 - 4 weeks) flavanone 
intervention on BP and endothelial function (Table 1.3) [59, 60]. Whilst Morand et al., [59] 
conducted a 4 week intervention feeding 292 mg/d hesperidin (a class of flavanones) 
given as a food source (i.e. orange juice) or a supplement to 23 overweight men, the 500 
mg/d hesperidin supplement intervention by Rizza et al., [60] lasted 3 weeks and was 
performed in 24 adults with metabolic syndrome. Morand et al., [59] found a decrease in 
diastolic BP (DBP) induced by both, the orange juice and the hesperidin supplement, but 
no improvement in endothelial function (assessed by microvascular reactivity) or increase 
in plasma nitric oxide (NO) metabolites (NOx, i.e. nitrate, nitrite and nitroso species) 
(Table 1.3). In contrast, Rizza et al., [60] did not show a decrease in DBP, but observed 
an improvement in endothelial function (assessed by flow mediated dilatation (FMD) of the 
brachial artery) (Table 1.3). In addition, neither of the two studies observed an effect of 
hesperidin on systolic BP (SBP) [59, 60]. Possibly due to differences in study design (e.g. 
hesperidin dose, study duration and baseline CVD risk of study population) and different 
methods used to assess endothelial function, the two studies reported equivocal findings. 
A possible explanation for a DBP but not a SBP lowering effect of flavanones (as 
observed by Morand et al., [59]) may indicate that flavanones reduce total peripheral 
resistance rather than cardiac output [61]. Both of these cross-over designed RCTs in 23 - 
24 participants were adequatly powerer to detect clinically relevant potential effects of 
short-term flavanone intake (i.e. 3-4 week) on blood pressure and endothelial function [59, 
60], with Rizza et al., [60] reporting that n = 20 participants were needed to detect a 2% 
change in FMD with a power of 80 % and a significance level of 5 %. 
Within the same study, Morand et al., [59] also examined potential acute effects of 
flavanones on endothelial function 6 h following a single dose of 292 mg hesperidin (Table 
1.3). While microvascular reactivity was improved by both consumption of the orange juice 
and the hesperidin supplement, no acute changes in NOx plasma concentrations were 
found [59]. These acute improvements in microvascular reactivity were associated with 
the significantly elevated mean plasma concentrations of hesperetin of 0.86 ± 0.10 μM 
following the orange juice (Pearson’s correlation: r = 0.698, P = 0.0001) and 0.77 ± 0.16 
μM following the hesperidin supplement intervention (Pearson’s correlation: r = 0.434, P = 
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0.039) compared to no detection after the control intervention. Plasma vitamin C 
concentration was also significantly elevated 6 h after the orange juice intervention 
relative to 6 h after the hesperidin supplement and control interventions (i.e. mean ± SEM: 
70.5 ± 4.6 μM compared to 52.8 ± 4.6 μM and 50.8 ± 4.6 μM, respectively; P < 0.001). 
Across the findings of Morand et al., [59] the orange juice intervention consistently 
showed greater effects in comparison to the hesperidin supplement intervention (Table 
1.3). Whilst these results provide evidence that hesperidin partly mediates the 
cardioprotective effects of orange juice, other potentially bioactive compounds in orange 
juice (e.g. narirutin, flavones, vitamin C, β-carotenes, folate and fibre) are possibly 
exerting additive and/or synergistic effects [23]. 
In addition to beneficial effects of flavanones on endothelial function and BP, an RCT 
reported flavanones to acutely improve CV autonomic function [62]. Measuring heart rate 
variability, 1 h after administration of 500mg glucosylhesperidin (a synthesised from 
hesperidin with a short absorption time) to 11 healthy women (age range: 18-22 years), a 
decrease in cardiac sympathetic nervous activity and an increase in cardiac 
parasympathetic nervous activity was reported compared to the control intervention [62]. 
Hence, hesperidin-induced modulations of the autonomic nervous system (ANS) might be 
a further mechanism by which flavanones exert cardioprotective effects [18]. 
Altogether, these three recent RCTs suggest that flavanones exert beneficial CV effects 
through a reduction in DBP and an improvement in endothelial function [59, 60, 62]. 
However, there are insufficient data available to provide scientific evidence and a number 
of limitations need to be addressed. 
Table 1.3 – Randomised controlled trials examining the effects of flavanones on blood pressure 
and endothelial function 
     
Study 
Participants/ age 
(mean ± SD) 
duration/ 
study intervention/ dose Mean effect
1 
[95% CI] 
Short-term flavanone interventions: 
Morand 
et al., 
2011 [59] 
23 overweight men/ 
56 ± 5 y 
4 wk/ 0.5 L orange juice/ 
292 mg hesperidin + 47 mg 
narirutin per day 
SBP: -3.0 mm Hg [-8.3, 2.3] 
DBP: -5.5 mm Hg* [-9.0, -2.0] 
Microvascular reactivity
2
: 52 % [-8, 113] 
NOx: 12.4 µM [1.4, 23.4] 
4 wk/ supplement/ 292 mg 
hesperidin per day 
SBP: 0.6 mm Hg [-8.3, 2.3] 
DBP: -3.2 mm Hg* [-9.0, -2.0] 
Microvascular reactivity
2
: 17 % [-44, 77] 
NOx: -3.2 µM [-15.0, 8.6] 
Rizza et 
al., 2011 
[60] 
24 adults with 
metabolic syndrome/ 
52 ± 2 y 
3 wk/ supplement/ 500 mg 
hesperidin per day 
SBP: 2.7 mm Hg [-1.3, 6.7] 
DBP: 0.6 mm Hg [-2.2, 3.4] 
FMD
2
: 2.5 %* [0.4, 4.6] 
Acute flavanone interventions: 
Morand 
et al., 
2011 [59] 
23 overweight men/ 
56 ± 5 y 
6 h/ 0.5 L orange juice/ 
292 mg hesperidin + 47 mg 
narirutin 
Microvascular reactivity
2
: 105 %**[55, 155] 
NOx: no mean effect (data not reported) 
6 h/ supplement/ 292 mg 
hesperidin 
Microvascular reactivity
2
: 48 % [-1, 98] 
NOx: no mean effect (data not reported) 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; NOx, plasma levels of nitric oxide 
metabolites; FMD, flow mediated dilatation; y, year; *P-value<0.05; **P-value<0.01 
1
Difference between 
control and experimental intervention; 
2
methods to assess endothelial function 
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Whilst intake of orange juice had more profound vascular effects than intake of an 
equivalent dose of hesperidin in a supplement compared to an energy matched control 
intervention [59], little is known about the potential additive/synergistic effects of the range 
of bioactive compounds found in orange juice and the importance of consuming these 
bioactive compounds within a natural food matrix as compared to a flavanone extract. 
The in vivo phase II metabolism of flavanones in humans has previously been established 
in a number of bioavailability studies and limited data are suggesting bioavailability of 
phenolic acid colonic breakdown metabolites (Section 1.6). However, Morand et al., [59] 
related acute flavanone vascular bioactivity to achieved total plasma concentrations of 
hesperetin (i.e. following enzymatic deconjugation of potential glucuronides/sulfates) 
independent of phase II metabolism and did not quantify plasma concentrations of 
phenolic acid metabolites. Hence, associations of flavanone vascular bioactivity to 
individual plasma hesperetin and naringenin phase II metabolites and phenolic acid 
metabolites remain to be examined. 
Research to date is particularly limited regarding the potential mechanisms by which 
flavanones exert effects on markers of CVD risk such as vascular function and BP. Whilst 
in vitro and animal studies suggest that flavanones may beneficially modulate a range of 
CV related cellular pathways (see Section 1.4.3 and 1.4.4), Morand et al., [59] is the only 
study to date that has explored potential effects of hesperidin on endothelial NO 
production suggesting no significant increase in plasma total NOx following acute or 4 
weeks daily orange juice or hesperidin supplement intake compared to control. However, 
as reported in the review of [63], plasma total NOx may be a biomarker of limited value 
because it does not solely originate from endogenously produced vasoactive NO from the 
endothelium, but also from dietary intakes, the gut microflora and inhaled NO. Thus, 
further studies are warranted which control for dietary NOx intakes and examine potential 
flavanone-induced increases of more closely related endothelial NO breakdown products; 
e.g. nitrite or S-nitrosothiols [64, 65]. In addition, a wider range of vascular related 
biomarkers need to be explored to further understand the mechanisms by which 
flavanones mediate beneficial CV effects. 
Whilst beneficial effects of 500 mg glucosylhesperidin on cardiac autonomic function have 
been reported as a mechanism by which flavanones are cardioprotective [62], it remains 
to be tested whether naturally occurring flavanones (e.g. hesperidin) at a dose achievable 
within a normal diet may also exert these effects. Furthermore, in addition to the HR 
variability methodology which [62] used, further potential effects of flavanones on cardiac 
autonomic function could be assessed using baroreflex sensitivity (BRS), which takes 
both HR and BP changes into account [18]. 
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In conclusion, flavanones may decrease DBP and improve endothelial function after a 3-4 
week intervention (i.e. short-term) [59, 60] and acutely improve endothelial function [59] 
and autonomic function [62]. However, there are insufficient data to provide scientific 
evidence about the potential CV protective effects of flavanones and the underlying 
mechanisms are unknown. Thus, further well-designed RCTs in the field of flavanone 
research are required. Whilst previously shown beneficial CV effects and their underlying 
mechanisms of action of flavanones need to be corroborated using complementary 
methodologies (e.g. peripheral arterial tonometry during reactive hyperaemia (PAT-RH) to 
test endothelial function, BRS to test autonomic function and plasma nitrite to test 
vascular NO production), additional potential beneficial CV effects of flavanones need to 
be assessed using unexplored markers of CVD risk such as arterial stiffness, and platelet 
activation. To further support the necessity of human RCTs, Sections 1.4.3 and 1.4.4 
review the findings of flavanone bioactivity in cell culture and animal models. 
1.4.3 In vitro studies suggesting potential mechanisms of action 
of flavanones on cardiovascular related pathways 
Reviews of in vitro studies in endothelial [66] and platelet cells [67] suggested that plant 
polyphenols, including flavanones, may beneficially modulate cellular pathways related to 
CV health. Whilst in cultured vascular endothelial cells, polyphenols have been suggested 
to enhance NO and prostacyclin and inhibit endothelin-1 (ET-1) production, thereby 
improving endothelial dependent vasodilatation and vascular homeostasis (Figure 1.3) 
[66], polyphenols have also been reported to inhibit platelet aggregation through 
downregulation of signalling cascades activated by platelet agonists [e.g. collagen, 
thrombin and adenosine-diphosphate (ADP)] [67] (Figure 1.4). For certain polyphenols, 
antiplatelet effects have been observed in similar magnitude to aspirin, a drug widely used 
in CVD prevention [67]. 
Following treatment of cultured endothelial cells with hesperetin, four studies reported a 
1.3 to 2.5 fold increase in NO production using various experimental settings; i.e. 
hesperetin in different forms (i.e. aglycones, glycosides or glucuronides), arterial or 
venous endothelial cell lines, incubation times ranging from 5min to 24h and doses 
ranging from 10µM to 100µM [60, 68-70]. Whilst Rizza et al., [60] also found a 1.8 fold 
increase in eNOS phosphorylation after hesperetin treatment at a physiological dose (i.e. 
1µM) in bovine aortic endothelial cells (BAEC) suggesting an increase in NO production, 
Chiou et al., observed no change in NO production in human umbilical vein endothelial 
cells (HUVEC) after incubation with 1µM hesperetin [68]. Yet, elevated eNOS 
phosphorylation was observed in HUVEC cells with hesperetin treatment at higher doses 
(10-100 µM) [68]. 
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Several underlying mechanisms by which hesperetin may elevate NO productions of 
endothelial cells have been suggested. Whilst hesperetin has been shown to stimulate NO 
synthesis through activation of endothelial nitric oxide synthase (eNOS) via upregulation 
of the PI3K/Akt/eNOS pathway [60, 68] and increased eNOS gene expression [69], 
hesperetin has also been observed to decrease NO inactivation through inhibition of 
superoxide generation partly via down-regulation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase and xanthine oxidase [68, 70]. 
Figure 1.3 – Mechanisms by which flavanones mediate vasodilatation 
 
Flavanones may potentially increase endothelial production of relaxing factors 
[i.e. nitric oxide (NO), prostacyclin (PGI2) and endothelium-derived 
hyperpolarising factor (EDHF)] and decrease contracting factors [i.e. 
endothelin-1 (ET-1)]; Abbreviations: eNOS, endothelial nitric oxide synthase; 
CaM, calmodulin; Ca
2+
, calcium; ROS, reactive oxidative species; PI3K, 
phosphatidyl-inositol 3 kinase; GTP, guanosine triphosphat; cGMP, cyclic 
guanosine monophosphat; sGC, soluble guanylyl cyclase (adapted from [66]) 
In addition to hesperetin-induced increases in NO production, further experiments related 
to potential beneficial cardiovascular effects of flavanones have been conducted using 
cultured endothelial cells. Hesperetin has been reported to inhibit strain-induced ET-1 
production mediated partly through upregulation of the NO and protein kinase G pathways 
[68]. Moreover, Liu et al., [69] not only examined hesperetin but also naringenin 
bioactivity; however, naringenin did not enhance NO production using the same cell 
model, treatment dose (i.e. up to 100 µM) and duration that showed an effect for 
hesperetin. Across all performed NO and superoxide experiments of Takumi et al., [70], 
hesperetin was observed to be more bioactive in its aglycone form than when bound to a 
glucuronide, the main flavanone metabolite absorbed in humans following flavanone 
intake [71, 72]. 
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In addition to beneficial modulation of endothelial cells, inhibitory effects of flavanones on 
platelet aggregation have also been suggested in animal platelet cells [73, 74]. This might 
be a further mechanism by which flavanones could decrease CVD risk because platelets 
play an important role in atherothrombotic risk and atherosclerosis progression [21]. 
Following in vitro treatment of platelets with hesperetin (aglycones or diglycosides; 10-
1600 μM), narirutin (i.e. naringenin-diglycoside; 170-1700 μM), or a citrus fruit extract (3-
10 mg/mL) and various platelet agonists (i.e. arachidonic acid, collagen, thrombin and 
ADP), decreased platelet aggregation has been observed in a dose dependent manner 
[73-75]. Whilst both naringenin and hesperetin inhibited thrombin-induced platelet 
aggregation and only hesperetin, but not naringenin, inhibited ADP-induced ex vivo 
platelet aggregation, hesperetin exerted particularly potent inhibition of collagen- and 
arachidonic acid mediated ex vivo platelet aggregation [74] (Figure 1.4). Inhibition of 
phospholipase C-γ2 phosphorylation, an enzyme specific to the collagen activation 
pathway, and inhibition of cyclooxygenase, which catalyses the reaction of arachidonic 
acid to vasoactive prostanoids, have been suggested as the responsible underlying 
mechanisms of action of hesperetin [73], in addition to a decrease in intracellular Ca2+, 
which is downstream of the ADP, collagen and thrombin activation pathways [76] (Figure 
1.4). 
Figure 1.4 – Schematic presentation of the known pathways leading to platelet activation and 
aggregation 
1, 2 
 
1
The main platelet agonists include collagen, thrombin, ADP and thromboxane A2 (TxA2). 
2
Platelet 
activation results in surface expression of the activated fibrinogen receptor (i.e. gpIIb/IIIa) and P-
selectin (i.e. as a result of dense granule release). Figure adapted from [76] 
A review by Kroon et al., [77] emphasised that in vitro research, which assesses flavonoid 
modulation of cellular pathways related to vascular function, should examine the effects of 
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polyphenol metabolites as they occur in vivo, at physiological doses (i.e. <10µM) and in a 
cell model which is affected by the pathology to be examined. However, whilst the majority 
of in vitro studies examined the effects of flavanone aglycones and glycosides on 
endothelial [60, 68, 69] or platelet cells [73-75], the study of Takumi et al., [70] examined 
the effects of hesperetin-7-glucuronide, a flavanone metabolite that has been identified in 
human bioavailability studies [71, 78]. Furthermore, only one study used endothelial cells 
of arterial origin, albeit from bovine and not human, and reported increased eNOS 
phosphorylation at 1 µM, a concentration that can be achieved from a portion of a 
flavanone rich food [71], whereas all other studies have used venous endothelial cells and 
observed beneficial vascular effects of flavanones only at concentrations ≥10 µM [68, 69]. 
It could be hypothesised that arterial endothelial cells, which have been reported to be an 
appropriate cell model to study atherosclerosis [79], are more responsive to flavanone 
treatment compared to venous endothelial cells. Hence, effects of hesperetin on 
endothelial NO and ET-1 production observed in HUVEC at supraphysiological 
concentrations, might be present at physiologically relevant concentrations (i.e. 1 µM) in 
arterial endothelial cells. 
In addition to potentiation of endothelium dependent vasodilatation, flavanones have also 
been reported to exert endothelium-independent vasodilatation. Following incubation of 
endothelium-denuded rat aortic rings with naringenin and hesperetin, vasodilatation has 
been observed; however only at doses several magnitudes above physiological 
concentrations (i.e. 100 µM) [80-83]. Elevations of cGMP and cAMP in vascular smooth 
muscle cells (VSMC) [81, 82] and activation of calcium dependent potassium channels 
[80, 83] have been proposed as the underlying mechanisms. However, it has been 
suggested that these observed effects on endothelium-independent vasodilatation might 
not occur in vivo due to the required supraphysiological concentrations [77]. 
Flavonoid subclasses other than flavanones have been studied provide a more 
comprehensive understanding of the mechanisms by which flavonoids may increase NO 
in the vascular endothelium. There is strong evidence to suggest that (-)-epicatechin, a 
flavonoid predominantly found in cocoa, is stored and methylated in HUVEC and that 
methylated (-)-epicatechin acts as a potent inhibitor of NADPH oxidase resulting in 
decreased superoxide production and, in turn, reduced elimination of endothelial NO [84-
86]. Mono-methylation of the catechol B-ring is of major importance making (-)-epicatechin 
structurally similar to apocynin, a pharmalogical NADPH oxidase inhibitor, and testing 45 
polyphenols, including flavanones, the authors conclude that inhibition of NADPH oxidase 
is an important acute mechanism by which flavaonoids increase endothelial NO [85, 86]. 
Another study reported that treatment of endothelial cells or coronary artery rings with a 
physiologically relevant dose of flavonoids and polyphenols from red wine stimulated 
eNOS activity by mild intracellular ROS production leading to Akt dependent 
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phosphorylation of eNOS at Ser1177 and dephosphorylation of eNOS at Threonine 495 
resulting in increased endothelial NO production [87]. Similarly to red wine polyphenols, 
equol, a metabolite of isoflavones mainly found in soy, has also been reported to stimulate 
eNOS activity in HUVEC even at concentrations as low as 100 nM, and exploring 
underlying mechanism revealed that equol enhances mitochondrial ROS production 
leading to increased Akt and ERK1/2 phophorylation upstream of the eNOS 
phosphorylation signalling pathway [88]. 
In summary, flavanones could potentially exert cardioprotective effects through 
endothelium dependent vasodilatation [60, 68, 69] and inhibition of platelet aggregation 
[73, 74] (leading to lower BP, slower atherosclerosis progression and reduced risk of 
thrombosis), but not through endothelium independent vasodilatation [77]. Further studies 
are required treating human platelets and arterial endothelial cell models, which are 
considered to be the most appropriate to study atherosclerosis [79], with flavanone 
metabolites at physiological concentrations [77], so that these data can inform human 
studies on the potential underlying cellular mechanisms by which flavanones exert 
beneficial CV effects. Ultimately, findings from in vitro cell culture studies first need to be 
translated to in vivo animal and human studies before firm conclusions can be made, as in 
vitro models can only simulate in vivo environments to a limited extent [89]. 
1.4.4 Animal studies exploring the potential protective effects of 
flavanones on CVD and possible underlying mechanisms 
In addition to cell culture studies, animal studies further substantiate potential 
cardioprotective effects of flavanones. These protective effects have been observed on 
primary endpoints, including stroke and coronary heart disease, as well as markers of 
CVD risk such as BP, endothelial function, CV autonomic function and platelet 
aggregation. 
Pretreatment of rats with 30 to 100 mg/kg/d of hesperidin for 7-15 days protected against 
ischemia/reperfusion (I/R) induced cerebral [90, 91] and cardiac damage [92] compared to 
control pretreatment. Following I/R induced damage of heart tissue leading to arrhythmia 
production and a drop in BP, Gandhi et al., [92] reported maintenance of mean arterial BP 
and a protective effect against arrhythmias owing to pretreatment with 100 mg/kg/d 
hesperidin.  
Hesperidin has been reported to acutely reduce BP in hypertensive rats [93]. Whilst no 
acute effects have been shown in normotensive rats that ingested 50 mg/kg hesperidin, 
hypertensive rats responded to oral administration of glucosyl-hesperidin (30 and 50 
mg/kg, but not 10 mg/kg) and intraperitoneal injection of 50 mg/kg hesperetin with a 
significant decrease in mean SBP by 7.9 %, 8.6 % and 12.3 %, respectively [93]. 
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Following treatment of isolated aortic rings of rats ex vivo or in vivo with hesperidin or 
naringin, improved endothelial function has been observed, which indicates for an 
enhancement in endothelial NO production [93-95]. Vascular protective effects of 
hesperidin have further been attributed to a decrease in inflammation and oxidative stress 
[90, 92]. Underlying mechanisms responsible for these effects of flavanones include 
eNOS phosphorylation [91], an increase in endogenous antioxidants (i.e. glutathione, 
superoxide dismutase and catalase) [90, 91, 93, 96] and reduced activity/gene expression 
of superoxide-generating enzymes (i.e. NADPH oxidase [95] and xanthine oxidase [96]). 
One study also reported hesperidin to inhibit platelet aggregation in mice and rats [74]. 
Performing the venous tail bleeding assay in mice to examine platelet aggregation, a 
single dose of either 10mg/kg hesperidin or 30mg/kg of a citrus fruit extract containing 
hesperidin has been shown to increase the bleeding time by 4.5 times compared to no 
treatment [74]. Following oral treatment of rats with hesperidin (10mg/kg) or citrus extract 
(100mg/kg), the same study also observed decreased ex vivo platelet aggregation when 
induced with collagen, arachidonic acid, ADP or thrombin. In accordance with in vitro 
findings [73, 74], hesperidin more potently inhibited collagen- or arachidonic acid-induced 
platelet aggregation compared to when induced with ADP or thrombin [74]. In terms of 
magnitude of effect, in both experiments, hesperidin and citrus extract inhibited platelet 
aggregation comparable to oral treatment with 50mg/kg aspirin. 
Overall, whilst the majority of studies examined hesperidin bioactivity and only one tested 
potential effects of naringin, flavanones may exert cardioprotective effects through 
reduced damage of ischemic tissue [90-92] and may decrease CVD risk through 
mediating a decrease in BP [93], an improvement in endothelial function [93, 95] and a 
reduction in platelet reactivity [74]. In order to see whether similar beneficial CV effects of 
flavanones, in particular hesperidin, occur in humans, further clinical RCTs are required. 
1.5 Properties and dietary aspects of flavanones 
Flavanones are characterised by a ketone substituent on the C ring and according to 
substituents on the A and B rings are sub-grouped to distinct types (Figure 1.5.1) [40]. As 
part of the human diet, hesperetin and naringenin (Figure 1.5.2) are the two most 
commonly consumed types of flavanones. Richly found in a range of citrus fruits and 
herbs (Table 1.4), they are mostly conjugated to a diglycosides and called hesperidin, 
narirutin or naringin (Figure 1.5.3) with naringin providing the bitter taste to grapefruits 
[97]. 
Historically, for the first time in 1949, flavanones have been associated with beneficial CV 
effects in which hesperidin was suggested to reduce capillary leakiness, oedema and leg 
swelling [74]. Furthermore, grapefruit (a rich source of naringin) has been a large area of 
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research due to its drug interaction [98]. This is attributed to naringin which is a potent 
modulator of transporter proteins and cytochrome p450 3A4 enzymes that influence both 
absorption and pharmacokinetics of compounds including flavonoids and drugs [98]. 
Figure 1.5 – Flavanones; classification and diglycosides occurring in citrus fruits 
 
1.5.1 Mean intakes and dietary sources of flavanones 
In a study across ten European countries, the mean dietary flavanone intake has been 
estimated as 34mg/d (±65 SD) and in the general UK population as 43mg/d (±65 SD) with 
citrus fruits and citrus derived juices and jams forming the main dietary sources [99]. 
Although flavanone intakes are a magnitude lower compared to intakes of most commonly 
consumed subclasses (i.e. anthocyanins and flavan-3-ols) [99], the high SDs suggest that 
a substantially higher flavanone intake can be achieved following a diet rich in citrus fruits. 
Sourced from the Phenol-explorer database, a summary of dietary components with 
highest flavanone content [100] can be found in Table 1.4. Taking the generally consumed 
portion sizes into account, citrus fruits are the main contributors to flavanone intake. 
Whilst 100 ml orange juice from concentrate contains on average 53 mg hesperidin and 6 
mg narirutin and 100 ml of grapefruit juice from concentrate 38 mg naringin, 2 mg 
hesperidin and 9 mg narirutin, whole citrus fruits can have up to 5 times more flavanones 
due to the high content in the solid parts, in particular the white pulp [101]. In contrast, 
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although herbs contain a high concentration of flavanones, their contribution to dietary 
flavanone intakes is negligible as only small amounts are generally consumed. 
Table 1.4 – Flavanone food sources and content
1 
 
 
Flavanone Mean content ± SD 
Citrus fruit juices (mg/100ml) 
  
Grapefruit, juice from concentrate Hesperidin  1.6 ± 0.9 
Naringin  37.8 ± 16.9 
Narirutin  9.2 ± 4.1 
Grapefruit, pure juice Hesperidin  0.7 ± 0.8 
Naringenin  1.6 ± 2.2 
Naringin  30.8 ± 15.1 
Narirutin  9.7 ± 4.8 
Grapefruit/Pummelo hybrid, pure juice Naringin 45.1 ± 7.9 
Narirutin 15.0 ± 6.8 
Lemon, juice from concentrate Hesperidin 25.0 ± 9.0 
Lemon, pure juice Hesperidin  17.8 ± 13.7 
Narirutin  0.6 ± 0.1 
Lime, pure juice Hesperidin 13.4 ± 4.2 
Narirutin  0.4 ± 0.2 
Orange [Blond], juice from concentrate Hesperidin 52.7 ± 5.8 
Narirutin  6.3 ± 1.2 
Orange [Blond], pure juice Hesperidin  25.9 ± 12.2 
Naringin  0.1 ± 0.5 
Narirutin  5.4 ± 3.1 
Orange [Blood], juice from concentrate Hesperidin  51.3 ± n/ax 
Narirutin  7.3 ± n/a 
Orange [Blood], pure juice Hesperidin  43.6 ± 18.0 
Narirutin  4.8 ± 1.3 
Pummelo, pure juice Naringin  8.5 ± 4.8 
Tangerine, juice from concentrate Hesperidin  36.1 ± 11.2 
Narirutin  6.0 ± 6.0 
Herbs (mg/100mg)   
Marjoram, dried Eriodictyol  3.0 ± n/a 
Mexican oregano, dried Eriodictyol  85.3 ± 11.6 
Naringenin 372.0 ± 42.2 
Peppermint, dried Hesperidin  480.7 ± 316.3 
Narirutin  127.5 ± 240.2 
Rosemary, fresh Naringin 55.1 ± 2.8 
1
Data sourced from the Phenol-explorer database [100] 
1.5.2 Impact of food processing on flavanone content and solubility 
Mechanical and thermal processing has been shown to affect the flavanone content in 
oranges [102]. For example following storage of blended oranges for 20 days at 4°C, a 8.1 
% decline in hesperidin content was observed [102]. 
In the citrus juice food matrix, flavanones are either soluble or precipitate to form insoluble 
aggregates [103]. As described by bioavailability studies (Section 1.6), the soluble 
flavanones are the most bioavailable [78]. Thus, flavanone solubility in orange juice 
following processing and storage has been examined [104]. Findings suggest that 
domestic squeezing of oranges resulted in a 27.2 % higher content of soluble flavanones 
compared to industrial squeezing and that freezing of orange juice for 1 month at -40 °C 
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decreased the soluble flavanones by 43.4 %; in contrast, pasteurisation and concentration 
only had a slight impact on flavanone solubility [104]. 
1.6 Bioavailability, pharmacokinetics and metabolism of 
flavanones 
Flavanone absorption, distribution, metabolism and excretion (ADME) in human has been 
an extensive area of research [105] and provides important information for the design of 
bioactivity studies [106]. 
Following intake of citrus containing mainly hesperidin, narirutin or naringin (Figure 1.5.3) 
at doses ranging from 103-441mg, flavanones were detected in plasma between 2 and 24 
h and were reported to have a half-life (T1/2) of 2.2 to 3.8 h, reaching a mean maximal 
plasma concentration (Cmax) of 0.19-5.99 µM between 4.4-6.8 h (Tmax) after intake [71, 72, 
78, 107, 108] (Table 1.5). 
The relatively late Tmax suggests that the site of major flavanone absorption occurs in the 
distal ileum and colon after hydrolysis of the ingested flavanone-diglycosides to flavanone 
aglycones (Figure 1.5.2) by the gut microflora [109]. In support, studies which measured 
the bioavailability of flavanone aglycones (i.e. small amounts occurring in tomatoes) [110] 
and enzymatically treated flavanone glucosides [111, 112] reported a decreased Tmax 
between 2 and 3.7 h. For orange juice, a mouth to colon transit time of 2.1 h (±1.3) was 
observed in the fasted state, which might explain the detection of trace amounts of 
flavanones in plasma already 2 h after intake (Figure 1.6.) [71, 72]. 
The observed differences in bioavailability data (Table 1.5) could be dependent on the 
characteristics of the flavanone foods, the fasting state of participants and differences in 
intestinal microflora and genetics between human individuals (Figure 1.6.2 & 3) [71, 72, 
78, 107, 108]. 
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Comparing flavanone subclasses and their dietary sources, naringenin (i.e. the major 
flavanone in grapefruit) has been observed to be more bioavailable than hesperetin (i.e. 
the major flavanone in oranges) [72, 107]. This discrepancy may be explained by 
differences in functional groups on the B-ring. Whilst a greater bioavailability can be 
achieved when increasing the flavanone dose [108], comparing several orange juices, 
Vallejo et al., [78] have shown that the amount of ingested soluble flavanones correlate 
better with flavanone bioavailability than the total amount of flavanone intake (correlation 
coefficient: 0.92 and 0.35, respectively). In contrast, Brett et al., [72] reported little impact 
of the food matrix on flavanone bioavailability because no differences in pharmacokinetic 
parameters were found following ingestion of either orange fruit or orange juice providing 
a similar flavanone dose (Table 1.5). 
In respect to the fasting state of participants, Mullen et al., [71] reported that orange juice 
intake in combination with yoghurt tended to delay the mean Tmax from 4.4 to 5.1 h and to 
decrease the mean Cmax by one third (Figure 1.6.1) [71]. In support, studies in non-fasted 
participants reported an even higher mean Tmax ranging from 5.3 to 6.8 h [72, 78, 108]. 
 
Figure 1.6 – Bioavailability of dietary flavanones in humans 
 
(1) mean hesperetin plasma concentration – time curve following ingestion of orange juice 
containing 103 mg hesperidin (adapted from [71]); (2 & 3): inter-individual differences in flavanone 
pharmacokinetics with each recording corresponding to one individual (adapted from [78] and 
[108], respectively) 
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Table 1.5 – Flavanone pharmacokinetics following intake of dietary citrus flavanones 
 
    Mean ± SD 
Study Intervention Dose (mL) 
flavanone 
intake (mg) Cmax (µM) T1/2 (h) Tmax (h) AUC0-24 (µmol*h/L) 
Relative urinary excretion 
(% of intake) 
Erlund et al., 
2001 [107] 
Orange juice
1
 400-760 
(8 mL/kg BW) 
103.6-196.9 2.8 ± 1.9 2.2 ± 0.1 5.4 ± 1.6 12.9 ± 9.8 6.4 ± 3.9 
Grapefruit juice
1
 137.2-260.7 6.0 ± 5.3 2.2 ± 0.8 4.8 ± 1.1 27.7 ± 26.3 30.2 ± 25.5 
Manach et al., 
2003 [108] 
Orange juice 500 132.6 0.5 ± 0.1  5.4 ± 0.4 4.6 ± 1.3 4.1 ± 1.2 
1000 265.1 1.5 ± 0.2  5.8 ± 0.37 10.6 ± 2.3 6.4 ± 1.3 
Mullen et al., 
2008 [71] 
Orange juice
1
 250 182.5 0.9 ± 0.2 3.6 ± 1.3 4.4 ± 0.5 4.1 ± 2.9 7.0 ± 2.3 
Orange juice and 150 ml full fat 
yoghurt
1
 
0.7 ± 0.2 3.8 ± 0.8 5.1 ± 0.4 3.0 ± 2.6 7.1 ± 2.3 
Brett et al., 
2008 [72] 
Orange fruit
2
 150 g 90.5 0.18 ± 0.12  6.4 ± 3.0 2.1 ± 1.4 8.5 ± 7.0 
Orange juice
2
 300 81.2 0.15 ± 0.90  5.3 ± 2.3 1.8 ± 0.9 7.4 ± 4.9 
Vallejo et al., 
2010 [78] 
Orange juice from concentrate
2
 400 116.8 0.3 ± 0.6  4.5 ± 0.7 1.22 ± 0.3 8.0 ± 1.7 
Orange juice from concentrate
2
 400 215.2 0.7 ± 0.2  6.8 ± 0.6 1.53 ± 0.3 2.4 ± 0.6 
Pulp enriched orange juice
2
 400 281.2 0.2 ± 0.0  6.5 ± 0.5 0.70 ± 0.1 1.5 ± 0.7 
Flavanone extract enriched 
orange juice from concentrate
2
 
400 440.8 1.5 ± 0.3  6.7 ± 0.3 5.83 ± 1.0 7.1 ± 1.5 
Orange flavonoid extract 
dissolved in water
2
 
400 207.2 1.6 ± 0.4  5.9 ± 0.7 5.00 ± 1.0 14.3 ± 4.4 
Abbreviations: AUC, area under the curve; BW, body weight; Cmax, maximal plasma concentration; T1/2, half life 
1 consumed by fasted participants unaccompanied by a meal; 2 consumed by fasted participants together with a controlled breakfast 
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Figure 1.7 – Flavanone metabolites identified in human biological samples after oral intake of dietary flavanones 
 
1. flavanone phase II metabolites that have been detected in human plasma following intake of orange juice [71, 72, 78, 
107, 108]; 2. five flavanone derived phenolic acids that have been identified in urine following intake of orange juice [113]. 
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Across all conducted studies, a high variance of the maximal flavanone plasma 
concentration has been reported between participants, which might be attributed to 
differences in the intestinal microflora and genetics of human individuals (Figure 1.6.2+3) 
[71, 72, 78, 107, 108]. To a small extent, flavanone bioavailability decreases with 
increasing age [72], whereas no influence of sex and BMI has been observed [72, 78]. 
Although no human data are available, the tissue distribution of flavanones has been 
examined in rats gavaged with radioactively-labelled naringenin [114]. The study 
demonstrated that flavanones can pass the blood brain barrier and are retained in the 
brain, heart, lungs, liver, spleen and kidneys for at least 18h where they potentially elicit 
bioactivity [114]. 
Whilst none or only trace amounts of flavanone aglycones have been detected in plasma, 
most flavanones are subject to phase II metabolism (i.e. flavanone-glucuronides, sulfates 
and -sulfoglucuronides) [71, 72] and further colonic metabolism to phenolic acids [78, 113] 
(Figure 1.7). Following intake of orange juice, while Vallejo et al., [78] identified phenolic 
acids in plasma and urine, Roowi et al., [113] observed a mean increase of five out of nine 
tested potential urinary phenolic acids in urine collected 5-24 h after orange juice intake 
compared to water intake (Figure 1.7.2). Although a complete pharmacokinetic profile for 
flavanone-derived phenolic acids remains to be established, total relative phenolic acid 
urinary excretion accounted for as much as 37 % of the ingested flavanones [113]. 
Regarding the excretion of flavanone conjugate phase II metabolites, collection of urine 
for 36 h following flavanone intake has demonstrated that most of the urinary excretion 
occurs between 6 and 24 h. The highest rate of 40 to 56 % of total urinary excretion was 
observed between 6 and 11 h and a residual excretion of 0.7 to 2.2 % between 24 and 36 
h [108]. Whilst a mean relative urinary excretion for flavanone-phase II metabolites (i.e. % 
of the flavanone intake) ranging between 1.5 and 30.2 % has been reported (Table 1.5) 
[71, 78, 107, 108], the remaining fraction is either not absorbed, subject to further 
metabolism to phenolic acids [78, 113] and eventually carbon dioxide [115] or eliminated 
through biliary excretion [109]. 
How the diverse microorganisms in the gut (i.e. gut microbiome) and their genomes (i.e. 
the metabolome) functionally contribute to human physiology are not well understood and 
have only recently become an extensive area of research [116]. For example, there is 
evidence to suggest that the gut microbiome of obese individuals includes more genes 
responsible for the capacity to extract energy from the diet compared to lean individuals 
[116, 117]. Similarly, the gut microbiome plays an important role in ADME of flavanones 
(and polyphenols), because the gut microbiome explains, to a large extent, the inter-
individual variability of flavanone absorption (Figure 1.6.2) and by which extent flavanones 
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are metabolised to phenolic acids [118]. Conversely, a diet rich in flavanones (and 
polyphenols) may also affect the composition of the gut microbiota and, in turn, influence 
the functional contribution of the microbiome [118]. 
In summary, flavanones are a relatively well absorbed flavonoid subclass with phase II 
flavanone metabolites reaching nano- to micromolar plasma concentrations between 4.4 
to 7 h after intake of citrus (Table 1.5) and a substantial fraction of ingested flavanones is 
metabolised by the gut microbiome and bioavailable in form of circulating phenolic acids 
[105, 113]. However, the pharmacokinetic parameters of these flavanone-derived phenolic 
acid metabolites remain to be established and acute human RCTs are required that relate 
flavanone bioactivity to circulating levels of flavanone phase II conjugates and phenolic 
acid metabolites. 
1.7 Established markers of CVD risk used in acute RCTs to 
examine cardioprotective effects of dietary compounds such 
as flavanones 
Potential beneficial effects of dietary components are commonly assessed through 
markers of CVD risk [119]. Since the conducted human RCT examined the potential acute 
effects of flavanones on vascular function (Chapters 3 & 4), this section introduces 
complementary as well as novel clinical markers of CVD risk and related blood biomarkers 
which might be acutely affected by dietary flavanones. 
1.7.1 Endothelial function plays a key role in vascular homeostasis 
and may be improved by dietary flavonoids 
Endothelial cells, which form the inner monolayer of the arterial wall, have an important 
regulatory role maintaining vascular homeostasis and conversely endothelial dysfunction 
substantially contributes to the development of atherosclerosis [4, 120]. In response to 
physical and chemical stimuli, endothelial cells secrete a range of factors to regulate 
vascular homeostasis (i.e. vascular tonus, structure, inflammation and thromboresistance) 
(Figure 1.8) [4, 17]. Whilst under physiological conditions, a balance is maintained 
between relaxing factors (e.g. nitric oxide and prostacyclin) and contracting factors (e.g. 
endothelin-1 (ET-1), thromboxane A2 and prostaglandin H2), persistent exposure to CVD 
risk factors causes endothelial dysfunction [17]. The consequences are an increase in 
vascular tonus, smooth muscle cell proliferation, vascular inflammation and platelet 
reactivity [17]. 
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Figure 1.8 – Endothelium and vascular homeostasis 
 
Range of factors released by endothelial cells which regulate vascular tonus, smooth muscle 
cell proliferation and platelet reactivity; abbreviations: EC, endothelial cells; SMC, smooth 
muscle cells; TXA2, thromboxane A2; PGH2, prostaglandin H2; ET-1, endothelin-1; CNP, C-
type natriuretic peptide; NO, nitric oxide; Adm, adrenomedullin; PGI2, prostacyclin; EDHF, 
endothelium derived hyperpolarising factor, cGMP, cyclic guanosinmonophosphate, K
+
, 
potassium (adapted from [130]) 
While most clinical methods to assess endothelial function are invasive (i.e. acetylcholine 
induced changes in coronary artery or microvascular blood flow) or technically demanding 
[i.e. brachial artery flow mediated dilatation (FMD)], digital vasodilator function measured 
after reactive hyperaemia by peripheral artery tonometry (PAT-RH) is a non-invasive and 
operator-independent method to assess endothelial function [121]. PAT-RH is a strong 
predictor of CVD risk as suggested by a 7 year prospective study in 270 outpatients 
reporting a significantly higher incidence of cardiovascular adverse events in patients with 
baseline endothelial dysfunction (i.e. PAT-RH < 1.5) [122], and correlations of PAT-RH 
and multiple CVD risk factors such as obesity, diabetes and hypertension were found in 
the Framingham Heart Study [123]. Even though two studies observed a significant 
correlation between PAT-RH and coronary microvascular endothelial function (i.e. r = 
0.41, P < 0.001; in 94 CAD patients) [124] and FMD (i.e. r = 0.55, P < 0.0001; in 89 
healthy subjects) [125], others found no correlation of PAT-RH with the Framingham CVD 
risk score and FMD in a community based US cohort (i.e. r = -0.01, P = 0.70, n = 1843) 
[126] or 222 middle-aged participants (i.e. r = 0.12, P = 0.06) [127]. Overall, and despite 
these inconsistent findings regarding the validation of PAT-RH against other measures of 
endothelial function, PAT-RH may provide useful information about peripheral endothelial 
function and was chosen for the present study due to its operator-independencdy. 
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As outlined in Section 1.4.2 and also documented in a systematic review [128], flavonoids, 
including flavanones [59, 60], have been suggested to improve clinical surrogate markers 
of endothelial function and this effect is partly mediated by an increase in endothelial NO 
bioavailability [129]. However, specifically for the flavanone subclass, more studies are 
required to provide scientific evidence. 
Blood biomarkers are commonly assessed to examine the potential underlying 
mechanism of action responsible for an improvement in endothelial function. Increased 
endothelial NO production, a key mediator of vasodilatation, was suggested to be 
responsible for approximately 60 % of the PAT-RH response [129], and can be measured 
indirectly through quantification of plasma nitrate, nitrite and/or nitroso species (e.g. S-
nitrosothiols) [65, 131]. Further available blood biomarkers that play a role in endothelial 
function include markers related to endothelial NO production (e.g. superoxide generating 
NADPH oxidase [132] and asymmetric dimethylarginine [133]), vasodilators (e.g. PGI2 [17] 
and hydrogen disulfide [134]), vasoconstrictors (e.g. ET-1 [135] and the renin-angiotensin-
aldosterone system (RAAS) [5]) and markers of vascular integrity (e.g. micro particles 
[136] and endothelial progenitor cells [137]). 
In summary, the PAT-RH is a useful method to test potential acute effects of dietary 
flavanones on endothelial function, and changes in related blood biomarkers need to be 
explored to understand the potential underlying mechanisms of action. 
1.7.2 Baroreflex sensitivity as a marker of CVD risk 
The autonomic nervous system (ANS), which consists of parasympathetic and 
sympathetic pathways, regulates most organ systems including control of short-term BP 
fluctuations [138]. 
In response to beat-to-beat changes in BP, the baroreceptors, which are stretch receptors 
located in the carotid sinuses and the aortic arch, reflexly elicit inverse changes in heart 
rate and arterial tonus via the ANS [139] (Figure 1.9). CV autonomic dysfunction, which is 
characterised by sympathetic overactivity and parasympathetic hypoactivity, is a 
prognostic marker of CVD events and has been associated with CVD risk factors such as 
hypertension and obesity [18, 139-141]. Furthermore, CV autonomic dysfunction has been 
closely linked with endothelial dysfunction [142] and a correlation between 
parasympathetic autonomic function and arterial stiffness was observed in healthy men 
[143].
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Figure 1.9 – The baroreceptor reflex in response to an increase in blood pressure1 
 
1 
The reflex also responds in the opposite way to a decrease in blood pressure.
 
Abbreviations: AVN, atrioventricular node; SAN, sino-atrial node (Figure adapted from [61]) 
Although the pathophysiology of autonomic dysfunction is not fully understood, decreased 
NO bioavailability [144, 145], increased levels of ET-1 [135] and superoxide-generating 
NADPH oxidase [146] in the brain may cause autonomic dysfunction. Moreover, at sites of 
the baroreceptors, impaired PGI2 production, decreased arterial distensibility, platelet 
aggregation and increased levels of oxidative stress were associated with autonomic 
dysfunction [147]. 
Baroreflex sensitivity (BRS) is a widely used technique to measure CV autonomic function 
which involves the assessment of changes in BP followed by ANS induced changes in the 
heart rate [139]. Whilst the gold standard method to quantify BRS involves injection of 
vasoactive drugs, there are non-invasive methods such as recording BP and heart rate 
changes that occur spontaneously or during simple physical tasks, e.g. strained breathing 
(i.e. Valsalva manoeuvre) [139]. 
Previous studies reported non-dietary flavanones to beneficially affect autonomic function 
[62, 148]. Assessing heart rate variability, intake of 500 mg non-dietary glucosyl 
hesperidin acutely decreased cardiac sympathetic and increased cardiac parasympathetic 
nerve activity in 11 healthy women compared to intake of control treatment [62]. Similarly, 
in rats, administration of 60 mg glucosylhesperidin has been shown to acutely decrease 
cutaneous sympathetic nervous activity [148]. To support this limited evidence, further 
studies are warranted that examine whether flavanones naturally occurring in our diet can 
also beneficially modulate autonomic function assessed through BRS, in participants at a 
higher risk of CVD and using a dose that can be achieved in a normal diet. 
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Flavanones may not only beneficially affect the arterial baroreceptors but also brain 
regions responsible for cardiac autonomic function, given the ability of flavanones to cross 
the blood brain barrier [114]. Hence, considering the pathophysiology of CV autonomic 
dysfunction, the mechanisms by which flavanones may improve CV autonomic function 
require examination through assessment of changes in blood biomarkers such as NO 
[144, 145], PGI2 [147], ET-1 [135], NADPH oxidase [146] and platelet activation [147]. 
1.7.3 Arterial stiffness as a predictor of CVD events and the beneficial 
effects of dietary flavonoids 
Stiffening of large central arteries (i.e. aorta and carotid arteries), respectively an increase 
in carotid to femoral pulse wave velocity (cfPWV) or central pulse wave reflection, are 
recognised markers of CVD risk and strong predictors of CVD events and mortality [20, 
149, 150]. Arterial stiffness is characterised by structural changes and hypertrophy of the 
arterial wall, in particular changes in vascular composition of scaffolding proteins (i.e. 
increase in collagen and decrease in elastin) and increased VSMC tone and proliferation 
[151, 152]. A range of factors have been suggested to contribute to the progression of 
central arterial stiffening, such as age, sex, smoking status, diabetes, chronic renal 
disease, elevated angiotensin II and endothelin-1 activity, salt intake, endothelial 
dysfunction and CV autonomic dysfunction [19, 143, 152, 153]. 
Since the pulse speed along the aorta strongly correlates with central arterial stiffness, 
cfPWV is considered the best surrogate marker of arterial stiffness and is an independent 
CVD risk marker for which reference values from a large healthy European population are 
available (Table 1.6) [153]. Using an oscillometric technique [i.e. the Vicorder equipment 
(Skidmore Medical, Bristol, UK)] with a cuff based system at the femoral and carotid 
arteries, cfPWV can be measured non-invasively and with little operator training 
dependence [20, 154, 155]. Regarding the method’s reliability, in a comparison with 
cfPWV measured by applanation tonometry, high repeatability of the oscillometric 
technique was reported by Hickson et al., [154], but not by van Leeuwen-Segarceanu 
[155]. 
Table 1.6 – cfPWV reference values from a healthy European population1 
   
Age category in years Mean cfPWV (± 2 SD) in m/s Median cfPWV (10-90 pc) in m/s 
<30 6.2 (4.7-7.6) 6.1 (5.3-7.1) 
30-39 6.5 (3.8-9.2) 6.4 (5.2-8.0) 
40-49 7.2 (4.6-9.8) 6.9 (5.9-8.6) 
50-59 8.3 (4.5-12.1) 8.1 (6.3-10.0) 
60-69 10.3 (5.5-15.0) 9.7 (7.9-13.1) 
≥ 70 10.9 (5.5-16.3) 10.6 (8.0-14.6) 
1 
n = 1455; Abbreviations: cfPWV, carotid to femoral pulse wave velocity; 10pc, the upper limit 
of the 10
th
 percentile; 90 pc, the lower limit of the 90
th
 percentile; Table adapted from [153] 
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A recent study demonstrated that central pulse wave reflection, another surrogate marker 
of arterial stiffness, can be accurately estimated as the central augmentation index (cAIx) 
using the same oscillometric technique [156]. The method involves estimation of central 
BP derived from non-invasive measures of brachial BP and has been validated against 
invasive and applanation tonometry measurements of central BP [156]. 
In a systematic review, Pase et al., [157] stated that whilst pooled data from four 
isoflavone interventions giving 80-118mg isoflavones/d for 5 to 12 weeks in healthy 
participants suggested a significant decrease in arterial stiffness, there were insufficient 
data for other flavonoid subgroups, with no studies examining flavanones. Nevertheless, 
two acute studies have reported beneficial acute effects on arterial stiffness following a 
single dose of flavan-3-ols provided as dark chocolate [158] or as tea [159] in healthy 
individuals. Endothelium dependent dilatation of resistant arteries, resulting in a decrease 
in pulse wave reflection, has been proposed as the underlying mechanism responsible for 
the acute beneficial effects of flavan-3-ols on arterial stiffness [158, 159]. Whether 
flavanones also improve arterial stiffness and what the underlying mechanisms might be 
remain areas of future research. 
1.7.4 Increased platelet activation plays a key role in 
atherothrombotic risk and may be decreased by dietary 
constituents 
Whilst platelets are important for primary haemostasis repairing vascular injuries, they 
also play a key role in the development of thrombi leading to coronary occlusion and 
stroke, and increased platelet activation and aggregation contributes to the progression of 
atherosclerosis [21]. 
In a pathophysiological state, there is an impaired interaction between endothelial cells 
and platelets [160]. Dysfunctional endothelium lacks its thromboresistant ability due to 
increased permeability, secretion of pro-coagulant compounds such as von Willebrand 
factor and collagen and decreased secretion of platelet-inhibitory mediators such as NO 
and PGI2, thereby increasing platelet reactivity [160]. Conversely, activated platelets 
promote endothelial dysfunction and atherosclerosis through secretion of soluble CD40L, 
P-selectin and matrix metalloproteinase [21, 161]. 
Whilst turbidimetric measurement of ex vivo platelet aggregation is the historical gold 
standard for the assessment of platelet function, quantification of P-selectin (i.e. a protein 
indicating platelet degranulation) and activated fibrinogen receptor (gpIIb/IIIa) expression 
on ex vivo stimulated platelets using whole blood flowcytometry is another recognised 
method to test platelet function [162]. Furthermore, circulating levels of soluble CD40L, P-
selectin, prothrombin fragments 1+2 or urinary levels of TXA2 metabolites are further 
available in vivo blood biomarkers of platelet function [163]. 
 39 / 150 
Platelet-inhibitory effects may be a potential mechanism by which dietary constituents 
such as flavonoids contribute to cardiovascular health. Whilst flavanones have been 
suggested to inhibit platelet aggregation in platelets in vitro [73-75] and in animals in vivo 
[74] (see Sections 1.4.3 & 4), and although a critical review of human RCTs found 
sufficient evidence to suggest that flavan-3-ols inhibit platelet aggregation [164], the 
potential platelet-inhibitory effects of flavanones in humans remains to be examined. 
1.8 Summary and concluding remarks 
The present literature review describes current knowledge on flavanones, their dietary 
occurrence, human ADME and potential CV benefits. Furthermore, remaining limitations 
on existing data that need to be addressed in future research were discussed and some of 
these gaps were addressed to some extent in the present work. 
In summary, CVD is one of the main causes of mortality in the UK [1] and intake of dietary 
components is a modifiable risk factor with an impact on the development of CVD [22]. 
Flavanones may be an important dietary component, given the high content of flavanones 
in citrus fruits and juices, both of which are highly consumed worldwide [99], and 
flavanones being a relatively well-absorbed flavonoid subclasses [109]. Indeed, a body of 
epidemiological evidence suggests an inverse association of flavanone/citrus fruit intake 
and RR of CVD [43-52] and in vitro and animal studies reported beneficial effects on 
underlying vascular function and BP. 
However, there are insufficient in vivo human data to determine if dietary flavanones have 
beneficial CV effects and the potential underlying mechanisms by which flavanones may 
exert these beneficial CV effects remain poorly understood. To date, there are two RCTs 
suggesting beneficial acute or short-term (i.e. 3-4 weeks) effects of orange juice or 
hesperidin (doses ranging between 292mg and 500mg) intake on DBP and endothelial 
function in different study populations (i.e. healthy overweight men and adults with 
metabolic syndrome). 
In conclusion, further human RCTs are warranted to corroborate previously reported 
beneficial effects of dietary flavanones on endothelial function, assess potential benefits 
on unexplored markers of CVD risk (e.g. CV autonomic function, arterial stiffness and 
platelet activation) and relate findings in these markers of CVD risk to potential changes in 
blood biomarkers to explore the underlying mechanism of action. Moreover, potential 
additive/synergistic beneficial CV effects of flavanones with other bioactive compounds 
found in the food matrix of orange juice and associations with plasma concentrations of 
absorbed individual flavanone metabolites require further examination. The aim of this 
PhD research project was to systematically review existing human RCTs on flavanones 
and CVD risk markers (including vascular, metabolic and inflammatory) (Chapter 2), and 
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to conduct an acute human dietary RCT (Chapters 3-5) to address research gaps 
identified in the literature and systematic review (Chapter 1+2). 
1.9 PhD hypothesis 
It is hypothesised that a single dose of flavanones, given as a supplement or within 
orange juice, acutely improves markers of CVD risk at times of anticipated peak plasma 
flavanone concentration (i.e. 5 h after intake) in men at mild to moderate CVD risk (10 to 
20 % over 10 years based on the British Hypertension Society (BHS) risk calculator [38]). 
Flavanones reach (sub)micromolar plasma concentrations between 4 and 8 h after their 
intake and may, in turn, exert acute cardioprotective effects over a prolonged period. 
However, the present study was constrained to examining potential effects only at 5 h 
after intake of flavanones because of limited hours of study nurse cover and concurrent 
implementation of 2 further acute flavonoid intervention RCTs by the same research 
group. 
Specific PhD objectives: 
1. To systematically review existing human RCTs on flavanones and markers of CVD risk. 
2. To examine potential acute effects of hesperidin on markers of CVD risk; specifically, 
digital endothelial function, CV autonomic function, central arterial stiffness and platelet 
activation. 
3. To assess CV plasma biomarkers to explore potential underlying mechanisms of action 
by which flavanones may improve markers of CVD risk. 
4. To investigate potential additive/synergistic effects of bioactive compounds in the 
orange juice matrix; in particular testing the effect of orange juice versus matched 
hesperidin and vitamin C versus matched vitamin C. 
5. To quantify flavanone-derived phenolic acid metabolites in plasma and potentially 
identify novel metabolites. 
6. To explore associations between acute changes in CVD risk markers with plasma 
concentrations of individual flavanone metabolites. 
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Chapter 2. Flavanone extracts, flavanone-rich foods 
and CVD risk markers; a systematic review of 
randomised controlled trials 
2.1 Introduction 
Epidemiological evidence suggests an association between an increased intake of 
flavanones and citrus fruit and a lower relative risk of coronary heart disease (CHD) [49-
51] and stroke [43, 45-48], with support from in vitro and animal studies [60, 94, 165], yet 
a causal relationship in human has not been established. In a previous  systematic review, 
two studies on flavanones [166, 167] were included in a systematic review of flavonoids 
and cardiovascular (CV) disease (CVD) risk (papers search up to July 2007 [128]) and 
since this date, a number of additional RCTs have been published relating to the effect of 
flavanones on markers of CVD risk. However, there is no systematic review of 
randomised controlled trials (RCTs) examining the effects of flavanones and citrus fruit on 
markers of CVD risk. 
The aim of this systematic review, therefore, was to provide an updated assessment of 
RCTs examining potential cardioprotective effects of flavanones. To do this, the 
methodology of this systematic review has followed the Cochrane handbook of systematic 
reviews [168] and built upon our group’s previous systematic review [128]. A systematic 
review protocol was developed, to include a flavanone specific search strategy, study 
selection criteria, data collection method and data analysis strategy to answer the primary 
research question. 
2.2 Objectives 
This systematic review was conducted to examine the effects of acute as well as chronic 
flavanone intake on CVD risk biomarkers. The primary aim was to explore potential effects 
of flavanones on related clinical markers of CVD risk, including blood pressure (BP), 
endothelial function, autonomic function and arterial stiffness and associated blood 
biomarkers (e.g. nitric oxide metabolites (NOx) and endothelin-1). Secondary outcome 
measures included biomarkers of lipid status, metabolism, inflammation, platelet 
aggregation and venous insufficiency. 
Secondary study aims were to explore how the specific constituents of flavanones (e.g. 
hesperetin, naringenin and eriodictyol), intervention dose, intervention duration, studied 
participants (i.e. healthy, at elevated baseline CVD risk or with CVD) and food matrix (i.e. 
flavanone extracts or flavanone-rich foods) might influence the benefits of flavanones in 
reducing CVD risk. 
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2.3 Methodology 
2.3.1 Criteria for study inclusion 
This systematic review was restricted to RCTs of either parallel or crossover design that 
were conducted in adults (> 18 years old) and gave a dose of flavanones orally as an 
extract, as a pure compound or within a food source (i.e. citrus fruits) which must have 
been compared with a control group receiving a closely matched control intervention. 
Study endpoints had to include markers of CVD risk, i.e. systolic and diastolic BP (SBP 
and DBP), endothelial function, autonomic function, arterial stiffness, biomarkers of 
vascular function, plasma lipids, inflammatory biomarkers, biomarkers of platelet 
aggregation (e.g. thrombin and von Willebrand Factor), metabolic biomarkers (e.g. plasma 
glucose and insulin) and venous insufficiency. 
Exclusion criteria also included: 
 No translation to English, German, French or Spanish 
 Multifactorial intervention in which the effect of flavanones could not be isolated 
 Study populations with pregnant or breastfeeding women 
 Participants with renal problems, inflammatory conditions (e.g. rheumatoid 
arthritis) or terminal cancer 
Studies of short-term (i.e. 2-12 weeks) and chronic (>12 weeks) design were included, as 
were acute studies that made CVD risk marker assessments between 3 and 8 h after a 
single intake of flavanones. In acute studies, this postprandial time period (i.e. after 3 to 8 
h), coincides with the highest flavanone concentration in plasma [71, 78], and, therefore, 
is likely to represent the period when flavanones may exert beneficial CV effects. 
2.3.2 Search strategy 
The Cochrane Library, MEDLINE, EMBASE, CINAHL and AMED were searched by using 
flavanone terms to January 2013. Indexing and text terms as well as truncation and 
sensitive RCT and human filters [169] were used in the following format: [human adult] 
AND ([flavanones OR flavanone-rich food text terms) OR (flavanones or flavanone-rich 
food indexing terms]) AND human RCT filter. Figure 2.1 illustrates the MEDLINE search 
strategy that was employed and which was adapted for the other database searches due 
to differences in search syntax. Furthermore, reference lists of included studies were 
reviewed to identify any other potential studies that may not have been identified in the 
searches. 
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Figure 2.1 – MEDLINE Ovid search strategy for flavanone randomised controlled trials 
MEDLINE (Ovid) 
# Searches 
1  randomized controlled trial.pt. 
2  controlled clinical trial.pt. 
3 randomized.ab. 
4 control.ab. 
5 clinical trials as topic.sh.# 
6 randomly.ab. 
7 trial.ti. 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 exp animals/ not humans.sh. 
10 8 not 9 
11 (flavanone* or hesper* or narin* or narirutin or eriodictyol or citrus or orange* or grapefruit* or 
lemon* or lime* or pummelo* or tangerine* or satsuma*).ti,ab. 
12 exp flavanones/ or exp hesperidin/ 
13 exp citrus/ or exp citrus aurantiifolia/ or exp citrus paradisi/ or exp citrus sinensis/ 
14 11 or 12 or 13 
15 10 and 14 
terms ending with “/” are indexing terms and exploded if proceeding “exp”; “*” is the truncation term, 
e.g. narin* might stand for naringenin or naringin. Abbreviations: .pt, publication type; .ab, abstract; 
.ti, title; sh, medical subject heading (MESH) 
2.3.3 Study selection 
Titles and abstracts were screened for inclusion and those clearly not meeting the 
inclusion criteria were excluded. In addition to screening by the main author MS (Manuel 
Schär), a second reviewer, PC (Dr Peter Curtis), independently screened the full search to 
minimise potential screening error occurrences. Full texts were obtained, and inclusion 
criteria applied for studies remaining after the initial abstract screen. Again, the two 
reviewers (MS and PC) independently assessed full texts for inclusion; additionally, a 
subset of the full texts were checked by Dr Lee Hooper [128]. Any disagreement in study 
inclusion/exclusion was resolved in a joint meeting. For studies that could not be included 
because randomisation was not reported, authors were contacted for clarification. 
2.3.4 Data extraction and validity of studies 
From the studies that met the inclusion criteria, data were extracted using an adapted 
data extraction form from our group’s systematic review [128]. Extracted data included 
bibliographic data, randomisation, blinding, adverse events reporting, intervention 
(including duration, design, dose, form and control), participant’s characteristics (i.e. age, 
sex, medication use, lipid status and BP), sample size, dropout rate, study compliance 
and outcome measures. Authors were contacted when data on outcome measures were 
missing (e.g. baseline values). 
Further data extraction to assess the validity of studies included randomisation procedure, 
allocation concealment, masking of participants and study scientists to the intervention, 
industry funding, participant drop outs, intervention compliance and selective outcome 
reporting. 
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2.3.5 Data synthesis 
For continuous data in parallel studies, the number of participants and the means ± SD of 
changes between baseline and post intervention values or absolute post intervention 
values, were used. The data were excluded from analysis if the difference between 
baseline measures of the experimental and control intervention was greater than the 
difference between post-intervention and baseline for at least one arm. For continuous 
data in crossover studies, mean differences (MDs) ± standard error (SE) between the 
experimental and the control group were used. If these were not provided, absolute post 
intervention values of the experimental and control group were used separately, despite a 
consequent reduction in the power of crossover studies to detect effects [170]. For studies 
examining a time-response relationship, only the data collected at the time-point of 
highest treatment effect were used. When necessary, SDs were calculated from SE, 
confidence intervals (CI) or P-values [171]; where different units were reported, data were 
converted to international system units. If non-numerical data were reported, data values 
were estimated from figures. For studies with multiple experimental interventions, means 
and SDs were combined in order to achieve a single pair-wise comparison or if only MDs 
were reported the experimental group showing more effects was used [171]. 
2.3.6 Data analysis 
Due to the small number of studies published, the main analysis was conducted grouping 
together interventions with flavanone extracts and interventions with flavanone-rich foods. 
An exception was made for studies which examined bitter orange extract (Nature’s Way, 
Utah, US); these were analysed separately, because as well as being a source of 
flavanones, a compound in bitter orange (i.e. synephrine) used for weight loss treatment 
has also been examined for adverse CV effects [172]. 
Meta-analysis was conducted using the REVMAN software (version 5.1.2; The Cochrane 
Collaboration, Oxford, United Kingdom) with the DerSimonian and Laird random effect 
model [173, 174]. MDs ± SEs were obtained from parallel studies and crossover studies 
that reported means ± SDs for the experimental and control group separately by 
performing meta-analyses of continuous data. Then using MDs ± SEs from all studies, 
meta-analyses of generic inverse variance were conducted to receive the pooled effect 
[173]. Where meta-analyses contained <3 pair-wise comparisons or <50 participants, data 
were presented in a summary of findings table [175]. 
Sensitivity analyses were performed to test the quality of trials included in the meta-
analysis, and risk of bias was summarised in a table. A Cochrane’s test for heterogeneity 
was performed to verify whether studies included in a meta-analysis examine the same 
underlying size of effect. P, indicating variation in effect size, and I2, indicating 
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inconsistency among studies, were considered as reporting heterogeneity when <0.1 and 
>50 %, respectively [176]. 
2.4 Results 
Figure 2.2 displays the flow diagram outlining the search results for this systematic review. 
After roughly deleting duplicates, the search yielded 1766 papers, of which 1715 were 
excluded in the screening process. Of the 51 papers, which appeared potentially eligible 
(after abstract scanning), full texts were collected for closer assessment, and 41 papers 
were excluded which resulted in a final set of 10 papers that met the inclusion criteria. 
Figure 2.2 – Systematic review flow diagram 
 
The 10 included RCTs examined the effects of citrus fruits (n = 3), flavanone supplements 
(n = 4), both (n = 1) or bitter orange extract (n = 2) on CVD risk markers (Table 2.1). CVD 
risk markers that were assessed included primary outcomes; BP (n = 2), endothelial 
function (n = 2) and biomarkers of vascular function (n = 1) and secondary outcomes; 
plasma lipids (n = 7), inflammatory biomarkers [i.e. CRP, interleukin-6, von Willebrand 
Factor, soluble intracellular adhesion molecule (sICAM) and soluble vascular cell 
adhesion molecule (sVCAM)] (n = 2), metabolic biomarkers (i.e. plasma glucose and 
insulin sensitivity) (n = 2), and venous insufficiency (n = 1). Across all studies, the 
flavanone intervention consisted of doses ranging from 292 to 1000 mg and was 
compared with a control intervention. The studies had a median of n = 19 participants, 
lasted 3 h to 8 weeks with 5 studies performed in healthy study populations, 4 in patients 
with elevated CVD risk and one whose study population is not clear. 
Titles and abstracts excluded 
because they did not meet inclusion 
criteria or were duplicate (n = 1715)
Full texts assessed for inclusion (n = 51)
Full texts excluded (n = 41) due to: 
• no adequate control (n = 10)
• no randomisation (n = 7)
• multifactorial intervention (n = 8)
• only in Japanese (n = 3)
• acute outcomes at irrelevant postprandial  time points (n = 6)
• no CV outcome meeting inclusion criteria (n = 6)
• weight loss included as study objective (n = 1)
Included papers (n = 10)
Primary outcomes:
• endothelial function (n = 2)
• blood pressure (n = 6)
Search results to January 2013:
• AMED (n = 111)
• CENTRAL (n = 989)
• CINAHL (n = 567)
• EMBASE (n = 1444)
• MEDLINE (n = 1201)
• Total roughly de-duplicated (n = 1766)
Secondary outcomes:
• blood lipids (n = 7)
• inflammatory markers (n = 2)
• lipoprotein oxidation (n = 2)
• glucose metabolism (n = 3)
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Table 2.1 – Characteristics of included studies investigating flavanones and CVD risk biomarkers 
         
Study 
Study 
design 
n 
(E/E/C) Participants 
Age 
(years)
1
 
Study 
duration Intervention Outcome 
Rizza et 
al., [60] 
crossover 24/24 adults with metabolic 
syndrome partly 
medicated
2
 
52 ± 10 3 wk hesperidin supplement (500mg)/d vs  
control supplement/d 
BP, FMD, blood lipids, glucose 
metabolism, inflammation 
Morand et 
al., 2011 
[59] 
crossover 23/23/23 healthy men 56 ± 5 Acute: 
(6 h) 
500ml orange juice/d (292 mg hesperidin) 
vs 292 mg hesperidin supplement/d vs 
control supplement/d 
BP, microvascular reactivity, blood 
lipids, glucose metabolism, 
inflammation 
Demonty et 
al., 2010 
[177] 
parallel 59/64/65 moderately 
hypercholesterolaemic 
adults 
60 ± 9 4 wk hesperidin supplement (800mg/d) vs  
naringin supplement (500mg/d) vs  control 
supplement 
blood lipids 
Bui et al., 
2006 [178] 
crossover 15/15 healthy adults 26 ± 2 6 h single dose of bitter orange supplements 
(900mg) (flavanone concentration 
unknown) vs control supplement 
BP and HR 
Gorinstein 
et al., 2006 
[179] 
parallel 19/19/19 hypertriglyceridemic 
patients with CHD 
Range: 
39 - 72 
4 wk 1 blonde grapefruit/d vs  1 red grapefruit/d 
vs usual diet 
blood lipids 
Min et al., 
2005 [180] 
crossover 18/18 healthy adults 24.9 ± 4.4 8 h 1 bitter orange supplement (450mg) vs  1 
control supplement 
BP and HR arrhythmia index 
Gorinstein 
et al., 2004 
[181] 
parallel 22/22/22 hypercholesterolaemic 
patients with CHD 
Range: 
48 - 66 
4 wk 1 sweetie/d vs  2 sweeties/d vs  usual diet blood lipids 
Vinson et 
al., 2001 
[182] 
crossover
2 
16/10 not reported 53 ± 10 8 wk 3 supplements of 990 mg vitamin C + 
2700 mg citrus extract/d vs 2 supplements 
of 1000mg vitamin C/d 
blood lipids 
Harats et 
al., 1998 
[183] 
parallel 19/17 healthy men 19.8 range: 
18 - 23 
8 wk controlled diet + 1.1l orange juice/d 
(600mg flavanones) vs controlled diet 
blood lipids 
Cospite et 
al., 1989 
[166] 
parallel 43/45 adults with chronic 
venous insufficiency 
Range: 
20 - 72 
8 wk hesperidin supplement (900mg diosmin 
and 100mg hesperidin) vs control 
supplement (900mg diosmin) 
venous insufficiency (calf and ankle 
circumference after 15 min walking) 
Abbreviations: n, number of participants per arm; CVD, cardiovascular disease; E, experimental interventions; C, control intervention; d, day; BP, blood pressure; HR, heart rate; 
CHD, coronary heart disease; FMD, flow mediated dilatation; LDL, low density lipoproteins; 
1
mean ± SD unless stated 
2
each participant was assigned to two of four intervention 
supplements; 
2
 Participants were prescribed to the following therapies: antidiabetic (n = 17), antihypertensive (n = 10), statin (n = 1) and antiplatelet (n = 3) 
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Table 2.2 – Risk of bias assessment of included studies 
 
Study 
Sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Masking of 
participants and 
personnel 
(performance bias) 
Masking of 
outcome 
assessors 
(detection bias) 
Incomplete 
outcome data 
(attrition bias) 
Selective 
reporting 
(reporting bias) 
Carry-over 
effect 
(other bias) 
Total per study: 
(low risk/unclear/ 
high risk) 
Rizza et al., [60] 
Low risk Low risk Low risk Low risk Low risk Low risk Unclear 6/1/0 
Morand et al., 2011 [59] 
Unclear Unclear Unclear Unclear Low risk Low risk NA 2/4/0 
Demonty et al., 2010 [177] 
Low risk Low risk Low risk Low risk Low risk Low risk Low risk 7/0/0 
Bui et al., 2006 [178] 
Low risk Low risk Low risk Low risk Low risk Low risk Low risk 7/0/0 
Gorinstein et al., 2006 [179] 
Unclear Unclear High risk Unclear Low risk High risk NA 1/3/2 
Min et al., 2005 [180] 
Unclear Low risk Unclear Unclear Low risk Low risk Low risk 4/3/0 
Gorinstein et al., 2004 [181] 
Unclear Unclear High risk Unclear Unclear High risk NA 0/4/2 
Vinson et al., 2001 [182] 
Unclear Low risk Unclear Unclear Unclear Low risk Low risk 3/4/0 
Harats et al., 1998 [183] 
Unclear Low risk High risk Unclear Unclear Low risk NA 2/3/1 
Cospite et al., 1989 [166] 
Unclear Unclear Unclear Unclear Low risk Low risk NA 2/4/0 
Total per domain: 
(low risk/unclear/high risk) 
3/7/0 6/4/0 3/4/3 3/7/0 7/3/0 8/0/2 4/1/0 34/26/5 
NA, not applicable due to parallel design 
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Across the 10 included studies, there was variation in the risk of bias of which half were 
assessed as “low risk”, 44 % as “unclear” and 6 % as “high risk” (Table 2.2). Whilst for 
most studies the risk of bias assessment was unclear, the studies of Morand et al., [59], 
Rizza et al., [60] and Bui et al.,  [178] addressed the risk of bias extensively and were the 
only RCTs that explained the methods used for randomisation and blinding. In comparison 
to the 7 day washout period in the majority of studies, with 3 days the study of Rizza et al., 
[60] might have had some risk of bias. The two studies of [179, 181] were assessed as 
being at high risk of bias, mainly because baseline values were neither reported nor 
provided after contacting the authors. Furthermore, Gorinstein et al., [179, 181] together 
with Harats et al., [183] used a usual diet as control intervention which indicates that 
participants were not blinded to the intervention. 
2.4.1 Primary outcomes: blood pressure, endothelial function and 
NOx 
The data from 2 studies that examined effects of short-term (i.e. 3 - 4 weeks) flavanone 
intake on BP and endothelial function were mixed [59, 60]. Following a flavanone 
supplement intervention, Rizza et al., [60] observed an improvement in mean brachial 
artery flow mediated dilatation (FMD) by 2.5 % (95 % CI: 0.4, 4.6), but no effect on DBP in 
adults with metabolic syndrome (Table 2.3). In contrast, a study in overweight men by [59] 
reported that flavanones given as a supplement or within orange juice both reduced mean 
DBP by -3.2mm Hg (95 % CI: -6.1, -0.3) and -5.5mm Hg (95 % CI:, -9.0, -2.0) 
respectively, and the orange juice intervention tended to increase mean NOx plasma 
concentration (12.4µmol/L 95 % CI: 1.4, 23.4; P = 0.08). However, there was no change in 
NOx plasma concentration following the supplement and no change in microvascular 
reactivity in either intervention (i.e. orange juice and flavanone supplement) [59]. 
The same study [59] also explored acute effects of flavanones on endothelial function at 6 
h following single/acute intake and reported an improvement in microvascular reactivity in 
the orange juice intervention [105 % (95 % CI: 55, 155)] and a trend towards an 
improvement in the flavanone supplement intervention [48 % (95 % CI: -1 %, 98 %)], but 
no change in NOx (data not shown) (Table 2.4). 
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Table 2.3 – Summary of findings for short-term effects of flavanones on CVD risk markers 
 
Outcome Study 
Daily experimental 
intervention 
Mean 
effect
1 
[95 % CI] 
Blood pressure 
Systolic (mm Hg) Morand et al. orange juice -3.0 [-8.3, 2.3] 
  
hesperidin supplement 0.6 [-5.5, 6.7] 
 
Rizza et al. hesperidin supplement 2.7 [-1.3, 6.7] 
Diastolic (mm Hg) Morand et al. orange juice -5.5** [-9.0, -2.0] 
  
hesperidin supplement -3.2* [-6.1, -0.3] 
 
Rizza et al. hesperidin supplement 0.6 [-2.2, 3.4] 
Endothelial function and NOx 
Flow mediated dilatation (%) Rizza et al. supplement 2.5* [0.4, 4.6] 
Microvascular reactivity (%) Morand et al. orange juice 52 [-8, 113] 
  
hesperidin supplement 17 [-44, 77] 
NOx (µmol/L) Morand et al. orange juice 12.4 [1.4, 23.4] 
  
hesperidin supplement -3.2 [-15.0, 8.6] 
Vascular Inflammation  
   
CRP (mg/L) Morand et al. orange juice 0.3 [-0.1, 0.8] 
  
hesperidin supplement -0.1 [-0.4, 0.3] 
hsCRP (mg/L) Rizza et al. hesperidin supplement -0.7** [-0.5, -0.9] 
Interleukin-6 (pg/mL) Morand et al. orange juice -0.2 [-0.7, 0.2] 
  
hesperidin supplement 0.2 [-0.6, 1.0] 
Von Willebrand Factor (U/mL) Morand et al. orange juice -0.1 [-0.7, 0.6] 
  
hesperidin supplement 0.1 [-0.4, 0.6] 
sICAM (ng/mL) Morand et al. orange juice 28.1 [-17.4, 73.6] 
  
hesperidin supplement -4.9 [-62.3, 52.5] 
 
Rizza et al. hesperidin supplement -4.0 [-19.0, 11.0] 
sVCAM (ng/mL) Morand et al. orange juice -323.0* [-617, -29] 
  
hesperidin supplement -242.0 [-557, 73] 
 
Rizza et al. hesperidin supplement -28.0 [-71, 15] 
Metabolic markers  
   
Glucose (mmol/L) Morand et al. orange juice -0.1 [-0.5, 0.3] 
  
hesperidin supplement -0.2 [-0.6, 0.2] 
 
Rizza et al. hesperidin supplement -0.2 [-0.5, 0.1] 
Insulin (pmol/L) Morand et al. orange juice -1.9 [-22.3, 18.5] 
  
hesperidin supplement -1.1 [-4.2, 2.0] 
 
Rizza et al. hesperidin supplement -6.0 [-15.9, 3.9] 
Venous insufficiency 
Ankle circumference (mm) Cospite et al. hesperidin supplement -5.64** [-8.7, -2.6] 
Calf circumference (mm) Cospite et al. hesperidin supplement -1.69 [-3.8, 0.4] 
Abbreviations: CVD, cardiovascular disease; CI, confidence interval; NOx, nitric oxide metabolites; 
CRP, C-reactive peptide; hsCRP, high-sensitivity CRP; sICAM, soluble intracellular adhesion 
molecule; sVCAM, soluble vascular cell adhesion molecule; 
1
 difference between the mean in the 
experimental intervention and the mean in the control intervention; P-values: * < 0.05; ** < 0.01 
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2.4.2 Secondary outcomes: plasma lipids 
Blood lipids were analysed by pooling together the findings of 6 studies (Figure 2.3). 
Whilst the overall effects of a short-term (i.e. 3 to 8 weeks) flavanone intervention showed 
a small increase in plasma high density lipoprotein cholesterol (HDL-C) levels [0.04 
mmol/L (95 % CI: 0.00, 0.08)], no effect was observed on plasma levels of low density 
lipoprotein cholesterol (LDL-C) [-0.30 mmol/L (95 % CI: -0.75, 0.15)], total cholesterol (TC) 
[-0.32 mmol/L (95 % CI: -0.73, 0.09)] and triglycerides (TG) [-0.19 mmol/L (95 % CI: -0.39, 
0.02)]. 
Within subgroup analyses, in individuals with metabolic syndrome and prescribed to CVD 
related medication (i.e. antidiabetic, antihypertensive, statin and/or antiplatelet) or with a 
past history of CVD events, an increase in HDL-C [0.06mmol/L (95 % CI: 0.02, 0.10)] and 
a decrease in LDL-C [-0.64 mmol/L (95 % CI: -1.07, -0.22)], TC [-0.64 mmol/L (95 % CI: -
1.04, -0.24)] and TG [-0.25 mmol/L (95 % CI: -0.48, -0.01)] was found, whereas no 
changes were observed in studies examining healthy populations (Figure 2.3). Given the 
differences in study designs, as expected, both meta-analyses on blood lipids showed 
significant heterogeneity (HDL-C: P = 0.04, I2 = 56 % and LDL-C: P<0.00001, I2 = 97 %). 
In the subgroup meta-analyses, while the heterogeneity disappeared in the healthy study 
population, it remained for the subgroup of studies examining individuals with metabolic 
syndrome and prescribed CVD related medication or with a past history of CVD events. 
Table 2.4 – Summary of findings for acute effects of flavanones on CVD risk markers 
 
Outcome Study 
Experimental 
intervention 
Mean 
effect
1 
[95 % CI] 
Endothelial function and NOx 
Microvascular reactivity (%) Morand et al. orange juice 
2 
105** [55, 155] 
  hesperidin supplement 
2 
48 [-1, 98] 
NOx (µmol/L) Morand et al. orange juice or 
supplement 
2 
No effect (data not 
reported) 
Bitter orange extract     
SBP (mm Hg) Min et al. bitter orange extract -1.0 [-6.9, 4.9] 
 Bui et al. bitter orange extract 7.3 [-1.7, 16.3] 
DBP (mm Hg) Bui et al. bitter orange extract 2.6 [-4.8, 10.0] 
Heart rate (bpm) Bui et al. bitter orange extract 4.2 [-4.6, 13.0] 
Abbreviations: CVD, cardiovascular disease; CI, confidence interval; NOx, nitric oxide 
metabolites; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
1
 difference between 
the mean in the experimental intervention and the mean in the control intervention; 
2 
both 
containing a matched dose of 292mg hesperidin 
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Figure 2.3 – Meta-analysis of flavanones and blood lipids 
 
Meta-analysis of short-term (3 to 8 wk) flavanone interventions and blood lipids in mmol/L: 1) high density lipoprotein cholesterol (HDL-C), 2) low density lipoprotein – 
cholesterol (LDL-C), 3) total cholesterol (TC) and 4) triglycerides (TG); study populations were sub-grouped as either individuals with established CVD/metabolic 
syndrome and prescribed medication (i.e. antidiabetic, antihypertensive, statin and/or antiplatelet) or healthy; Meta-analysis used the DerSimonian and Laird random 
effect model [174]. 
2) LDL-C1) HDL-C
3) TC 4) TG
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2.4.3 Secondary outcomes: vascular inflammation, metabolic 
biomarkers, venous insufficiency and bitter orange extract 
In two studies, short-term effects of flavanones on inflammatory and metabolic biomarkers 
were examined [59, 60] (Table 2.3). Morand et al., [59] found a decrease in sVCAM 
[−323ng/mL (95 % CI: −617, −29)] following the orange juice intervention, but not the 
flavanone supplement, and Rizza et al., [60] observed a decrease in high-sensitivity CRP 
[-0.7mg/L (95 % CI: -0.5, -0.9)]. However, neither of the studies observed a change in any 
of the other biomarkers measured including Interleukin-6, von Willebrand Factor, sICAM, 
glucose and insulin. 
Furthermore, one study suggested supplementation with hesperidin (100 mg/d) for 8 
weeks improved venous insufficiency [166] (Table 2.3). Following a single dose of bitter 
orange extract (containing an unknown dose of flavanones according to the manufacturer 
and 6 % synephrine), two studies did not observe a postprandial effect (i.e. 3-8 h after 
intake) on BP and heart rate in healthy individuals [178, 180] (Table 2.4). 
2.5 Discussion 
This is the first systematic review that focused on flavanone extracts, flavanone-rich foods 
and CVD risk markers. The systematic search identified 10 RCTs (n = 2 acute, n = 7 
short-term and n = 1 both) that examined potential effects of flavanones on a range of 
markers of CVD risk. While there were sufficient data (i.e. ≥3 studies and ≥50 participants 
per intervention group) for meta-analyses on blood lipids and to stratify between study 
participants, the available data regarding the effects of flavanones on BP, endothelial 
function and plasma NOx were insufficient to draw definite conclusions. Moreover, data 
were insufficient to determine how flavanone subclass, intervention duration, intervention 
dose and food matrix may influence the cardiovascular benefits of flavanones. 
Two studies to date, although with inconsistent findings, suggested that short-term (i.e. 3-
4 week) intake of hesperidin or orange juice may reduce DBP by -3.2 to -5.5 mm Hg, 
improve endothelial function and tended to increase plasma NOx concentrations [59, 60] 
(Table 2.3). Inconsistency in findings may be explained because Rizza et al., [60] studied 
participants with metabolic syndrome that were prescribed to CVD related medication, had 
a 3 weeks intervention duration with 500 mg/d hesperidin supplementation and used FMD 
to assess endothelial function, whereas Morand et al., [59] examined potential effects of 
292 mg/d hesperidin ingestion (as a supplement and within 500 ml orange juice) for 4 
weeks in overweight healthy men and measured microvascular reactivity to assess 
endothelial function. In addition, Morand et al., [59] examined the acute effects of a single 
dose of orange juice or a flavanone supplement (providing 292 mg hesperidin) and 
observed benefits on endothelial function at 6 h after intake, which were not supported by 
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increases in vascular NO production (i.e. as assessed by plasma concentration of NOx) 
(Table 2.4). 
Thus, further studies are warranted to provide scientific evidence on potential effects of 
flavanones on vascular markers of CVD risk. Future directions might include studies in 
healthy populations at mild to moderate CVD risk, interventions with longer study 
durations (> 4 weeks), investigations of potential food matrix effects (i.e. 
additive/synergistic effects with other bioactive compounds in citrus fruits including 
flavones, vitamin C, β-carotenes), different flavanone doses (i.e. to assess a dose-effect 
relationship), flavanone forms (e.g. naringin) and assessing unexplored markers of CVD 
risk such as central arterial stiffness [184], CV autonomic function [18] and vascular-
related biomarkers (e.g. nitrite [185], S-nitrosothiols [185], NADPH oxidase [132], 
endothelin-1 [135] and angiotensin II [5]). Furthermore, to elucidate the potential 
underlying mechanisms by which flavanones exert cardiovascular effects, acute RCTs are 
required in which cardiovascular bioactivity can be directly associated with achieved 
plasma flavanone metabolite concentrations. 
A greater number of studies (n = 6) have examined the effects of flavanones and citrus 
fruit on blood lipids. The conducted meta-analyses suggest that there is a small beneficial 
effect for individuals with elevated CVD risk (i.e. with metabolic syndrome and prescribed 
CVD related medication or with past history of CVD event), but not for healthy adults 
(Figure 2.3). However, these results should be interpreted with caution due to data 
heterogeneity and high risk of bias of the two studies of Gorinstein et al., [179, 181], 
specifically because they did not report whether their study population had similar blood 
lipid concentrations at baseline. 
Thus, there is sufficient evidence to conclude that flavanones do not improve the lipid 
profile in healthy individuals up to doses of 600 mg/d and durations of 8 weeks, yet in 
individuals with metabolic syndrome and patients with established CVD, further short-term 
studies (i.e. several weeks to months) with low risk of bias are required to verify reported 
lipid lowering effects. Whilst animal studies suggest flavanones do lower blood lipids 
through a decrease of fatty acid metabolism and an increase in hepatic lipid β-oxidation 
[165, 186], the underlying mechanism in human remains to be established. 
Overall, the observed beneficial CV effects of flavanones may be of clinical importance. 
Although improvements were moderate, if the effects are sustained in the long term, a 5 
mm Hg decrease in DBP may account for a 22 % and 41 % reduced risk of stroke and 
CHD, respectively [187], a 2.5 % increase in FMD has been suggested to decrease CVD 
risk by 20 % [188] and a 0.64 mmol/L lower plasma TC concentration has been 
associated with a 32 % reduced risk of CHD [189]. 
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Limitations of the few RCTs (n = 10) that have been performed to date include small 
numbers of participants, substantial differences in baseline values between the 
intervention groups. Only three studies adequately reported how risk of bias was 
minimised, and in two studies it was not clearly stated how data were reported (e.g. post 
intervention values, changes from baseline or mean differences between the experimental 
and control interventions). Furthermore, some outcome measures were assessed using 
different approaches, such as FMD and microvascular reactivity to assess endothelial 
function making it difficult to pool the effects. Given these various limitations, it might be 
that reported effects are overestimated. 
In summary, this systematic review outlines the findings from RCTs to date on flavanones 
and CVD risk markers. Having identified only 10 published RCTs, this systematic review 
illustrates that the area of flavanone research remains to be extended with further RCTs 
that address current limitations. However, the available limited data suggest that 
flavanones may decrease diastolic BP, improve endothelial function and blood lipid status, 
inhibit inflammation and reduce venous insufficiency. 
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Chapter 3. Acute flavanone randomised controlled 
trial in men at mild to moderate risk of CVD: study 
protocol and methods 
3.1 Rational for study design 
3.1.1 Rational for acute design, study population, intervention 
materials and dosage 
An acute study design was chosen to identify potential physiological and cellular 
mechanisms by which dietary flavanones exert potential cardioprotective effects, as this 
offers a number of advantages over a short-term intervention (i.e. several weeks). First, a 
beneficial change in CVD risk biomarkers can be related to actual presence of flavanone 
metabolites in plasma, thereby providing more evidence for a causal link between 
flavanones and improvements in markers of CVD risk. Second, given that each 
experimental period consists of only one day, potential confounders such as dietary and 
exercise restrictions can be strictly controlled making the study design more robust. Third, 
establishing potential acute beneficial effects of flavanones serves as an initial step to 
inform the design of future longitudinal studies (i.e. study population, flavanone dose and 
CVD risk biomarkers). Despite these advantages, it is acknowledged that acute studies 
provide little evidence for a potential CV health benefit of flavanones and short-term and 
chronic (i.e. weeks to years) flavanone RCTs are of fundamental importance to examine 
these potential benefits. 
Males at mild to moderate CVD risk, but otherwise healthy were chosen as the study 
population. In the UK, men are at a higher CVD risk than women [1], and early 
modification of dietary and lifestyle factors has been reported highly effective in primary 
prevention of CVD [190]. Thus, this population could particularly benefit from bioactive 
dietary compounds such as flavanones to reduce CVD progression. 
Flavanones in orange juice were used in this study as flavanones are a poorly studied 
subclass in respect to potential vascular effects in humans in vivo and orange juice is the 
main source of flavanones in the human diet [48]. As identified in the conducted 
systematic review (Chapter 2), there is limited evidence suggesting beneficial CV effects 
of dietary flavanones in humans [59, 60]. Orange juice from concentrate has been chosen 
as the dietary intervention product because oranges are a rich source of flavanones 
(mean ± SD flavanone content: 53 ± 6 mg/100ml of juice (n = 6); in-house analysis 
Appendix 1) and account for 82 % of total dietary flavanone intake [48]. Furthermore, with 
hesperidin and narirutin accounting for 80 % and 10 % of the total flavonoid content, 
respectively [100], orange juice from concentrate has a relatively simple flavanone profile 
and, therefore, a closely matched flavanone extract for the flavanone supplement 
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intervention was commercially available. The pharmacokinetics of flavanones from orange 
juice have been established in a number of studies [71, 72, 78, 107, 108], which provided 
necessary information for the design of this acute bioefficacy study. In particular, 
flavanones reach a peak plasma concentration between 4.4 and 6 h after intake of orange 
juice and flavanone bioavailability strongly correlates with soluble flavanone in orange 
juice [78], due to which the present study assessed markers of CVD risk at 5 h post 
intervention and selected an orange juice with a high amount of soluble flavanones. 
This study provided 320 mg hesperidin in the orange juice intervention and flavanone 
supplement intervention which was anticipated to attain a flavanone plasma concentration 
in the low micromolar range. This is a concentration that has previously been linked with 
beneficial effects on endothelial function in several acute interventions with flavanones 
[59], flavan-3-ols [191, 192] and isoflavones [193]. With a pint of orange juice from 
concentrate providing on average 300 mg hesperidin [100], the tested dose could also be 
achieved within a general UK diet. As orange juice flavanone content is variable [38], the 
orange juice required for this trial was bought from a single batch of orange juice, and the 
flavanone content was assessed in-house to determine the amount of orange juice 
providing 320 mg of hesperidin. 
3.1.2 Rational for selection of clinical measurements 
In this acute study, the effects of hesperidin on endothelial function, CV autonomic 
function and central arterial stiffness were assessed using non-invasive clinical 
measurements. Impaired endothelial function is considered to occur early in the stage of 
atherosclerosis and, therefore, endothelial function is a common outcome measure to 
assess the effects of dietary compounds [17, 194]. Whilst Morand et al., [59] reported an 
acute improvement in microvasculature endothelial function after intake of flavanones, this 
acute study examined endothelial function in the digital artery using a validated method 
[124, 125, 195]. 
To the author’s knowledge, assessment of potential acute effects of dietary flavanones on 
arterial stiffness and autonomic function were novel in the field of dietary flavanones and 
CVD risk markers. Both measures have been suggested as independent predictors of 
CVD risk and development of hypertension [18, 184], and were assessed using validated 
methods [154, 196]. 
3.1.3 Rational for selection of CV biomarkers to assess vascular NO 
production, NADPH oxidase and platelet function 
NO has a half-life of a few seconds in blood and, therefore, its more stable metabolites 
(i.e. nitrate, nitrite and nitroso species) are commonly measured to estimate the amount of 
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NO produced by the vasculature [197]. In this study, plasma nitrite concentrations were 
chosen as the biomarker of vascular NO production because it is a more accurate 
indicator than plasma total NO metabolite concentration [64, 198] and based on the 
methodology optimised in this laboratory, nitrite concentrations could be quantified with 
greater reproducibility than nitroso species, another sensitive biomarker of vascular NO 
production [65]. 
A few methods are available to assess NADPH oxidase in humans in vivo, these include 
its genetic expression through quantification of serum soluble gp91phox by ELISA [199], and 
its activity in neutrophils using flow cytometry [200]. In the present study, assessment of 
serum soluble gp91phox was performed because it allowed time-efficient batch analysis of 
frozen samples. 
Platelet function can be assessed using a range of methodologies including platelet 
aggregation in platelet rich plasma (the historic gold standard), automated platelet function 
analysis or quantification of activation-dependent platelet surface proteins (i.e. P-selectin 
and activated gpIIb/IIIa (i.e. fibrinogen receptor) (Figure 5.1); using whole blood platelet 
activation flow cytometry) [162, 201]. The latter method was chosen because it is a whole 
blood based assay (i.e. potentially less artefactual variability than assays in platelet rich 
plasma) and has been proven as a sensitive method for the monitoring of antiplatelet 
agents [162] and dietary compounds such as flavan-3-ols [202]. Furthermore, the chosen 
method allowed simultaneous assessment of distinct platelet activation pathways [162]. 
As proposed by animal and in vitro research [73, 74], collagen and arachidonic acid 
mediated platelet activation may be most potently inhibited by flavanones followed by 
ADP and thrombin. For the present study, a method was successfully optimised to assess 
potential inhibitory effects of flavanones on the ADP and the collagen activation pathways, 
but not for the arachidonic acid pathway (Section 1.7.4), possibly because it would have 
required samples to be at 37 °C [203]. 
3.2 Participants and methods 
3.2.1 Study population 
16 healthy men aged 50 - 75 years with an estimated absolute 10 year CVD risk of 10 - 20 
% (British Hypertension Society (BHS) risk calculator [204]; assessed at screening) were 
recruited locally through advertisement and collaboration with GP practices. Study 
exclusion criteria were: smoking (within the last 3 months), past history or existing medical 
condition likely to affect study outcome measures (i.e. CV, hepatic, renal, digestive, 
haematological, neurological thyroidal disease, diabetes or cancer), use of lipid lowering 
(i.e. statins), antihypertensive or vasodilator medication, resting SBP / DBP > 160 / 95 mm 
Hg, use of antibiotics and flu vaccination ≤ 3 months before and during study participation, 
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intake of flavonoid containing dietary supplements ≤ 1 month before and during study 
participation. Prescription to antiplatelet medication was not part of the protocol’s 
exclusion criteria, but medication intake was recorded and, for consistency, participants 
who had a prescription were asked to maintain their antiplatelet medication intake during 
study participation. Specifically, participants had no gastrointestinal disease and were not 
on antibiotics or had vaccinations (for 3 months prior and during study participation), both 
of which are factors that could affect the gut microflora and, in turn, flavanone metabolism 
and absorption [205, 206]. 
The study, which not only consisted of the herein described flavanone trial, but also an 
isoflavone and anthocyanin trial, was approved by the East of England Research Ethic 
Committee Norwich (ref 11/EE/0233) and the Norwich & Norfolk University Hospital 
Research & Development [ref 2011DIET01S (66-05-11)], followed the principles declared 
in the Declaration of Helsinki Revised Version (2008) and was registered at 
clinicaltrials.gov (registration no: NCT01530893). Prior to study commencement, written 
informed consent was obtained from each participant and all subsequent screening visits 
and experimental periods were performed at the Clinical Research and Trial Unit at the 
University of East Anglia. 
3.2.2 Dietary intervention products 
6 orange juices were sourced from 5 local commercial suppliers (i.e. Aldi, Brakes, 
Cooperative, Tesco and Waitrose) and from the Florida Department of Citrus (FDOC; 
Lake Alfred, Florida) with the latter being an orange juice previously used in flavanone 
intervention studies [59]. Flavanone extract was provided by Monteloeder (Alicante, 
Spain) and carboxymethyl-cellulose (CMC) by Dow Wolff Cellulosics (Bitterfeld, 
Germany). White opaque gelatine capsules were purchased from Fragon (Minneapolis, 
Minnesota), and vitamin C (i.e. L-ascorbic acid), fructose, glucose, sucrose and 
nitrate/nitrite free Buxton bottled water from commercial shops. 
Hesperidin, narirutin and vitamin C were quantified in the 6 orange juices and the 
flavanone extract using an in-house developed HPLC method (Method and Results in 
Appendix 1). Amongst the 6 orange juices, the FDOC orange juice was selected because 
it had the highest content of soluble hesperidin (i.e. 23 %), which has been reported an 
important factor influencing flavanone bioavailability [78]. To provide a hesperidin dose of 
320 mg, 767 mL (≈3 servings [207]) of FDOC orange juice were required, and 
subsequently the hesperidin-matched flavanone extract and the control interventions were 
matched to the orange juice in terms of vitamin C, sugars and amount of liquid consumed 
(Table 3.1). Additionally for the flavanone extract intervention, capsules were filled with 
flavanone extract containing 320 mg hesperidin. All required supplements and sugar 
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sachets were prepared in an analytical kitchen using calibrated analytical scales, whereby 
two researchers verified that amounts were accurately weighted out. 
A single batch of products was used throughout the study, and potential degradation of 
the study intervention products was minimised by use of monitored storage conditions. 
FDOC concentrate was stored at -20 °C, and compound capsules and sugar sachets 
were held within a temperature monitored pharmacy room. 
After study completion, content and solubility of flavanones and vitamin C were 
reanalysed in the orange juice to verify potential changes during storage at -20 °C over 
several months (Appendix 1, Table 2). There was no flavanone degradation with even a 
marginal increase in hesperidin content and in narirutin solubility, which may be due to 
variability between the different tins of orange juice concentrate. On the other hand, 
vitamin C levels in the orange juice were reduced from 57.3 mg/100 mL pre-study to 
46.7mg/100ml post-study (P<0.01; Appendix 1, Table 2). 
Table 3.1 – Composition of the dietary interventions 
 
 Dietary intervention 
 
Orange juice Supplement Control 
Drink volume (mL) 767 767 767 
Supplements (#) CMC (2) 
Flavanone (1) 
vitamin C (1) 
vitamin C (1) 
CMC (1) 
Sugar
1
 (g) 68 68 68 
Hesperidin
2
 (mg) 320 320 0 
Narirutin
2
, (mg) 48 16 0 
Vitamin C
2
, (mg) 439 439 439 
Sinapic acid
3
 (mg) 6 ND ND 
Caffeic acid
3
 (mg) 3 ND ND 
Ferulic acid
3
 (mg) 27 ND ND 
Courmaric acid
3
 (mg) 11 ND ND 
1 
Matched sugar composition based on data provided by the Florida 
department of citrus: 16.6 g glucose, 18.0 g fructose and 33.4 g sucrose. 
2 
quantified in-house using HPLC. 
3 
based on reported mean contents in 
orange juice [208]. Abbreviations: CMC, carboxymethyl-cellulose;
 
ND, not 
determined. 
This study aimed to compare potential beneficial CV effects when 320 mg hesperetin are 
ingested in orange juice or as a dose matched supplement (Table 3.1). Even though the 
flavanone extract consisted of 80 % flavanones [as assessed in-house pre- and post-
study using HPLC (Appendix 1)], plasma concentrations of flavanone phase II metabolites 
were not elevated 5 h after the flavanone extract intervention relative to the control 
intervention [mean ± SD: 60 ± 96 nM and 18 ± 6 nM, respectively; P = 0.87; (method 
described in Chapter 5)]. These achieved plasma flavanone concentrations were 
considerably lower than anticipated and levels below 100 nM may not be physiologically 
important. Thus, the CVD risk marker data of the flavanone extract intervention were 
considered unreliable to assess potential beneficial CV effects of flavanones  
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3.2.3 Study design 
To test potential acute effects of orange juice providing 320 mg hesperidin and 48 mg 
narirutin on biomarkers of CVD risk, a carefully controlled single-blinded crossover RCT in 
16 men was conducted. On three experimental periods (≥ 1 week apart), participants 
underwent CV measurements and received three dietary interventions (in random order): 
1) orange juice, 2) a sugar, energy and vitamin C matched flavanone extract and 3) sugar, 
energy and vitamin C matched control, whereby independent scientists allocated 
participants to computer-generated random intervention sequences. 
Participants were asked to follow a range of lifestyle restrictions to minimise variability 
between experimental periods (Figure 3.1). For 4 weeks prior to, and during the entire 
study, participants abstained from dietary supplements containing flavonoids and 
maintained their intake of non-flavonoid containing dietary supplements. For 3 days before 
each experimental period, participants followed a diet low in 4 flavonoid subclasses (i.e. 
flavanones, flavan-3-ols, anthocyanins and isoflavones) and other bioactive foods (i.e. oily 
fish, nuts and garlic). Participants received a table with foods that were classified as “to 
avoid”, “to restrict” and “alternatives” based on a consensus made by the study team 
using information from the phenol-explorer [100, 209] and USDA databases [210] and a 
previous study in the department [211] (Appendix 2). To note, despite a fair amount of 
flavan-3-ols in tea, due to the habitual intake in the present study population, participants 
were only asked to refrain from tea intake for 1 day prior to each experimental period. 
Prior to each experimental period, participants also refrained from strenuous exercise (for 
48 h) and avoided foods containing alcohol, caffeine and nitrate/nitrite (for 24 h). In 
addition, on the night before each experimental period, participants consumed a low-
flavonoid standardised ready meal (i.e. a bread roll with either a beef lasagne or sundried 
tomato pasta; kept consistent for each participant) providing sufficient volume for the 
population group studied. The low levels of flavonoids present in these meals originated 
from tomatoes, estimated to contain less than 1 mg flavonoids/meal [100], and small 
quantities of onion, red wine and oregano. Thus, no interacting effects on the study 
outcome were anticipated from consumption of this standardised ready meal after which 
participants fasted for at least 10 h prior to arrival at the Clinical Research and Trial Unit. 
Compliance to lifestyle restrictions, occurrence of adverse events and intake of medication 
were checked at each experimental period using questionnaires. To estimate participants’ 
habitual energy intake, 24 h food recall data were collected on the 3rd or 2nd day before 
each visit (method described in Section 3.2.9). 
As described in further detail hereafter, each experimental period started with 
anthropometric measurements, collection of baseline CV measurement data and a blood 
sample, followed by intake of the dietary intervention and collection of the CV 
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measurement data and a blood sample at 5 h post intervention (Figure 3.1) (5 h being the 
anticipated timepoint of maximal flavanone absorbance [71]). Between the dietary 
intervention and the post intervention CV measurements, participants were allowed to 
leave the research facility. 
Factors potentially influencing the study outcome were standardised where possible. Each 
experimental period started between 0730 and 0830 to minimise circadian variability. CV 
measurements were performed following in-house developed standard operating 
procedures (SOPs) and conditions of participants and clinical rooms were controlled. 
Clinical rooms were kept quiet, lighted-subdued and at ambient temperature (22-24°C), 
participants were asked to micturate and attend a ≥ 15 min supine rest before start of the 
CV measurements and remained supine during the measurements. Furthermore, before 
assessments of CV autonomic function and endothelial function involving finger BP 
measurements, finger temperature was monitored and where necessary participants’ 
hands were warmed with blankets. Following a standardised sequence, CV 
measurements consisted of brachial BP, CV autonomic function, central arterial stiffness 
and digital endothelial function, and were always performed on the same body side of the 
participant. On the contralateral side and embedded in the sequence of CV 
measurements, blood samples were collected and immediately processed and stored at -
80 °C unless stated otherwise (Figure 3.1). To ensure blinding and allocation concealment 
of the dietary intervention, study drinks were freshly prepared in opaque bottles by 
independent scientists, and together with the supplements were administered by the 
research nurses who were not involved in data collection and analysis (Figure 3.1). 
Furthermore, the research nurses verified that within 15 min, participants consumed the 
dietary intervention (i.e. both supplements and the entire study drink which included 
rinsing the opaque bottle twice with nitrate/nitrite free water). 
Throughout the experimental period, participants’ diet was controlled. In addition to the 
dietary intervention, participants ate 2 cheese sandwiches and 1 light yoghurt (containing 
660 kcal, 31.1 g protein, 95.6 g carbohydrate and 26.8 g fat) consistently 1.5 h after the 
dietary intervention. Moreover, participants were allowed to drink nitrate/nitrite free water 
ad libitum and a light meal was provided at the end of the visit. 
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Figure 3.1 – Overview of the experimental periods: preparations, schedule, and dietary interventions 
 
1
given in random order. 
2
 consisted of 2 cheese sandwiches and a vanilla yoghurt. Abbreviations: NEM, N-ethylmaleimide, DTPA, diethylenetriaminepentaacetic acid; 
NADPH, nicotinamide adenine dinucleotide phosphate; NSAID, non-steroidal anti-inflammatory drugs 
Standard meal
0 h
Anthropometric measurements
1.5 h
Cardiovascular measurements
and blood collection
Cardiovascular measurements
and blood collection
Preparations:
• ≥ 1 week wash-out between visits
• 3 days low flavonoid diet
• 2 days exercise restrictions
• 1 day alcohol, caffeine and nitrate/nitrite 
restrictions
• Standardised evening meal
• Only water and study meals 10 h prior and 
during the experimental period
24 h food recall
Adverse event and medication check
5 h
Orange juice, supplement or control intervention
Supine rest (15 min)
Blood pressure
(10 min)
Autonomic function 
(25 min)
Blood collection *
(10  min)
Arterial stiffness 
(15 min)
Endothelial function
(25 min)
* Blood processing:
Plasma for nitrite analysis:
• Immediate centrifugation (4500g, 3min) of heparinised blood
• Isolation and preservation of plasma with NEM and DTPA
• Immediate freezing on dry ice
• -80 C storage in light protected tube until analysis
Serum for analysis of NADPH oxidase expression:
• Ensured blood clotting time of 30-60min at room temperature
• Serum isolation and storage at -80 C until analysis
Platelet activation whole blood flow cytometry:
• Collection and processing of sodium citrated blood with careful 
handling to avoid artefactual activation
• Record of NSAID or aspirin intake within last 10 days
• Incubation of fresh whole blood with platelet agonists, fluorochrome
labelled antibodies and formalin fixation
• Flow cytometric analysis on same day
Plasma for flavanone metabolite analysis:
• Heparin vacutainer stored on ice and plasma isolation within 2 h
• Acidification with ascorbate (1mM end concentration)
• Storage at -80 C until analysis
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3.2.4 Anthropometric measurements 
Participants (wearing no shoes and light clothing) had their height (in m) and weight (in 
kg) measured (in duplicate) using calibrated and levelled stadiometer and scale, 
respectively. During each measurement, participants were standing in an upright position 
and the head was positioned in the Frankfurt plane for the height measurement. The body 
mass index (BMI) was calculated from the mean height and weight using the equation: 
weight/height2. 
3.2.5 Oscillometric blood pressure 
Brachial BP measurements were performed using a calibrated and BHS validated Omron 
705IT (Omron Healthcare Co., Kyoto, Japan) with appropriate sized cuffs (medium 22-32 
cm or large 32-42 cm). The BP cuff was placed 2 cm above the antecubital fossa and 
snug with only one finger fitting between the cuff and the arm. 3 measurements were 
taken 3 min apart from each other and the average SBP, DBP and heart rate was 
calculated from the last two readings. Further readings were taken if the variation was > 
10 %. 
3.2.6 Assessment of autonomic function using beat-to-beat blood 
pressure and pulse interval 
Equipment. For CV autonomic function testing, a Portapres unit (TNO Biomedical 
Instrumentation, Amsterdam, Netherlands) was used which was equipped with a height 
correction unit, finger BP cuffs (sizes: small, medium and large), a USB-serial and port 
cable laptop connection and Beatscope software. Further equipment included a 
sphygmomanometer device, 20 mL BD plastic syringes and a hand thermometer. 
Data acquisition. A finger BP cuff of appropriate size (i.e. inflatable part not overlapping) 
was placed snug on the middle finger centred over the proximal phalanges. The height 
correction unit was nulled and placed with one sensor on the finger cuff and one at heart 
level. In Beatport of the Beatscope software and in the Portapres control unit, gender, 
age, anthropometric and BP values of the participant were entered. 
To ensure good quality recordings of continuous finger arterial BP data, prior to data 
acquisition, the participant’s finger temperature was monitored and acclimatised if < 28 
°C. Furthermore, the Portapres has a built-in calibration system (Physio-Cal) that 
calibrates the BP recording every 10-70 beats (time between calibrations increases when 
recording quality improves). Hence, a ≥ 5 min run-in recording period was held to allow 
stabilisation of the BP signal and ensure a Physio-Cal rate exceeding 30 beats. During the 
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CV autonomic function measurements, Physio-Cal was turned off to provide uninterrupted 
recordings, whilst calibration was repeated in-between measurements. 
CV autonomic function was assessed through measurements of spontaneous baroreflex 
sensitivity (BRS) [212] and the Valsalva manoeuvre (i.e. a standard clinical test of 
autonomic function) [213]. Data for spontaneous BRS were recorded for 12 min while 
participants were at rest, quiet and with minimal movement. For the Valsalva manoeuvre, 
participants blew into a 20 mL syringe connected to a sphygmomanometer to achieve a 
pressure of 40 mm Hg for 15 seconds after which they rested quietly and with minimal 
movement for 45 sec. The Valsalva manoeuvres were performed three times with 1 min 
rest between assessments. 
Data analysis. From the original finger BP data, sampled at 100 Hz, beat-to-beat SBP 
(i.e. BP maximum) and pulse interval (PI; i.e. time interval between two BP maxima) data 
were automatically extracted by the Beatscope software (Appendix 3, Figure 1). 
Subsequently, markers of autonomic function were derived, including BRS in the 
frequency and time domain and the Valsalva ratio. 
BRS in the frequency domain was calculated through power spectral analysis as 
described in the literature [214, 215] and using MATLAB with the Signal Processing 
Toolbox (Release 2013a, The MathWorks, Inc., Massachusetts, USA). 12 min resting 
SBP and PI signals were visually inspected and spikes such as ectopic beats or 
movement artefacts were manually removed using linear interpolation, and recordings 
with more than 2 % ectopic beats were rejected from further analysis (Appendix 3, Figure 
2). Linear trends were removed and the signals were subtracted from their mean. To 
produce a uniform time axis, SBP and PI signals were resampled at a frequency of 2 Hz. 
The power spectra were then estimated using Welch’s method with sections of 1024 
samples multiplied by a Hanning window and 75 % overlap between sections. Obtained 
power spectra were smoothed using a 13 point triangular window, and powers of SBP and 
PI in the low frequency band (i.e. 0.05 to 0.15 Hz) were calculated through numerical 
integration. BRS was obtained by calculation of the α-index (αBRS; square root of the 
ratio of the powers of PI and SBP in the low frequency band) (Appendix 3, Figure 2). 
BRS in the time domain was automatically calculated from the 12 min resting beat-to-beat 
SBP and PI data using a cross-correlation BRS (xBRS) algorithm written by Westerhof et 
al., [216] and provided within a software package by the manufacturer (TNO Biomedical 
Instrumentation, Amsterdam, Netherlands). Briefly, whilst artefacts were automatically 
excluded, signals were resampled at 1 Hz intervals and the cross-correlation between 
SBP and PI were fitted over 10 seconds sliding windows and with a delay in PI of 0 to 5 
seconds (Appendix 3, Figure 3). Using the delay that gives the highest cross-correlation 
coefficient and if the cross-correlation reaches significance at P < 0.01, the corresponding 
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regression slope was accepted as an xBRS estimate. Because of log-normal distribution, 
the xBRS data were reported as the geometric average of xBRS estimates collected over 
the 12 min. 
Average HR variability during the 3 Valsalva manoeuvres was analysed by taking the ratio 
of the minimal HR over the maximal HR (i.e. Valsalva ratio), whilst ectopic beats were 
manually excluded. 
3.2.7 Assessment of endothelial function using peripheral arterial 
tonometry in the digital artery 
Equipment. The EndoPAT equipment (Endo-PAT2000, Itamar Medical, Caesarea, Israel; 
using software version 3.4.4) comprised a main unit, a pneumatic plethysmograph, 
connected via pneumo-electric tubes to two finger probes consisting of inflatable latex 
aircushions surrounded by rigid external cases. Further equipment included a 
sphygmomanometer with a BP cuff, two arm supports, foam anchors, medical tape and a 
thermometer probe. 
Data acquisition and analysis. Endothelial function was measured in the digital artery as 
the increase in peripheral arterial tonometry during reactive hyperaemia (PAT-RH). 
Participants rested both hands comfortably on the arm supports. The EndoPAT finger 
probes were placed on both index fingers, with the pneumo-electric tubes attached to the 
participants’ index fingers and the finger probes not touching anything (ensured through 
the use of the arm supports, medical tape and foam anchors). The BP cuff of the 
sphygmomanometer was placed snug on the upper arm (side of CV measures), while the 
measurement in the contralateral side served as a control. 
To ensure good quality recordings, prior to data acquisition, participants’ finger 
temperature was monitored and acclimatised with blankets if < 28 °C. Throughout the 15 
min total recording, participants were asked to keep still and quiet; in particular, not 
moving the finger probes. Following the first 5 min of baseline recording (Figure 3.2; 
Baseline period), the BP cuff was inflated for 5 min to 200 mm Hg or systolic BP plus 
60mm Hg (whichever was higher) to stop arterial blood flow (Figure 3.2; Occlusion). If the 
signal did not indicate a complete stop of arterial blood flow, the pressure was further 
increased step-wise up to 300mm Hg as necessary. Subsequently, recordings continued 
for an additional 5 min after deflation of the BP cuff to measure occlusion-induced reactive 
hyperaemia (Figure 3.2; Test period). The PAT-RH index indicating digital artery 
endothelial function was automatically calculated by the software as the ratio of average 
finger pulse volume amplitude post occlusion (i.e. 1 min interval starting 1.5 min after cuff 
deflation) to baseline (i.e. 3.5 min interval before cuff inflation) and corrected for systemic 
changes recorded in the control arm (Figure 3.2). 
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Figure 3.2 – Recording peripheral arterial tonometry during reactive hyperaemia 
 
Figure adapted from [217]; PAT-RH, peripheral arterial tonometry-reactive hyperaemia index 
3.2.8 Assessment of central arterial stiffness 
Equipment. The Vicorder equipment (Skidmore Medical, Bristol, UK) consisted of the 
main device, two pneumatic tubes, a BP cuff for the neck and a medium-size BP cuff. The 
main device was connected via a USB cable to a laptop on which Vicorder software 
version 3.1 was installed. 
Data acquisition. Central arterial stiffness, an established independent marker of CVD 
risk [184, 218], was assessed by carotid to femoral pulse wave velocity (cfPWV) and the 
central augmentation index (cAIx). 
For cfPWV, participants had the upper body inclined by 15 and a pillow placed centred 
under the thoracic spine so that the head leaned backwards freeing up the carotid artery 
along the neck. This position ensured good quality recordings of carotid pulse wave 
traces. The neck cuff was placed snug with its inflatable part over the carotid artery and 
the medium-sized BP cuff was placed snug on the proximal side of the thigh. The path 
length was obtained by taking the average of two tape measurements between the carotid 
cuff and the thigh cuff (mid-points of the cuffs) to the nearest cm. In the Vicorder software, 
path length and participants’ BP were entered and a time-window of 7 seconds was 
selected, which captures cfPWV variation over an average breath cycle. During the 
measurements, participants were asked to avoid swallowing, stay still and quiet. Using the 
Vicorder’s digital oscillometric technique, at least three reproducible carotid and femoral 
pulse wave traces were recorded. The software automatically calculated cfPWV using the 
transit time between the upstrokes of carotid and femoral pulse wave traces and the path 
length (Figure 3.3A), whilst operators verified quality and reproducibility of three 
Test/baseline ratio of tested arm Test/baseline ratio of control arm
Control 
arm
Occluded
arm
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recordings in real time [i.e. ensuring < 10 % cfPWV variation and > 6 beat counts (i.e. 
internal quality control)]. 
Figure 3.3 – Carotid to femoral pulse wave velocity and pulse wave reflection 
 
A: Typical carotid and femoral pulse wave traces used for the assessment of carotid to 
femoral pulse wave velocity (i.e. Δ L / Δ t). (figure adapted from [184]) 
B: Typical central pulse wave traces in young and old participants used for the 
assessment of central augmentation index (i.e. ΔP / PP); note the prominent second 
systolic peak in the old participant (*). (figure adapted from [219]) 
Abbreviations: Δ t; transition time; Δ L, path length; ΔP, augmentation pressure; PP, 
pulse pressure 
For cAIx, the medium-size BP cuff was placed snug over the upper arm and 2 cm above 
the antecubital fossa. Participants were asked to stay still and quiet during recordings of 
brachial pulse wave traces. Central pulse wave traces were transferred from these 
brachial recordings by the software and the cAIx calculated as the central augmentation 
pressure relative to the central pulse pressure (Figure 3.3B). Three measurements were 
taken with good quality and reproducibility (i.e. < 10 % cAIx variation and > 6 beats) as 
assessed in real time by the operator. Because of strong correlation with heart rate, the 
cAIx was additionally reported at a normalised heart rate of 75 bpm [220]. 
3.2.9 Estimation of participant’s energy intake using 24 h recall 
One or two days before each experimental period, participants’ dietary intakes were 
estimated using a standard 24 h food recall questionnaire. Participants were asked to 
A
B
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estimate portion sizes using household measures and provide details on the brand names 
of consumed products. Using published food portion size data [207] and the food 
composition database Weighted Intake Software Package (WISP; version 4; Tinuviel 
Software, Anglesey, United Kingdom), mean daily energy intakes were estimated. 
3.2.10 Analysis of plasma nitrite using reductive gas-phase 
chemiluminescence 
3.2.10.1 Equipment and chemicals 
Materials. The chemiluminescence detector 88 (CLD88) was purchased from Eco 
Physics (Duernten, Switzerland) and included a purge vessel system for liquid sample 
analysis, a nitrogen gas cylinder, a pressure regulator (operating in the mbar range), a 
110 ml/min sampling probe, and Chart software (EDAQ, Dublin, Ireland). Two recirculating 
heating and chilling water baths were obtained from Grant Instruments (Shepreth, UK), 
100 μL Hamilton syringes, human male serum, sodium nitrite, potassium iodide, iodine, N-
ethylmaleimide (NEM), sulfanilamide and diethylenetriaminepentaacetic acid (DTPA) from 
Sigma Aldrich (Dorset, UK). Light protected amber tubes were purchased from Fisher 
Scientific (Loughborough, UK), lint free wipes from Distinctive Medical (Cheshire, UK) and 
2 mL heparin vacutainers and 20 mL plastic syringes from Bunzl Healthcare (London, 
UK). Acetic acid glacial, hydrochloric acid, sodium hydroxide and acetone were from the 
communal lab supply. To avoid potential nitrite contamination, fresh MilliQ grade water 
(18.2 MΩcm-1) was used and all glassware was washed. No nitrite contamination was 
detectable in plasticware and heparin vacutainers. 
3.2.10.2 Method 
Blood processing. Due to an 11 minute half-life of nitrite in blood [221], 2 mL freshly 
collected heparinised blood was immediately processed and nitrite preserved following the 
procedure described by Nagababu et al., [222]. Briefly, blood was centrifuged for 3 min at 
4500 g and room temperature, plasma was isolated and aliquoted into labelled light 
protected amber tubes containing NEM and DTPA (final concentrations: 6.5 mM and 0.1 
mM, respectively; NEM prepared fresh every day). Samples were vortexed for 5 seconds, 
immediately frozen on dry ice and stored at -80 °C until analysis. 
Plasma nitrite analysis. Plasma nitrite was quantified using reductive gas-phase ozone-
based chemiluminescence as previously described by Feelisch et al., [223]. Briefly, 100 
μL of plasma samples (in triplicate, one freeze thaw cycle and freshly thawed on ice) were 
injected into a purge vessel containing an iodide/triiodide reaction mixture (kept at 60 °C), 
which selectively reduces nitrite and nitroso species to gaseous NO. The NO was then 
transported by nitrogen via a condenser and sodium hydroxide trap (both kept at 0 °C) to 
the chemiluminescence detector. There, NO undergoes a light-emitting reaction with 
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ozone which is detected by a photomultiplier and recorded (Figure 3.4). Nitroso species 
were selectively quantified through pretreatment of plasma with acidified sulfanilamide 
(i.e. a chemical which prevents reduction of nitrite); however, using the in-house method 
optimised in this laboratory, sulfanilamide treated samples created a signal below the limit 
of detection. Hence, the signal obtained from injection of sulfanilamide-free samples was 
interpreted as originating predominantly from nitrite. To avoid cross-contamination 
between injections, syringes were carefully cleaned with MilliQ and acetone and dried 
using lint free wipes. Quantification of plasma nitrite was based on a six point standard 
curve of freshly prepared standards (concentration range: 0 to 200 nM) and a quality 
control (i.e. commercially available serum) was injected regularly. Intra-assay and inter-
assay %CV were 4.2 % and 3.3 %, respectively. 
Figure 3.4 – Raw NO signals recorded following injection of nitrite standards or plasma 
 
3.2.11 Assessment of NADPH oxidase gene expression 
Serum samples were sent to Professor Violi’s group (Rome, Italy) for quantification of 
serum soluble gp91phox, a subunit of NADPH oxidase, using their developed and validated 
ELISA method [199]. Briefly, samples were analysed in duplicate (1 freeze/thaw cycle), 
and the assay involved the use of anti-gp91phox (Santa Cruz Biotech, Santa Cruz, US) 
coated plates and spectrophotometric quantification against standard curves of gp91phox 
peptide (New England Peptide, Gardner, US). The assay’s intra- and inter-day %CV were 
5.8 % and 6.7 %, respectively. 
3.2.12 Platelet activation whole blood flow cytometry 
The following platelet activation whole blood flowcytometry method was based on the 
protocol published by Krueger et al., [224]. 
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3.2.12.1 Materials 
The fluorophore-conjugated monoclonal antibodies anti-human CD61-allophycocyanin 
(APC), anti-human CD62P-phycoerythrin (PE) and Isotype Control Mouse IgG1 PE were 
purchased from eBioscience (San Diego, USA), and anti-human PAC-1-fluorescein 
isothiocyanate (FITC), Isotype Control Mouse IgM, κ FITC, compensation beads, staining 
buffer and sodium citrate vacutainers from BD bioscience (San Jose, USA). The platelet 
agonists ADP, crosslinked CRP and phorbol 12-myristate 13-acetate (PMA) were 
obtained from Alpha Laboratories (Hampshire, UK), the Biochemistry Department of the 
University of Cambridge (Cambridge, UK) and Sigma Aldrich (Dorset, UK), respectively. 
Megamix calibration beads were purchased from Biocytex (Marseille, France), 
paraformaldehyde from Fisher Scientific (Loughborough, UK) and minisart CA 0.2 μm 
sterile CA syringe filters from Sartorius Stedim (Surrey, UK). Modified HEPES/Tyrode’s 
(HT) buffer solutions and 1 % formalin fixation solution were prepared in-house and 
syringe filtered. 
Fluorophore-conjugated monoclonal antibodies, platelet agonists and buffers were from a 
single batch, prepared and stored following instructions of the manufacturer and Krueger 
et al., [224]. Prior to study commencement, individual antibodies were mixed together in 
the right proportion to a mastermix (Table 3.2), batch aliquoted out into 1.5 ml 
polypropylene Eppendorf test tubes and stored in the dark at 4 °C. Due to potential 
photobleaching, antibodies were kept in the dark during storage and incubation periods. 
To minimise ex vivo platelet activation, all reagents were acclimatised to room 
temperature before usage. 
3.2.12.2 Method 
Blood collection. To minimise ex vivo platelet activation, a 21-G needle was used, the 
first 18 ml of blood was collected for purposes other than platelet activation, and the 
tourniquet was removed prior to collection of blood in a sodium citrate vacutainer 
dedicated for platelet activation analysis. Whole blood was mixed with the sodium citrate 
anticoagulant by gentle inversion of the vacutainer for 3 times and kept at room 
temperature until analysis. 
Test sample preparation. Within 30 min after the blood collection, working solutions of 
platelet agonists (i.e. 5 μg/mL CRP, 10 μM ADP or 10 μM PMA) were prepared fresh, and 
whole blood was diluted 1:10 and mixed by gentle pipetting. 2 control samples were 
prepared to test proper functioning of the assay and 3 test samples were prepared (i.e. 
non-activated, ADP activated and CRP activated) for each timepoint (i.e. baseline and 5 
h). Platelet agonists, HT buffer and diluted whole blood were added to each test tube and 
mixed by gentle tapping (Table 3.2). Final concentrations of antibodies and platelet 
agonists were previously optimised in-house through performance of titration experiments 
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[[225]; Section 5.1.4] ensuring saturation of CD62p-PE and PAC1-FITC binding, 
submaximal ADP and CRP induced ex vivo platelet activation and maximal PMA induced 
ex vivo platelet activation. Following 20 min incubation at room temperature, samples 
were fixed with 400 μL filtered 1 % formalin, incubated for 15 min at room temperature 
and subsequently stored at 4°C until analysis on the flow cytometer. 
Table 3.2 – Platelet activation: sample preparation 
 
 Test samples  Control samples 
 Non-activated ADP activated CRP activated  Isotype PMA 
Antibody 
mastermix 
1 μL CD61-APC 
2.5 μL CD62p-PE, 
10 μL PAC1-FITC 
1 μL CD61-APC 
2.5 μL CD62p-PE, 
10 μL PAC1-FITC 
1 μL CD61-APC, 
2.5 μL CD62p-PE, 
10 μL PAC1-FITC 
 1 μL CD61-APC 
0.6 μL iso-PE, 
0.5 μL iso-FITC 
1 μL CD61-APC 
2.5 μL CD62p-PE, 
10 μL PAC1-FITC 
Agonist (end 
concentration) 
n/a 2.5 μL ADP WS 
(1 μM) 
2μL CRP WS 
(0.4μg/mL)
 3
 
 n/a 2.5 μL PMA WS 
(1 μM) 
HT buffer 6.5 μL 4 μL 6.5 μL  17.9 μL 4 μL 
dWB
 
5 µL 5 µL 5 µL  5 µL 5 µL 
Abbreviations: CD61-APC, anti-human integrin β3 antibody conjugated to allophycocyanin fluorophore; CD62p-
PE, anti-human P-selectin antibody conjugated to phycoerythrin fluorophore; PAC1-FITC, anti-human activated 
fibrinogen receptor antibody conjugated to fluorescein isothiocyanate fluorophore; WS, working solution; CRP, 
collagen related peptide (WS: 10μg/mL); ADP, adenosine diphosphate (WS: 10 μM); PMA, 10 μM phorbol 12-
myristate 13-acetate (WS: 10 μM); dWB, diluted whole blood; HT buffer, HEPES/Tyrode’s buffer; 
Flow cytometry data acquisition. Flow cytometry analysis was performed using a BD 
Accuri C6 flow cytometer and CFlow software (Becton Dickinson, NJ USA). Samples were 
run on the same day of test sample preparation and the time from sample fixation to data 
acquisition was kept consistent. 10’000 platelet events were collected in each test sample 
using a 14 μL/min flow rate and a 20’000 FSC-H threshold. Platelet events were identified 
based on light scatter (Figure 3.5 A) and presence of integrin β3 (i.e. protein expressed on 
resting and activated platelets; detected through CD61-APC binding) (Figure 3.5 B). 
Platelet activation was assessed as % of platelets with positive P-selectin or activated 
fibrinogen receptor expression (i.e. two proteins expressed on platelets that are activated; 
detected through CD62p-PE and PAC1-FITC binding, respectively) on platelets under 
basal conditions (Figure 3.5 D) and upon ex vivo stimulation with CRP or ADP (Figure 3.5 
C). The assay’s intra-day and inter-day coefficient of variation (%CV) were 5.1 % and 9.6 
%, respectively. 
Before collection of platelet data, cytometer cleanliness was tested by detecting less than 
200 events in 50 μL ultrapure water run at a flow rate of 33 μL/min and 80’000 forward 
scatter threshold (prior to platelet data collection) and flow cytometer performance was 
verified by running calibration beads (before and after platelet data acquisition). The same 
gating strategy in logarithmic scale was applied throughout the whole study. Using beads, 
colour compensation between fluorophores PE and FITC was established and applied to 
all biological sample data. FL-1 (filter 530/30 nm; green spectrum) was corrected by 4.21 
% due to CD62p-PE excitation and FL-2 (filter 585/40 nm; blue spectrum) was corrected 
by 6.85 % due to PAC1-FITC excitation. No colour compensation was required for the 
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APC fluorophore which was assessed by FL-4 (filter 675/25nm; red spectrum) and does 
not excite into FL-2 or FL-1. 
Figure 3.5 – Platelet activation whole blood flow cytometry: data acquisition 
 
Assessment of platelet activation by whole blood flow cytometry. A: log FSC-A/ log SSC-A plot: 
light-scatter profile of diluted whole blood with platelets broadly identified based on size. B: log 
FL4-A/ log SSC-A plot of events in the “Platelets” gate. Platelets were identified based on 
expression of integrin β3, a protein expressed on rested and activated platelets. C and D: Log FL2-
A/ log FL1-A plot gated on identified platelets. This plot indicates the amount of activated fibrinogen 
receptor and P-selectin expression, two proteins that are expressed on activated platelets. Platelet 
activation is assessed in platelets activated ex vivo with collagen related peptide (CRP) or 
adenosine diphosphate (ADP) (C) or in platelets under basal conditions (i.e. non-activated) (D). 
Abbreviations: SSC-A, side scatter area; FSC-A, forward scatter-area; FL4-A, FL2-A and FL1-A, 
fluorescence bandpass filters (675/25 nm, 585/40 nm and 530/30 nm, respectively); FI, 
fluorescence intensity 
3.2.13 Flavanone metabolite analysis in plasma 
3.2.13.1 Materials 
Compound standards. Naringenin-7-glucuronide was purchased from Bioquote (York, 
UK). Sulfate and glucuronide conjugated phenolic acids (protocatechuic acid-3-
glucuronide, protocatechuic acid-4-glucuronide, vanillic acid-4-glucuronide, benzoic acid-
4-glucuronide, isovanillic acid-3-glucuronide, protocatechuic acid-3-sulfate, protocatechuic 
acid-4-sulfate, vanillic acid-4-sulfate, isovanillic acid-3-sulfate and benzoic acid-4-sulfate) 
were synthesised at the University of St Andrews (UK) as previously published [226]. 
Hesperetin, naringenin, phloridzin, taxifolin and the subsequently listed 53 phenolic acids 
(CAS number) were purchased from Sigma-Aldrich (Dorset, UK): [2,4-
dihydroxybenzaldehyde (95-01-2), 2,4-dihydroxybenzoic acid (89-86-1), 2,4-
dihydroxycinnamic acid (614-86-8), 2.3-dihydroxybenzoic acid (303-38-8), 2-hydroxy,4-
methoxybenzaldehyde (673-22-3), 2-hydroxy,4-methoxybenzoic acid (2237-36-7), 2-
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methoxybenzoic acid (579-75-9), 3,4-dihydroxybenzaldehyde (139-85-5), 3,4-
dihydroxyhydrocinnamic acid (1078-61-1), 3,4-dihydroxyphenylacetic acid (102-32-9), 3,4-
dimethoxybenzoic acid methyl ester (2150-38-1), 3,5-dihydroxybenzoic acid (99-10-5), 3-
hydroxybenzoic acid (99-06-9), 3-hydroxycinnamic acid (14755-02-3), 3-
hydroxyphenylacetic acid (621-37-4), 3-methoxybenzoic acid (586-38-9), 3-
methoxycinnamic acid (6099-04-3), 3-methyl hippuric acid (27115-49-7), 3-methyl gallic 
acid (3934-84-7), 4-hydroxybenzaldehyde (123-08-0), 4-hydroxybenzoic acid (99-96-7), 4-
hydroxybenzyl alcohol (623-05-2), 4-hydroxyphenylacetic acid (156-38-7), 4-
methoxybenzaldehyde (123-11-5), 4-methoxybenzoic acid (100-09-4), 4-methoxycinnamic 
acid (830-09-1), 4-methyl hippuric acid (27115-50-0), 4-valerolactone (57129-69-8), 5-
oxo-5-phenylvaleric acid (1501-05-9), 5-phenylvaleric acid (2270-20-4), 6-
methoxysalicyclic acid (3147-64-6), alpha hydroxyhippuric acid (16555-77-4), apocynin 
(498-02-2), caffeic acid (331-39-5), dihydroferulic acid (1135-23-5), ferulic acid (537-98-4), 
gallic acid (149-91-7), hippuric acid (495-69-2), homovanillic acid (306-08-1), 
hydrocinnamic acid (501-52-0), isoferulic acid (537-73-5), isovanillic acid (645-08-9), 
methyl 3,4,5-trihydroxybenzoate (99-24-1), methyl 3,4-dihydroxybenzoate (2150-43-8), 
methyl vanillate (3943-74-6), p-coumaric acid (501-98-4), phloretic acid (501-97-3), 
phloroglucinol aldehyde (487-70-7), protocatechuic acid (99-50-3), salicyclic acid ( 69-72-
7), sinapic acid (530-59-6), syringic acid (530-57-4) and vanillic acid (121-34-6)]. 3-
hydroxyhippuric acid (1637-75-8) was purchased from Enamine Ltd (Kiev, Ukraine). Stock 
solutions of all pure compounds were prepared at 5 mg/mL in dimethyl-sulfoxide, and the 
stock solutions containing phenolic acid, taxifolin and phloridzin were stored at room 
temperature, whilst stock solutions containing flavanone or synthesized phenolic acid 
glucuronides and sulfates were stored at -80 °C. 
Solvents. Hydrochloric acid, formic acid, dimethyl-sulfoxide and methanol were obtained 
from Sigma-Aldrich (Poole, Dorset, UK), and acetonitrile from Fisher Scientific 
(Loughborough, UK). All solvents and MilliQ water (18.2 MΩ cm-1) were of HPLC grade 
quality and glassware was washed with HPLC grade solvent prior to use. 
Consumables. Strata-XTM solid phase extraction columns (6 mL, 500 mg, 88 Å), Kinetex 
pentafluorophenyl HPLC column (2.6 μM, 100 x 4.6 mm, 100 Å) and SecurityGuard 
ULTRA Cartridges (pentafluorophenyl, 2 x 4.6 mm) were purchased from Phenomenex 
(Macclesfield, UK). Sterile filtered, human male serum, a Hamiltion syringe (1 mL volume) 
and acrodisc polytetrafluoroethylene syringe filters (13 mm Ø, 0.45 μM pore size) were 
purchased from Sigma-Aldrich (Dorset, UK). 
3.2.13.2 Method 
Plasma solid phase extraction. Flavanones and phenolic acids were extracted following 
previously developed and validated methods [227] with minor modifications. Briefly, 1 mL 
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of acidified plasma was spiked with an internal standard (i.e. phloridzin at 5 μM) and 
subsequently extracted using solid phase extraction cartridges. These were washed with 
12 mL of 0.1/99.9 v/v hydrochloric acid/water, dried for 30 min under vacuum, soaked in 
0.1/99.9 v/v hydrochloric acid/methanol for 10 min and eluted into glass vials with 7 mL 
0.1/99.9 v/v hydrochloric acid/methanol. Samples were evaporated to complete dryness 
under speedvac at room temperature. The dried samples were resuspended in 250 μL of 
mobile phase (0.1/5/94.9, v/v/v, FA/MeOH/MilliQ) and sonicated in an ultrasonic cold 
water bath for 15 min at room temperature. Samples were syringe filtered, spiked with an 
internal standard (i.e. taxifolin at 5 μM) and stored at -80 °C until analysis. The mean ± SD 
extraction efficiency of phloridzin was 71.8 ± 12.9 %. 
HPLC-MS2 analysis. Samples were analysed following a previously developed and 
validated method [227] with adaptation for quantification of flavanones metabolites. 
Briefly, the HPLC-electrospray ionisation-MS2 system consisted of an Agilent 1200 series 
HPLC coupled to an AB Sciex 3200 series Q-Trap electrospray ionisation mass 
spectrometer operated using Analyst software (v. 1.5, Applied Biosystems/MDS Sciex). 
Compound separation was achieved on a pentafluorophenyl column attached to a 
Security Guard ULTRA maintained at 37 °C with a flow gradient consisting of 1.5 mL/min 
at 0 min, 1 mL/min from 7 to 14 min and 1.5 mL/min from 14 to 32 min and a sample 
injection volume of 5 μL. The mobile phase consisted of 0.1/99.9 v/v water/formic acid (A) 
and 0.1/99.9 v/v acetonitrile/formic acid (B); and mobile phase gradient consisting of: 1 % 
B at 0 min, 7.5 % B at 7 min, 7.6 % B at 14 min, 10 % B at 17 min, 12 % B at 18.5 min, 
12.5 % B at 20 min, 30 % B at 24 min, 90 % B from 25 to 28 min and 1 % B from 29 to 32 
min. Flavanone metabolites and internal standards were detected by scheduled multiple 
reaction monitoring (sMRM). The following compound dependent parameters were 
optimised using syringe infusion (in negative and/or positive sMRM mode): declustering 
potential, entrance potential, collision energy and collision exit potential (Table 3.3). 
Optimised MS2 source parameters were 40 psi curtain gas, 700 °C Temperature, 60 psi 
nebulizer gas, 60 psi auxiliary gas and -4000 V or 5500 V ion spray voltage; the latter 
depending on negative or positive MRM mode, respectively. 
If pure standards were not commercially available, methods to identify and quantify 
flavanone metabolites were developed using a pooled plasma extract (i.e. plasma 
collected 5 h after the orange juice intervention and pooled from n = 13 participants) 
(Figure 3.6). sMRM transitions and parameters were obtained from the literature [71, 228] 
or derived from the fragmentation pattern of the flavanone aglycones or phenolic acids by 
adding the m/z of glucuronide (i.e. 176) or sulfate (i.e. 80) to the precursor ion and 
appropriate MS2 fragment. 113 m/z was also added as a MS2 fragment for putative 
glucuronide conjugated phenolic acids as it is a commonly reported fragment of glucuronic 
acid [229]. 
 75 / 150 
Figure 3.6 – sMRM method development and screening strategy for the identification of 23 
flavanones and their phenolic metabolites 
 
1
 Pure compounds were commercially available or synthesised. 
2
 Pure compounds were not 
commercially available and identification was based on known transitions. 
3 
Collected 5 h after 
the orange juice intervention and pooled from n = 13 participants. 
4 
For 9 compounds, 
concentrations were not significantly different 5 h after the orange juice intervention compared to 
the control intervention and 4 compounds were below the limit of quantification. Abbreviations: 
sMRM, scheduled multiple reaction monitoring. 
 
Compounds were identified based on 3-5 sMRM transitions and retention time (RT) of the 
pure standard (if available). From all 158 compounds originally considered as potential 
flavanone metabolites, 23 were identified as flavanone metabolites (Figure 3.6) in the final 
analysis of all clinical samples using optimised sMRM methods (Table 3.3) (i.e. compound 
concentration was significantly elevated 5 h post orange juice intervention relative to the 
control).
67 tested compounds1
- hesperetin, naringenin & eriodictyol
- naringenin-7-glucuronide
- 54 phenolic acids
- 5 phenolic acid sulphates
- 5 phenolic acid glucuronides
10 compounds with 
poor detection limit
Analysis of pooled plasma3
57 tested compounds1
- hesperetin, naringenin & eriodictyol
- naringenin-7-glucuronide
- 43 phenolic acids
- 5 phenolic acid sulphates
- 5 phenolic acid glucuronides
91 tested putative compounds2
- 2 hesperetin-glucuronides
- 2 hesperetin-diglucuronides
- hesperetin-sulphate
- hesperetin-glucuronide-sulphate
- 2 naringenin-glucuronides
- naringenin-diglucuronide
- naringenin-glucuronide-sulphate
- naringenin-sulphate
36 compounds
- hesperetin and naringenin
- 2 hesperetin-glucuronides
- 2 naringenin-glucuronides
- 2 hesperetin-diglucuronides
- eriodictyol-glucuronide
- eriodictyol-diglucuronide
- eriodictyol-glucuronide-sulphate
- eriodictyol-sulphate
- 38 phenolic acids-glucuronides
- 38 phenolic acid-sulphates
Compounds detected
in pooled plasma3
112 compounds not 
detected in pooled plasma3
- 15 phenolic acids
- 7 phenolic acid-glucuronides
- 6 phenolic acid-sulphates
13 compounds not identified 
as flavanone metabolites4
23 compounds
- hesperetin and naringenin
- 2 hesperetin-glucuronides
- 2 naringenin-glucuronides
- 2 hesperetin-diglucuronides
- 9 phenolic acids
- 6 phenolic acid glucuronides
Compounds identified 
as flavanone 
metabolites
Analysis of pure standards
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Table 3.3 – sMRM transitions, parameters and detection limits of identified flavanone metabolites 
 
Metabolite 
sMRM 
mode 
RT 
(min) 
LOD
 
(nM) 
R
2
 
Precursor 
ion (m/z) 
MS
2
 fragments 
(m/z) 
DP 
(V) 
EP 
(V) 
CE 
(V) 
CXP 
(V) 
Previously 
identified by 
(biofluid)
1
 
Flavanone aglycones            
Naringenin - 25.6 0.1 1.000 271 177, 151*, 119, 107 -57 -5 -25, -25, -25, -45 -3 [72] (P, U) 
Hesperetin - 25.7 0.1 0.998 301 286, 242, 164* -59 -5 -27, -27, -35 -1 [72] (P, U) 
Flavanone phase II metabolites:            
Hesperetin-diglucuronide
2
 - 19.5 2.5 N/A 653 477*, 301, 286, 176 -86 -5 -30 -7 [78] (P, U) 
Hesperetin-diglucuronide
2
 - 23.0 2.1 N/A 653 477*, 301, 286, 176 -86 -5 -30 -7 [78] (P, U) 
Hesperetin-glucuronide
2
 - 24.2 4.1 N/A 477 301*,286, 257, 242 -86 -5 -30 -7 [71, 72, 78] (P, U) 
Hesperetin-glucuronide
2
 - 24.8 1.0 N/A 477 301*,286, 257, 242 -86 -5 -30 -7 [71, 72, 78] (P, U) 
Naringenin-7-glucuronide - 24.0 0.2 0.998 447 271*, 176, 151 -41 -5 -27, -22, -42, 0 [72, 78] (P, U) 
Naringenin-glucuronide
2
 - 24.3 1.0 N/A 447 271*, 176, 151 -41 -5 -27, -22, -42, 0 [72, 78] (P, U) 
Phenolic acid metabolites            
Benzoic acid-4-glucuronide - 3.1 0.6 0.998 313 175, 137, 113, 93* -54 -7 -15, -20, -20, -54 -2  
Hydroxyhippuric acid
2, 3
 - 4.5 4.1 N/A 194 150, 93*, 121 -39 -5 -20, -27, -38 -2  
3-hydroxyhippuric acid - 5 2.4 1.000 194 150*, 93, 121 -39 -5 -20, -27, -38 -2 [113] (U) 
Isovanillic acid-3-glucuronide - 5.2 4.1 0.996 343 152, 113, 167*, 175, 108 -60 -4 -40, -20, -20, -15, -55, -2  
Vanillic acid-4-glucuronide - 6.5 5.1 0.990 343 152, 113, 167*, 175, 108 -60 -4 -40, -20, -20, -15, -55, -2  
Hippuric acid - 7 778.5 0.997 178 77, 132, 134* -40 -3 -22, -22, -18 0 [113] (U) 
Iso/vanillic acid-glucuronide
2, 3
 - 7 4.6 N/A 343 152, 113, 167*, 175, 108 -60 -4 -40, -20, -20, -15, -55, -2  
4-hydroxybenzoic acid - 7.1 18.9 1.000 137 65, 75, 93* -35 -5 -44, -50, -20 -2 [113] (U) 
4-hydroxyphenylacetic acid - 7.1 148.5 0.994 151 123, 93, 79, 107* -50 -7 -25, -25, -25, -17 -2 [113] (U) 
3-hydroxyphenylacetic acid - 8.3 7.9 0.994 151 121, 107*, 92.9, 65 -26 -7 -13, -16, -12, -34 0 [113] (U) 
Isovanillic acid + 9.9 13.9 0.997 169 151, 125, 65, 93* 27 6 19, 12, 34, 19 6  
Vanillic acid + 10.3 9.2 0.998 169 151, 125, 65, 93* 27 6 19, 12, 34, 19 6  
Iso/ferulic acid-glucuronide
2, 3
 - 10.2 2.8 N/A 369 193*, 113, 134, 178 -28 -9 -23, -23, -23, -18 0  
Dihydroferulic acid-3-glucuronide
2, 3
 - 11.5 28.9 N/A 371 151, 195*, 113, 121, 136 -40 -8 -18, -35, -35, -35, -20 0  
Dihydroferulic acid - 17.1 5.4 1.000 195 151, 136*, 119, 121, 149 -40 -8 -18, -20, -16, -35, -18, 0 [113] (U) 
*sMRM transition used for quantification; 
1 
P, plasma; U, urine; 
2 
site of conjugation could not be ascertained as identification was based on known transitions where 
pure standards for isomers were not available or separation of isomers was chromatographically not possible; 
3 
putatively identified compound which could have 
different isomeric configuration. Abbreviations: sMRM, scheduled multiple reaction monitoring; RT, Retention time; LOD, limit of detection (Signal/Noise = 3); R
2
, 
linear regression coefficient of standard curve; N/A, putative metabolite, i.e. no analytical standard was available to make standard curve; MS
2
, tandem mass 
spectrometry; DP, declustering potential; EP, entrance potential; CE, collision energy; CXP, collision exit potential. 
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Quantification was established using the most intense sMRM transition and matrix-
matched baseline-adjusted standard curves (concentration range: 0 to 51.2 μM over 11 
points) (Table 3.3). Where pure standards were not available, quantification was 
conducted relative to standard curves of compounds with the most similar structure, such 
as 3-hydroxyhippuric acid was used to quantify hydroxyhippuric acid and vanillic acid-
glucuronide was used to quantify dihydroferulic acid-glucuronide. The limit of detection, 
which was calculated by Analyst software, was established for each compound as the 
concentration of a peak with a signal to noise ratio of 3, and used as the threshold for 
quantification. A quality control consisting of taxifolin spiked into serum extract at 50 μM 
was run every 12 injections and the between-run coefficient of variation was established 
as 8.6 %. 
3.2.14 Quantification of vitamin C 
EDTA plasma was immediately isolated from fresh blood, deproteinised, mixed with 
diethylenetriaminepentaacetic acid (250 μM) and frozen on dry ice. Vitamin C was 
analysed using ascorbate assay kits (No. 7004240) from Cayman Chemical (Ann Arbor, 
Michigan, USA). Intra- and inter-assay coefficients of variation (%CV) were 3.3 % and 
13.8 %, respectively. 
3.2.15 Statistical analysis 
A sample size of 14 participants to complete the study was calculated to be sufficient to 
detect clinically relevant effect sizes of dietary flavanones for PAT-RH, (i.e. the primary 
endpoint of the trial), with a power of 80 % and a significance level of 5 %. The clinically 
relevant effect size and expected variability for PAT-RH [expressed as standard 
deviations (SD)] was 0.35 ± 0.4 [122]. For secondary endpoints (i.e. BP, Valsalva ratio, 
BRS, cfPWV, cAIx, platelet activation, plasma nitrite and serum soluble gp91phox), the 
sample size of the present RCT is comparable to previous acute crossover RCTs that 
tested vascular effects of flavonoids (range: 10 - 22 participants) [158, 159, 192, 193, 202, 
230-232]. 
Following a pre-established statistical analysis plan and whilst investigators remained 
blinded to the dietary interventions, data were statistically analysed using a per protocol 
approach [233]. Effects of the dietary interventions on study endpoints were analysed 
using a linear mixed model specific for crossover studies (described by Jones and 
Kendward [234]). In this model, subjects nested within intervention sequence were 
included as a random effect and intervention sequence, experimental period, baseline 
values and dietary intervention as fixed effects. No carry-over effects were observed as 
assessed by addition of the period and dietary intervention interaction to the linear mixed 
 78 / 150 
model (i.e. P-value of > 0.05). If the mixed model showed a significant difference, pairwise 
comparisons between interventions were performed on least-square means with Tukey 
adjustment. Model assumptions were assessed through diagnostic plots (i.e. histograms 
and boxplots of baseline and 5 h post intervention data, and histograms, Q-Q plots and 
fitted versus residual plots of model residuals) and objective tests (i.e. Shapiro Wilk test to 
assess normality of the data and model residuals, and Levene test to assess homogeneity 
of variance of the data). 
Exploratory associations between markers of CVD risk and plasma concentrations of 
flavanone and phenolic acid metabolites (i.e. changes from baseline to 5 h post orange 
juice intervention which were deemed potentially physiologically important [i.e. defined as 
≥ 100 nM mean increases)] were assessed by Pearson’s correlation and multivariate 
regression analysis. 
Due to the exploratory nature of this study, statistical tests were not adjusted for multiple 
comparisons. Data are presented as means ± SD and an effect was considered significant 
when the P-value was < 0.05. The statistical analysis was performed using R 3.0.1 (R 
Foundation for Statistical Computing). 
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Chapter 4. Acute vascular and cardiac autonomic 
response after intake of flavanones in orange juice: 
in healthy men at mild to moderate CVD risk 
4.1 Introduction 
Cardiovascular (CV) disease (CVD) is the cause of one in three deaths in the UK with 
men at a higher risk than women [1]. A change in modifiable risk factors may have the 
potential to decrease disease burden and death; in particular, encouraging a diet rich in 
fruit was reported to have the third highest impact after reducing blood pressure (BP) 
levels and smoking [37]. For example, a diet rich in fruit and vegetables has been linked 
with a decreased risk of CVD by an odds ratio of 0.7 (99 % CI: 0.64-0.77) [235], and 
phytochemicals in fruits and vegetables such as flavonoids may partly be responsible for 
these cardioprotective effects [38]. 
A growing body of epidemiological evidence suggests that intake of citrus fruit and 
flavanones, a polyphenol compound mainly consumed in citrus fruits, is inversely 
associated with both mortality and incidence of coronary heart disease and stroke [43-51, 
54, 236]. In two large cohort studies, a high flavanone intake has been linked with a 19 % 
reduction in risk of ischemic stroke [Relative risk (RR): 0.81 (95 % confidence interval (CI): 
0.66–0.99; P = 0.038)] [48] and a 22 % reduction in risk of coronary heart disease [RR: 
0.78 (95 % CI: 0.65-0.94; P = 0.010)] [49] when comparing upper and lower quintile of 
flavanone intake in cohorts of 70,000 and 35,000 participants followed up for 14 and 16 
years, respectively, and using multivariate models that adjusted for known confounding 
factors including estimated intake of vitamin C. In support of this epidemiological 
evidence, a number of in vitro and animal studies suggest that flavanones exert effects of 
potential relevance to CV health through an improvement in CVD risk biomarkers 
including BP, endothelial and autonomic function [60, 62, 74, 93, 94, 148]. 
Despite these promising epidemiological, in vitro and animal data, the systematic review 
conducted in Chapter 2 clearly demonstrated that there are currently insufficient data from 
human randomised controlled trials (RCTs) to determine the CV benefits of dietary 
flavanones. There are also gaps in our understanding of the underlying mechanisms of 
action of flavanones and their metabolites in humans. Whilst the conducted meta-analysis 
of 6 short-term RCTs (duration range: 3 to 8 weeks) suggested that flavanones lower 
mean blood total cholesterol by 0.64 mmol/L (95 % CI: -1.04, -0.24) compared to control 
in a population at an elevated CVD risk but not at a mild to moderate CVD risk (Chapter 2; 
Figure 2.3), the effect of dietary flavanones on BP and vascular function is poorly 
understood. Two short-term RCTs found no effects of flavanones on systolic BP (SBP) but 
equivocal findings on endothelial function and diastolic BP (DBP) [59, 60]. Following a 
short-term (i.e. 3 – 4 weeks) flavanone intervention, Morand et al., [59] reported a 
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decrease in DBP, with no effect on endothelial function, conversely Rizza et al., [60] 
observed an improvement in endothelial function but no change in DBP (Table 4.1). 
These inconsistencies in effects on DBP and endothelial function may be explained by 
inter-study differences such as flavanone dose (i.e. 292 mg versus 500 mg hesperidin), 
study duration (i.e. 3 versus 4 weeks), study population [healthy overweight men and 
adults with metabolic syndrome (defined by the [NCEP ATP] III Criteria [237])] and the 
method used to measure endothelial function [i.e. forearm microvascular reactivity and 
brachial artery flow mediated dilatation (FMD)]. 
Morand et al., [59] not only examined short-term effects of flavanones (i.e. 4 weeks 
intervention), but also reported acute effects of 292 mg hesperidin on endothelial function 
in the microvasculature measured 6 h after intake of orange juice or a dose-matched 
hesperidin supplement (consumed together with a light meal) in healthy overweight men 
(Table 4.1). Whilst these beneficial effects were associated with a similar hesperetin 
plasma concentration achieved after intake of orange juice and a flavanone extract (i.e. 
mean ± SEMs: 860 ± 100 nM and 770 ± 160 nM respectively, P = 0.64), the orange juice 
dietary intervention resulted in greater effects on endothelial function. This apparent 
difference may be partly attributable to significantly higher plasma concentrations of 
vitamin C after the orange juice intervention compared to the flavanone extract and control 
interventions (i.e. mean ± SEMs: 70.5 ± 4.6 µM, 52.8 ± 4.6 µM and 50.8 ± 4.6 µM 
respectively, P < 0.001). Given that vitamin C has been suggested to acutely improve 
endothelial function [238-242], additive or synergistic beneficial effects of flavanones and 
vitamin C may have occurred. 
Table 4.1 – Randomised controlled trials examining the effects of flavanones on blood pressure 
and endothelial function 
     
Study 
Participants/ age 
(mean ± SD) 
duration/ 
study intervention/ dose Mean effect
1 
[95% CI] 
Short-term flavanone interventions: 
Morand 
et al., 
2011 [59] 
23 overweight men/ 
56 ± 5 y 
4 wk/ 0.5 L orange juice/ 
292 mg hesperidin + 47 mg 
narirutin per day 
SBP: -3.0 mm Hg [-8.3, 2.3] 
DBP: -5.5 mm Hg* [-9.0, -2.0] 
Microvascular reactivity
2
: 52 % [-8, 113] 
NOx: 12.4 µM [1.4, 23.4] 
4 wk/ supplement/ 292 mg 
hesperidin per day 
SBP: 0.6 mm Hg [-8.3, 2.3] 
DBP: -3.2 mm Hg* [-9.0, -2.0] 
Microvascular reactivity
2
: 17 % [-44, 77] 
NOx: -3.2 µM [-15.0, 8.6] 
Rizza et 
al., 2011 
[60] 
24 adults with 
metabolic syndrome/ 
52 ± 2 y 
3 wk/ supplement/ 500 mg 
hesperidin per day 
SBP: 2.7 mm Hg [-1.3, 6.7] 
DBP: 0.6 mm Hg [-2.2, 3.4] 
FMD
2
: 2.5 %* [0.4, 4.6] 
Acute flavanone interventions: 
Morand 
et al., 
2011 [59] 
23 overweight men/ 
56 ± 5 y 
6 h/ 0.5 L orange juice/ 
292 mg hesperidin + 47 mg 
narirutin 
Microvascular reactivity
2
: 105 %**[55, 155] 
NOx: no mean effect (data not reported) 
6 h/ supplement/ 292 mg 
hesperidin 
Microvascular reactivity
2
: 48 % [-1, 98] 
NOx: no mean effect (data not reported) 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; NOx, plasma levels of nitric oxide 
metabolites; FMD, flow mediated dilatation; y, year; *P-value<0.05; **P-value<0.01 
1
Difference between 
control and experimental intervention; 
2
methods to assess endothelial function 
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The aim of the herein reported acute human RCT was to examine the potential 
physiological mechanisms by which flavanones may exert beneficial CV effects as 
suggested by the epidemiological and short-term RCT data as described above. Clinical 
measurements of endothelial function, central arterial stiffness and CV autonomic function 
were chosen as they are sensitive markers of a range of physiologically important 
systems in maintaining CV health; i.e. endothelial regulation of vascular homeostasis [17], 
haemodynamics of central arteries [184] and BP regulation by the autonomic nervous 
system [18], respectively. Whilst these three clinical measures are established 
independent markers of CVD risk [18, 122, 149] and CV autonomic function is a marker 
preceding the development of hypertension [18], to the author’s knowledge, there are 
currently no data available on potential effects of dietary flavanones on CV autonomic 
function and arterial stiffness. This RCT also aimed to explore the importance of the food 
matrix on the biological effects of flavanones, by testing acute vascular response following 
intake of dietary flavanones in orange juice or a hesperidin matched supplement. In 
addition and unlike previous research [59], the present study accounted for the potential 
effects of vitamin C by matching the flavanone extract intervention and control intervention 
with the vitamin C present in the orange juice intervention. This may further our 
understanding of potential additive/synergistic effects between bioactive dietary 
compounds such as flavanones and vitamin C. Further study aims, were to explore 
potential acute effects of flavanones on circulating CVD risk biomarkers (Chapter 4) and 
to associate changes in markers of CVD risk with plasma concentrations of individual 
flavanone metabolites including phase II metabolites and phenolic acids (Chapter 5). 
4.2 Results 
Overall for all three flavonoid intervention trials, 61 eligible participants were identified 
after obtaining written informed consent from potential volunteers and assessing study 
inclusion criteria during clinical screening visits. 16 of these eligible participants were 
allocated to the flavanone trial and randomised to the intervention sequence. Amongst 
them, n = 2 discontinued trial participation after the first experimental period (n = 1 was 
excluded due to an infection and n = 1 withdrew due to time commitment) and data from n 
= 2 participants (i.e. 3 experimental periods) were excluded due to non-compliance with 
dietary restrictions (as uncovered by plasma nitrite concentrations greater than mean + 3 * 
SD; described in Chapter 4). Additionally, for cfPWV and cAIx, data from n = 1 participant 
(i.e. both experimental periods) were excluded due to low quality recordings (i.e. beat 
counts ≤ 6) and for αBRS, data from n = 4 participants (i.e. 5 experimental periods) were 
excluded due to > 2 % ectopic beats. The 15 study participants were healthy men (age 
range 51-69) at an estimated mean absolute 10 year CVD risk of 15.7 % (range: 10 - 20 
%; BHS criteria [204]) assessed at screening (Table 4.2). Whilst 6 participants (40 %) had 
stage 1 hypertension, 10 participants (73 %) were mildly hyperlipidemic (Table 4.2) [204]. 
 82 / 150 
Table 4.2 – Characteristics of study participants at screening (n = 15) 
 
 
mean ± SD Range 
n (%) outside 
recommendations 
BHS [204] 
recommendations 
n 15    
Age (y) 60.3 ± 6 51-69   
Absolute CVD risk (%) 15.7 ± 0 10-20   
Relative CVD risk 24.6 ± 18.8 1-61   
BMI (kg/m2) 25.7 ± 3.5 22-35 6 (40) <25 
SBP (mm Hg) 137.0 ± 12.2 111-155 6 (40) <140 
DBP (mm Hg) 83.1 ± 6.6 73-94 4 (27) <90 
Glucose (mmol/L) 4.9 ± 0.6 3.9-6 0 (0) <6.1 
Blood lipids: (mmol/L)   11 (73)  
Total cholesterol 5.3 ± 0.6 4.2-6.5 9 (60) <5 
HDL-C 1.31 ± 0.32 0.9-1.9 4 (27) >1 
LDL-C 3.5 ± 0.5 2.6-4.4 11 (73) <3 
Triglyceride 1 ± 0.4 0.6-2.3 1 (7) <1.7 
Abbreviations: SEM; standard error of the mean; BHS, British Hypertension Society; CVD, cardiovascular 
disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C and 
LDL-C, high and low density lipoprotein cholesterol, respectively. 
Participants reported good compliance to dietary and exercise restrictions prior to and 
during the experimental periods (Figure 3.1). In particular, the low mean plasma 
concentration of flavanone metabolites at baseline further suggests that participants 
adhered to the 3 day citrus fruit free diet (Table 4.3). Moreover, mean baseline plasma 
concentrations of vitamin C of fasted participants (i.e. ≈ 32 μM) were relatively low in 
comparison to levels reported in the literature (e.g. mean ± SD of 47.2 ± 6.5 μM [243]), 
which further supports good adherence to the dietary restrictions. 
5 h after the orange juice intervention, plasma concentration of phase II flavanone 
metabolites was significantly elevated (P < 0.001) relative to the control intervention 
(Table 4.3; refer to Table 3.3 for correlation coefficients of standard curves and to Figure 
6.1 for a typical spectral trace). At baseline and 5 h after the control intervention, a low 
plasma concentration of flavanone phase II metabolites was detected. Plasma 
concentrations of vitamin C were similar at baseline and increased by the same extent 5 h 
after the dietary interventions (P = 0.27) (Table 4.3), which was expected since dietary 
interventions provided the same dose of vitamin C. 
Food habits and lifestyle did not change between the orange juice and control 
interventions as suggested by a similar mean energy intake (i.e. 1635 ± 541 kcal; 1749 ± 
591 kcal; P = 0.61) and BMI (i.e. 26.4 ± 3.9 kg/m2; 25.6 ± 3.9 kg/m2; P-value: 0.53). 
Likewise, participants’ baseline characteristics of CV measurements were similar between 
the dietary interventions (i.e. P > 0.05) (Table 4.3). No significant acute change in BP, HR, 
RHI, xBRS, Valsalva ratio and cfPWV was observed 5 h after the orange juice intervention 
compared to the control intervention (Table 4.3), conversely, cAIx was significantly higher 
and αBRS was significantly decreased 5 h after the orange juice interventions compared 
to the control. However, the significant effect on cAIx was attenuated and lost significance 
when normalised to a HR of 75 bpm (Table 4.3). 
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Table 4.3 – Markers of cardiovascular risk at baseline and 5 h following interventions in men at moderate cardiovascular disease risk 
1
 
 
 Mean ± SD  
 
Placebo 
 
Orange Juice 
 
Flavanone extract 
 
 
BL 5h ∆ 
 
BL 5h ∆ 
 
BL 5h ∆ P
3
 
SBP (mm Hg) 80.4 ± 6.5 74.8 ± 7.6 -5.6 ± 4.5 
 
78.5 ± 6.7 74 ± 7.2 -4.5 ± 4.5 
 
80.8 ± 7.4 75.6 ± 7.2 -5.2 ± 4.2 0.83 
DBP (mm Hg) 128.4 ± 8.9 123.2 ± 7.5 -5.1 ± 10.7 
 
126.9 ± 6.6 124.5 ± 10.6 -2.4 ± 8.5 
 
127.1 ± 7.6 123.9 ± 9.6 -3.2 ± 7.5 0.75 
HR (bpm) 55.9 ± 7.9 59.9 ± 8.5 4 ± 5.1 
 
54.2 ± 7.3 59 ± 8.1 4.8 ± 4 
 
54.5 ± 8.2 58.3 ± 7.6 3.7 ± 4.7 0.82 
PAT-RH index 2.83 ± 0.72 2.71 ± 0.7 -0.13 ± 0.39 
 
2.82 ± 0.46 2.73 ± 0.69 -0.09 ± 0.44 
 
2.85 ± 0.81 2.69 ± 0.59 -0.16 ± 0.52 0.93 
xBRS (ms/mm Hg) 8.4 ± 3.3 8.5 ± 3.4 0.1 ± 2.5 
 
10.8 ± 5.8 9 ± 3.3 -1.8 ± 4.2 
 
11.4 ± 5.4 9.7 ± 3.9 -1.7 ± 3.9 0.83 
αBRS (ms/mm Hg) 8.3 ± 3.2 8.7 ± 3 0.3 ± 3.7 
 
9.5 ± 3.9 7.3 ± 3.1 -2.2 ± 2.2* 
 
ND ND ND < 0.05 
Valsalva ratio 1.6 ± 0.28 1.62 ± 0.29 0.02 ± 0.16 
 
1.62 ± 0.29 1.67 ± 0.38 0.06 ± 0.16 
 
1.68 ± 0.37 1.72 ± 0.3 0.04 ± 0.24 0.99 
cfPWV (m/s) 9.9 ± 1 9.9 ± 0.8 0 ± 0.9 
 
9.9 ± 1.3 9.6 ± 1 -0.3 ± 0.7 
 
9.4 ± 1.9 9.7 ± 1.6 0.2 ± 0.9 0.22 
cAIx (%) 25.1 ± 4.5 20.8 ± 4.3 -4.3 ± 2.4 
 
25.2 ± 3.9 22.8 ± 3.3 -2.5 ± 2.1** 
 
25.6 ± 4.4 22.7 ± 4.1 -2.8 ± 3.1 < 0.05 
cAIx@HR75 (%) 33.1 ± 7.6 26.9 ± 7.4 -6.2 ± 3.5 
 
34.8 ± 8.6 29.4 ± 5.7 -5.4 ± 4.7 
 
36 ± 8.6 30 ± 7.7 -6.1 ± 6 0.31 
Plasma flavanones (nM) 15 ± 11 18 ± 6 2 ± 10 15 ± 7 1601 ± 1331 1586 ± 1326**** 13 ± 11 60 ± 96 48 ± 99 P < 0.05 
Vitamin C (µM) 32.4 ± 12.2 50.1 ± 14.8 17.7 ± 9.5 
 
32 ± 14 47.8 ± 18.4 15.8 ± 8.6 
 
31.2 ± 9.4 52.6 ± 20.5 21.4 ± 14.5 0.235 
1 
Interventions were matched for sugar and vitamin C content, whilst the control intervention was free of flavanones, the orange juice and flavanone extract intervention were 
matched in hesperidin (dose: 320mg). The sample sizes for the interventions were n = 14 (control), n = 13 (orange juice) and n = 15 (Flavanone extract), except for cfPWV and 
cAIx [n = 13 (control), n = 12 (orange juice) and n = 14 (flavanone extract)] and αBRS [n = 10 (control) and n = 12 (orange juice)]. 
2
 Differences between the dietary interventions 
were established using a linear mixed model for crossover studies with baseline values on each experimental period as the covariate and significant changes were considered at a 
P-value of < 0.05. Differences between the orange juice or supplement intervention and the control intervention were assessed by post-hoc analyses with Tukey adjustment and 
are indicated as follows; *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Abbreviations: CV, cardiovascular; 5H – BL; 
 
5 h post intervention changes from baseline; SBP and DBP, 
systolic and diastolic blood pressure; HR, heart rate; PAT-RH, peripheral arterial tonometry-reactive during reactive hyperaemia; cfPWV, carotid to femoral pulse wave velocity; 
cAIx, central augmentation index; cAIx@HR75, cAIx normalised at a 75bpm HR. 
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4.3 Discussion 
Our data suggest that flavanones were highly bioavailable 5 h after intake of 3 servings of 
orange juice (providing 320 mg hesperidin and 48 mg narirutin) (Table 4.3), and that these 
absorbed flavanone metabolites from orange juice did not exert acute beneficial effects on 
BP, heart rate, arterial stiffness, endothelial and CV autonomic function in healthy men at 
a mild to moderate CVD risk compared with an energy and vitamin C matched control 
(Table 4.3). 
Amongst flavanone bioavailability studies, Mullen et al., [71] have previously reported that 
the mean ± SEM time of maximal flavanone phase II metabolite plasma concentration is 
at 4.4 ± 0.5 h after intake of orange juice when unaccompanied by a meal and in fasted 
participants. Thus, the herein measured mean flavanone phase II metabolite plasma 
concentration of 1.60 ± 1.33 μM at 5 h after intake of 368 mg flavanones in orange juice is 
likely to reflect maximal plasma concentration of flavanone phase II metabolites and is 
towards the upper end of previously reported concentrations (i.e. range: 0.2 to 1.6 μM) 
[71, 72, 78, 108], which may be due to the relatively high administered dose and solubility 
of hesperidin in the FDOC orange juice. 
Inconsistent with the orange juice intervention, plasma concentration of flavanone phase II 
metabolites were not elevated 5 h after intake of the dose-matched flavanone extract 
intervention. In turn, CVD risk marker data of the flavanone extract intervention were 
considered unreliable to assess potential beneficial CV effects of flavanones and were, 
therefore, omitted from analysis. In contrast to the present findings, another study 
reported a similar plasma flavanone concentrations after intake of the same dose of 
flavanones administered in a supplement or from orange juice [59]. A significant 
discrepancy might be that whilst participants of the conducted RCT were fasted and 
consumed the dietary intervention (i.e. a test drink and two supplements) without any 
accompanying meal, participants of Morand et al., [59] consumed their dietary 
interventions together with a meal, which may increase absorption of the water-insoluble 
hesperidin powder in the supplement. Indeed, animal studies have shown that the 
bioavailability of water-insoluble flavonoids was enhanced 7 to 14 fold when isolated 
flavonoids were consumed together with fish oils or dissolved in a polar aprotic liquid than 
when consumed with water [244, 245]. Thus, these findings may indicate that flavanone 
bioavailability depends on the food matrix in which flavanones are consumed and that 
supplements may be poorly bioavailable when consumed on an empty stomach. 
Alternatively, it could also be speculated that the timepoint of maximal flavanone 
metabolite concentration following flavanone extract intake may considerably differ from 5 
h post consumption. 
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Despite increased circulating levels of flavanones 5 h after the orange juice intervention, 
no beneficial acute effect of absorbed flavanones on BP, endothelial function, CV 
autonomic function and arterial stiffness was found compared with the energy and vitamin 
C matched control. 
Endothelial function was measured in the present study in the digital artery indicated by 
the PAT-RH index. Although no flavanone studies were included, a meta-analysis of 18 
studies (n = 255 participants) considering all six flavonoid subclasses provides strong 
evidence that flavonoids acutely improve endothelial function with an overall mean 
increase of 2.33 % (95 % CI: -1.58, -3.08) in FMD of the brachial artery [246]. In contrast 
with this and the limited evidence from another acute flavanone intervention [59] 
suggesting beneficial effects on endothelial function, the present study did not observe an 
acute beneficial effect of flavanones on endothelial function. Whilst the present acute 
flavanone intervention and the one by Morand et al., [59] were both in healthy men at a 
similar CVD risk, discrepant findings between the two studies may be explained by 
differences in the arterial sites and methods used to assess endothelial function (i.e. in the 
digital artery using PAT and in the forearm microvasculature using laser Doppler flow 
imaging and acetylcholine iontophoresis, respectively), dissimilarities in the control 
intervention (i.e. matched or not matched for vitamin C, respectively), the timepoint of 
measurement (i.e. 5 h and 6 h after flavanone intake, respectively) and the administered 
flavanone dose (i.e. 368 mg and 292 mg, respectively) which led to unequal mean plasma 
concentrations of absorbed flavanones (i.e. 1.60 and 0.86 μM, respectively). Although a 
number of studies validated digital artery endothelial function against invasive methods 
and FMD [124, 125, 195] and reported correlations with CVD risk [122, 123] and NO 
bioavailability [129], other studies found no correlation of digital artery endothelial function 
with the Framingham CVD risk score, microvascular reactivity and FMD [126, 127]. 
Moreover, whilst intake of 75 g glucose or smoking are known interventions to acutely 
decrease FMD by 30 and 60 %, respectively, these two established acute interventions 
did not induce a change in PAT-RH [247]. In summary, digital artery endothelial function 
assessed by the PAT-RH index may not have been the most sensitive method to detect a 
potential beneficial effect of flavanones on endothelial function. 
To the author’s knowledge, the present study is the first to examine potential acute effects 
of dietary flavanones on arterial stiffness and CV autonomic function. However, neither 
arterial stiffness nor CV autonomic function were acutely improved by flavanones as 
assessed by cfPWV and cAIx or BRS and the Valsalva ratio, respectively (Table 4.3) with 
the cAIx being significantly increased and the αBRS being significantly decreased 5 h 
after the orange juice intervention compared to the control intervention. 
In contrast to xBRS, which was similar between the two dietary interventions, the αBRS 
was significantly lower in the orange juice intervention compared to the control 
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intervention (Table 4.3). A possible explanation may be that unlike xBRS, αBRS is not a 
commercially available method and, therefore, less robust and more subjective in dealing 
with noise in the raw data. In contrast to the present findings on CV autonomic function, 
Takumi et al., [62] reported 500 mg non-dietary glucosyl hesperidin (reported to reach a 
Cmax of >10 μM [70]) to acutely improve autonomic function assessed using heart rate 
variability in young healthy women. This limited evidence from two studies may suggest 
that supraphysiological plasma concentrations of flavanone metabolites may be required 
to beneficially affect CV autonomic function. 
The cAIx was significantly higher 5 h after the orange juice intervention relative to the 
control intervention (Table 4.3). This could, at least in part, be explained by the 
participants’ HR since the significant difference was lost when the cAIx was normalised for 
HR of 75 bpm. Previous studies reported mixed findings regarding acute effects of 
flavonoids on arterial stiffness. Whilst three acute flavan-3-ol interventions reported a 
decrease in arterial stiffness [158, 159, 248], an acute anthocyanin intervention reported 
no improvement [232]. Together with the present data, this limited evidence may suggest 
that only certain flavonoid subclasses may decrease arterial stiffness. 
No acute effect of flavanones on BP was observed (Table 4.3). This is consistent with 
evidence from flavonoid meta-analyses [128, 249] which reported flavonoids to decrease 
DBP after daily intake over several weeks but not after acute intake. 
Despite a growing body of epidemiological evidence suggesting habitual intake of dietary 
flavanones and citrus fruits to reduce CVD risk [43-51, 54, 236] and supporting in vitro, 
animal and human studies [60, 62, 74, 93, 94, 148] reporting beneficial effects of isolated 
flavanones on CVD risk biomarkers including BP, endothelial function and CV autonomic 
function, data from this acute human RCT did not suggest an acute beneficial CV effect 5 
h after intake of a dietary flavanone intervention relative to a vitamin C matched dietary 
control intervention. In both the control and orange juice interventions, a similar increase 
in plasma vitamin C concentration from baseline to 5h post intervention was observed 
which may have prevented the detection of a potential flavanone-induced beneficial CV 
effect (Table 4.3). Indeed, a comparable increase in circulating levels of vitamin C of 20 
μM has been associated with a 30 % reduction in CVD mortality when sustained in the 
long term [243] and there are acute RCTs that report vitamin C to beneficially affect 
endothelial function [238-242] and autonomic function [250]. However, whilst these acute 
improvements were observed in regular smokers and patients with hypertension, 
hypercholesterolemia, CVD or diabetes, within the same studies, no effects were reported 
for apparently healthy participants [240-242]. Furthermore, vitamin C was administered at 
high oral doses ranging from 1 to 2 g or even through venous infusion reaching plasma 
concentrations unachievable through dietary intake but only through supplements. In 
summary, little is known regarding potential CV bioactivity of a physiological dose of 
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vitamin C on CVD risk biomarkers in a healthy population and, thus, vitamin C alone may 
have had beneficial CV effects in the present study. 
Whilst as a long-term goal, evidence for a potential health benefit of flavanone intake 
needs to be examined through the conduct of long-term RCTs, as a preliminary step, 
further acute RCTs are required to establish; a) populations that may benefit most from 
flavanone intake, b) optimal doses of flavanone intake consumed within a food matrix 
supporting flavanone absorption, and c) timepoints of flavanone CV bioefficacy linked to 
the presence of circulating flavanone metabolites. The present RCT and the other 
previous acute study by Morand et al., [59] examined the potential acute effects of 
flavanones in healthy men at a moderate CVD risk; however, potential effects in 
individuals at a higher CVD risk (e.g. smokers and patients with hypertension, 
hypercholesterolemia, metabolic disorder or past CVD event) remain to be examined. 
Whilst only 6 % of ingested flavanones have been recovered as phase II metabolites in 24 
h urine [71], 37 % of ingested flavanones have been recovered as phenolic acid 
metabolites predominantly in urine collected 5 - 24 h after orange juice intake [113]. Thus, 
potential acute cardioprotective effects of flavanones might occur later than 5 h after their 
intake. Although little is known regarding the dose-response of flavanones and CVD risk 
biomarkers, a meta-analysis including RCTs in all flavonoid subclasses reported an 
inverted U shape relationship between ingested flavonoid dose and FMD [246]. Morand et 
al., [59] linked their observed acute beneficial effects of flavanones on endothelial function 
to a mean plasma flavanone phase II metabolite concentration of 0.82 μM which was 
considerably lower than mean concentration of 1.48 μM reached in the present study that 
was not linked with an acute beneficial effect. Hence, an acute dose-response study is 
required to establish optimal flavanone intakes that elicit CV benefits. 
There were some limitations to the present study worth noting. Although the control 
intervention was matched for energy, vitamin C content and liquid volume against the 
orange juice intervention, orange juice also contains other potentially bioactive 
compounds which were not control for; including flavones, flavonols, carotenoids, vitamin 
B9 and folate [100, 210]. However, in comparison to the high content of hesperidin and 
vitamin C, the sum of these additional potentially bioactive compounds in orange juice is 
several magnitudes lower and, therefore, their contribution to potential beneficial CV 
effects of orange juice is potentially negligible. Although the flavanone dose administered 
in this study (i.e. 368 mg) can be achieved in a diet rich in citrus fruit, this dose was 
relatively high and does not reflect average flavanone intakes, such as estimated in 
several European countries (range: 24 to 51 mg/day) [99]. Even though the target of 14 
participants completing the study was achieved, quality assessment resulted in exclusion 
of data, in particular for arterial stiffness and αBRS endpoints, due to which statistical 
power to detect potential beneficial CV effects of flavanones may have been reduced. The 
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CVD risk estimation based on a one-off SBP and blood cholesterol assessment at 
screening might have been overestimated. In comparison to mean SBP assessed at 
baseline of the experimental periods, participants’ mean SBP at screening was 8 mm Hg 
higher which might have been caused by the white coat syndrome or participants were not 
adequately rested at screening before BP monitoring. Hence, some participants might 
have been at < 10 % CVD risk and may not have shown an acute CV response to 
flavanone intake. 
In conclusion, although plasma flavanones concentration was highly elevated 5 h after 
intake of orange juice but not after intake of a dose-matched flavanone extract, the 
present data suggest that flavanones from orange juice do not have acute beneficial 
effects on clinical markers of CVD risk in healthy men at a mild to moderate CVD risk 5 h 
post intervention compared with a vitamin C matched placebo intervention. Further acute 
flavanone RCTs that test importance of the food matrix, a dose-response and a longer 
time-course in various study populations are required to inform the design of short and 
long term RCTs that are required to examine a potential health benefit of dietary 
flavanones. 
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Chapter 5. Acute response of nitric oxide production, 
NADPH oxidase gene expression and platelet 
activation to flavanone intake in men at mild to 
moderate cardiovascular disease risk 
5.1 Introduction 
Epidemiological evidence has shown an inverse association between the intake of dietary 
flavanones and cardiovascular disease (CVD) mortality [48, 49] and limited evidence from 
two recent randomised controlled trials (RCTs) suggests that these cardiovascular (CV) 
beneficial effects of flavanones may partly be attributed to a reduction in diastolic blood 
pressure (BP) and an improvement in endothelial function [59, 60]. However, as clearly 
identified in the systematic review of human randomised controlled trials (RCT) (Chapter 
2), the underlying mechanisms by which flavanones mediate beneficial CV effects remain 
to be established and to the author’s knowledge, to date, no human RCTs have examined 
the potential inhibitory effects of flavanones on platelet function. 
Nitric oxide (NO), produced by endothelial NO synthase (eNOS), plays a key role in CV 
homeostasis [17]; in fact, reduced vascular NO production contributes to a range of CV 
disorders including endothelial dysfunction and atherosclerosis [17], hypertension [251], 
arterial stiffness [252], autonomic dysfunction [145] and increased platelet reactivity [253, 
254]. Treatment of cultured endothelial cells (from bovine arteries or human veins) with 10 
to 100μM hesperetin induced a significant increase in NO production [60, 68-70], 
accepting that these studies used supraphysiological concentrations and often flavanone 
forms different to circulating flavanone metabolites (i.e. predominantly glucuronide-
conjugates) [71]. Similarly, 4 weeks daily administration of 500 to 2000 mg flavanones per 
kg diet significantly elevated urinary nitrate excretion in stroke-prone spontaneously 
hypertensive rats [94]. Proposed subcellular mechanisms of action by which flavanones 
may increase vascular NO production include elevation of NO through increased eNOS 
activity [60, 68-70] and gene expression [69] and decreased inactivation of NO through 
inhibition of superoxide-generating nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase activity [70] and gene expression [93]. Despite these promising 
findings, a human RCT did not relate their observed improvement in endothelial function 
and reduction in diastolic BP after acute or 4 weeks flavanone intake, respectively, with an 
increase in plasma concentrations of total NO metabolites (NOx; a marker of endothelial 
NO production) in overweight men [59]. Given the limited evidence to date, further human 
RCTs are required to establish whether the mechanisms by which flavanones mediate 
potential beneficial CV effects may be through an increase in NO production and/or 
inhibition of NADPH oxidase. 
 90 / 150 
Platelets contribute in the early stages to atherosclerosis progression (by stimulation of 
monocyte and lymphocyte recruitment, macrophage activation, low density lipoprotein 
oxidation and cell proliferation via platelet derived growth factor; in particular at 
atherosclerotic sites) and play an important role in the development of arterial thrombosis 
which may result in an acute CV event [255, 256]. Indeed, increased susceptibility of 
platelets to activate and aggregate has been linked with a reduced risk of reoccurring 
coronary artery disease [10] and a large meta-analysis established that antiplatelet 
therapy (most commonly with aspirin) reduces CVD risk in secondary prevention by 25 % 
[257]. In primary prevention, however, a meta-analysis found only insufficient data to 
conclude that there is a net benefit of antiplatelet therapy on CV health because the 
therapy also increases risk of extracranial bleeding and haemorrhagic stroke [258]. 
Similarly to antiplatelet therapy, an inhibitory effect of dietary flavanones on platelet 
activation/aggregation might be a potential mechanism by which dietary flavanones 
mediate beneficial CV effects. Preclinical studies have observed potent inhibition of 
platelet aggregation when animal or human platelets were treated in vitro with 10 to 200 
μM flavanone aglycones or glycosides [73-75]. Moreover, a significantly decreased risk of 
cerebral thrombosis was reported in stroke-prone spontaneously hypertensive rats that 
were daily fed with 500 to 2000 mg flavanones per kg diet over 4 weeks [94], and acute 
inhibition of platelet aggregation and increased tail bleeding time were observed in rats 2 
h after oral administration of 10 mg hesperidin per kg body weight or 100 mg citrus extract 
per kg body weight in an extent comparable to 50 mg aspirin per kg body weight [74]. The 
in vitro studies observed flavanone induced inhibition of platelet aggregation following 
stimulation with several platelet activating/aggregating factors and most potently after 
collagen or arachidonic acid stimulated platelet aggregation [73, 74] (Figure 5.1). Jin et al., 
[73] reported that the subcellular mechanisms of action by which flavanones inhibit 
platelet activation/aggregation include inhibition of phospholipase C-γ2 phosphorylation, 
cyclooxygenase1 activity (i.e. two enzymes specific to the collagen and arachidonic acid 
activation pathways, respectively) and a decrease in intracellular Ca2+ (Figure 5.1). 
However, it is unclear if these effects translate to humans in vivo, in particular given that 
the animal studies fed relatively high flavanone doses [74, 94] and all in vitro studies used 
supraphysiological concentrations of flavonoid forms that do not occur in the circulation 
[73-75]. Limited evidence from one non-controlled human study did not observe inhibited 
ex vivo ADP, collagen or thrombin stimulated platelet aggregation after daily intake of 
250ml orange juice or grapefruit juice for 7 days in a healthy population, whereas 250ml 
grape juice per day, a rich source of anthocyanins containing 3 times more flavonoids 
than the citrus juices, inhibited ex vivo collagen stimulated platelet aggregation relative to 
baseline [259]. Given the promising in vitro and animal evidence and to clarify the null 
findings from one non-controlled human study, human RCTs are warranted that test 
potential effects of flavanones on platelet function. 
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Figure 5.1 – Schematic presentation of the known pathways leading to platelet activation
1, 2 
 
1
The main known platelet agonists include collagen, thrombin, ADP and thromboxane A2 (TxA2). 
2
Platelet activation results in surface expression of the activated fibrinogen receptor (i.e. 
gpIIb/gpIIIa) and P-selectin (i.e. as a result of dense granule release). Figure adapted from [76] 
In this chapter, data from the acute human RCT aimed to examine whether dietary 
flavanones from orange juice mediate potential beneficial CV effects, at least in part, by 
increasing NO production, as assessed by plasma nitrite concentrations, and by inhibition 
of NADPH oxidase expression, as assessed by serum soluble gp91phox concentration. 
Furthermore, the study aimed to explore potential acute inhibitory effects of dietary 
flavanones from orange juice on platelet activation under basal conditions and upon ex 
vivo collagen related peptide (CRP) or ADP activation. 
5.2 Results 
As previously described in Chapter 4, data from n = 15 participants were included in the 
analysis (n = 12 for both interventions, n = 2 for the control intervention and n = 1 for the 
orange juice intervention). These data were incomplete because n = 2 participants did not 
attend the second experimental period and n = 2 participants did not adhere to dietary 
restrictions (as uncovered by plasma nitrite concentrations greater than mean + 3 * SD). 
Additionally, for platelet activation, data from 3 experimental periods had to be excluded 
due to haemolysis of the sodium citrated blood. Furthermore, one participant was 
prescribed naproxen which is a non-steroidal anti-inflammatory drug; nevertheless, his 
platelet data were included in the analysis because he served as his own control in this 
crossover study. The study participants were healthy men (age range: 51 to 69 years) at 
an estimated mean absolute 10 year CVD risk of 15.8 % and 13.6 %, respectively (BHS 
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criteria [204]) (Table 5.1). Participants reported good compliance to dietary and exercise 
restrictions prior to and during the experimental periods. 
Table 5.1 – Characteristics of study participants at screening 
 
 
Mean ± SD Range 
n 15 
 
Age (y) 60.3 ± 6 51-69 
Absolute CVD risk (%) 15.7 ± 0 10-20 
BMI (kg/m2) 25.7 ± 3.5 22-35 
Systolic BP (mm Hg) 137 ± 12.2 111-155 
Diastolic BP (mm Hg) 83.1 ± 6.6 73-94 
Blood lipids: (mmol/L)  
 
TC/ HDL-C ratio 4.2 ± 1.0 2.7 - 5.8 
LDL-C 3.5 ± 0.5 2.6-4.4 
Triglyceride 1.05 ± 0.4 0.6-2.3 
Haematology:   
White cell blood count (10^9/L) 5.4 ± 1.4 3.5-8.4 
Red cell blood count (10^12/L) 4.9 ± 0.3 4.3-5.6 
Platelet blood count (10^9/L) 33.7 ± 49.5 176-389 
Haemoglobin (g/dL) 43.4 ± 2.4 13.3-163 
Haematocrit (%) 236.6 ± 54.8 38.4-47.6 
Abbreviations: CVD, cardiovascular disease; BMI, body mass index; 
BP, blood pressure; TC, total cholesterol; HDL-C and LDL-C, high 
and low density lipoprotein cholesterol 
At baseline, CVD risk biomarkers and vitamin C plasma concentrations (method and data 
reported in Chapter 3) were similar between the dietary interventions. Plasma 
concentration of total flavanone metabolites was significantly elevated 5 h after the orange 
juice intervention relative to the control intervention (mean ± SD: 1.60 ± 1.33 μM; P < 
0.0001). Negligible amounts of flavanone metabolites were present at baseline and 5 h 
after the control intervention (i.e. ≤ 0.02 μM). 5 h post intervention, the orange juice 
intervention did not mediate an acute significant change in plasma nitrite, serum soluble 
gp91phox, platelet activation (assessed as P-selectin and fibrinogen receptor expression on 
platelets under basal conditions or after ex vivo activation with ADP or CRP) compared to 
the control intervention (Table 5.2). 
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Table 5.2 – Biomarkers of cardiovascular risk at baseline and 5 h following interventions in men at moderate cardiovascular disease risk 1 
 
 Mean ± SD  
 
Placebo 
 
Orange Juice 
 
Flavanone extract 
 
 
BL 5h ∆ 
 
BL 5h ∆ 
 
BL 5h ∆ P 2 
Plasma nitrite (nmol/L) 54.8 ± 16.8 54.7 ± 21.9 -0.1 ± 16 58.9 ± 14.4 55.7 ± 18.2 -3.2 ± 15.6 ND ND ND 0.388 
Serum soluble gp91
phox
 (pg/mL) 49.5 ± 22.2 48.6 ± 13 -0.8 ± 22.1  50.3 ± 22.1 54.9 ± 22.4 4.6 ± 18.7  ND ND ND 0.828 
P-selectin expression: (%) 
3
             
Platelets under basal conditions 3.9 ± 4.4 1.9 ± 2.4 -1.9 ± 2.2  4.8 ± 3.7 2.9 ± 2.9 -1.8 ± 1.3  3.6 ± 3.5 2.9 ± 2.5 -0.7 ± 2.3 0.112 
ADP activated platelets 95.7 ± 3.1 93.7 ± 4.8 -2 ± 2.6  96.4 ± 2.9 94.5 ± 4.7 -1.9 ± 4.3  94.8 ± 4.4 94.8 ± 3.1 0 ± 2.5 0.269 
CRP activated platelets 86.8 ± 14.1 87.7 ± 12.2 0.9 ± 7.1  88.7 ± 12.7 87.8 ± 14.6 -0.9 ± 5.7  87.6 ± 14.2 86 ± 15.1 -1.6 ± 3.6 0.411 
Fibrinogen receptor expression: (%) 
3
             
Platelets under basal conditions 1.4 ± 1.7 1.6 ± 2 0.3 ± 1.3  1.5 ± 1 1.1 ± 0.8 -0.4 ± 0.5  1.3 ± 1.3 1.6 ± 1.5 0.2 ± 1.6 0.454 
ADP activated platelets 76.9 ± 11 73.6 ± 11.9 -3.2 ± 5.2  79.4 ± 10.1 75.5 ± 10.2 -4 ± 8.4  75.6 ± 12.8 75.6 ± 11.1 0 ± 4.9 0.202 
CRP activated platelets 79.7 ± 16.7 84.2 ± 10.2 4.5 ± 11.3  82.3 ± 14.1 82.1 ± 14.6 -0.2 ± 5.2  81.3 ± 16.6 80.9 ± 15.7 -0.4 ± 4.9 0.151 
1 
The sample sizes for the dietary interventions were n = 14 (control), n = 13 (orange juice) and n = 15 (flavanone extract), except for platelet activation (n = 12 for control and 
orange juice interventions). 
2 
differences between the dietary interventions were established using a linear mixed model for crossover studies with baseline values on each 
experimental period as the covariate. 
3 
expressed as % positive platelet events; ND, not determined 
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5.3 Discussion 
CV biomarker and platelet data from this RCT suggest that at 5 h post intervention, the 
orange juice intervention (767 ml; providing 320 mg hesperidin and 48 mg narirutin) did 
not acutely increase nitrite plasma concentrations, decrease serum concentrations of 
soluble gp91phox or inhibit platelet activation in men at a mild to moderate risk of CVD 
relative to a sugar and vitamin C matched control intervention (Table 5.2), even though 
plasma concentrations of flavanone metabolites were significantly elevated 5 h after the 
orange juice intervention (Chapter 6). 
Although a number of preclinical studies suggested that flavanones may enhance 
vascular NO production [60, 68-70, 94], a previous RCT did not observe an increase in 
total NO metabolite plasma concentrations after acute (i.e. at 6 h) or short-term (i.e. after 
4 weeks) intake of flavanones in overweight men [59]. To better understand these 
conflicting data, the present study assessed potential acute effects of flavanones on nitrite 
plasma concentrations which was reported to be a more accurate indicator of vascular NO 
production than total NO metabolite plasma concentrations [64, 198]. Furthermore, animal 
data suggested that flavanones may enhance vascular NO production through inhibition of 
NADPH oxidase gene expression [95] which led us to assess the potential acute effects of 
flavanones on serum concentration of soluble gp91phox, an in vivo marker of NADPH 
oxidase gene expression [199]. However, and consistent with total NO metabolite data of 
Morand et al., [59], no acute increase in plasma nitrite concentration or decrease in serum 
gp91phox was observed 5 h after the orange juice intervention relative to the control 
intervention in healthy men at a mild to moderate CVD risk. This is consistent with the 
present clinical data (Chapter 3) suggesting no acute beneficial effects of the orange juice 
intervention on endothelial function, arterial stiffness and CV autonomic function, three 
markers of CVD risk that are, at least in part, regulated by vascular NO [17, 145, 252]. In 
contrast, most other flavonoid subclasses have been reported to increase vascular NO 
production as reported by a number of acute human RCTs using a range of assessment 
methods (i.e. plasma concentrations of total NO metabolites, nitrite or nitroso species or 
urinary excretion of total NO metabolites), various study populations (i.e. healthy and 
smokers) and flavonoid doses (range: 80 to 200 mg) [191, 192, 230, 260, 261]. Mixed 
findings from two acute human RCTs are available regarding effects of flavonoids on 
NADPH oxidase gene expression, with one suggesting flavan-3-ols [260] to decrease 
serum concentration of soluble gp91phox in young smokers and one observing no change 
following an anthocyanin intervention in healthy men [232]. In summary, unlike these very 
similar acute RCTs intervening with other flavonoid subclasses, flavanones might not 
mediate potential beneficial CV effects in humans in vivo through enhancement of NO 
production or inhibition of NADPH oxidase gene expression, and further human RCTs are 
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required to establish the mechanisms by which dietary flavanones mediate potential 
beneficial CV effects. 
In a critical review of 25 human RCTs examining the effects of flavonoids on platelet 
function, sufficient evidence was found to suggest that intake of flavan-3-ols and cocoa 
containing foods inhibit platelet function with consumption of 100 g dark chocolate having 
an effect comparable to 81 mg aspirin, but only inconclusive data were available for other 
flavonoid subclasses and no data were published for flavanones [164]. Hence, to the 
author’s knowledge, the present acute human RCT was the first to examine potential 
inhibitory effects of dietary flavanones on platelet activation which have been suggested 
by a number of in vitro and animal studies [73-75, 94]. However, 5 h after intake of an 
orange juice intervention, no acute inhibition of platelet activation (under basal conditions 
or upon submaximal ex vivo stimulation with ADP or CRP) was observed in healthy men 
at a mild to moderate risk of CVD relative to a control intervention (Table 5.2). These data 
are consistent with a previous non-controlled human study that did not observe an 
inhibition of collagen, ADP or thrombin stimulated ex vivo platelet aggregation after daily 
intake of 250 ml orange juice or grapefruit juice for 7 days relative to baseline [259]. 
Overall, data from these two human studies suggest that inhibition of platelet 
activation/aggregation may not be a mechanism by which flavanones exert potential 
beneficial CV effects. However, further human studies are required to fully establish 
whether or not flavanones may inhibit platelet activation/aggregation. In particular, 
potential inhibitory effects of dietary flavanones on arachidonic acid stimulated ex vivo 
platelet activation/aggregation remain to be examined, because this particular pathway 
was reported to be potently inhibited by flavanones in in vitro and animal studies [73, 74]. 
Furthermore, whilst platelets were activated on average by 78 up to 96 % (Table 5.2), the 
acute human RCT of Rein et al., [202] observed inhibitory effects of flavan-3-ols at a much 
lower activation of platelets (i.e. 10 % or 60 % when stimulated with 20 μM epinephrine or 
20 μM ADP, respectively). Moreover, a number of human studies found attenuation of 
inhibitory effects up to no inhibition induced by flavan-3-ols or anthocyanins on platelet 
aggregation, the more platelet agonist was used [259, 262, 263]. Thus, in contrast to the 
herein used submaximal stimulation of platelet activation, further human RCTs need to 
examine potential inhibitory effects of flavanones on platelet activation/aggregation upon 
minimal to medium ex vivo stimulation by platelet agonists. Ideally, these studies include 
both platelet activation and aggregation assessments and use a range of platelet 
agonists. 
The following limitations in this study are worth noting. The present study had an acute 
study design with a single assessment at 5 h post intervention; however, flavanone 
derived metabolites were detected in urine up to 24 h after intake [113]. Therefore, an 
acute investigation over a longer time period may have been more adequate in fully 
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establishing potential mechanisms by which flavanones mediate beneficial CV effects and 
examine potential inhibitory effects on platelets activation. Furthermore, a human RCT 
with a short-term or chronic (rather than an acute) flavanone intervention would have 
provided more relevant information with regards to potential health benefits of a diet rich in 
flavanones and citrus fruits. Although to the author’s knowledge, this is the first human 
RCT that examined potential acute effects of flavanones on plasma nitrite concentrations, 
serum concentrations of soluble gp91phox and platelet activation and they were not acutely 
affected by intake of flavanones, inclusion of a wider range of assays may have provided 
a more complete understanding of the potential mechanism of action by which flavanones 
mediate beneficial CV effects. These assays include the assessment of plasma 
concentrations of nitroso species [192], urinary excretion of total nitric oxide metabolites 
[191], serum concentrations of asymmetric dimethylarginine (i.e. an endogenous eNOS 
inhibitor) [133], NADPH oxidase activity in neutrophils [232], plasma endothelin-1 [191] 
plasma prostacyclin/leukotriene ratio [264], platelet microparticles [202], plasma soluble P-
selectin or CD40L [265] and, as explained above, measuring both platelet activation and 
aggregation following only minimal to medium ex vivo stimulation with platelet agonists 
(i.e. similar to Rein et al., [202]), ideally using collagen and/or arachidonic acid ex vivo 
stimulation (as proposed by Jin et al., [73] and Yu et al., [74]). 
In conclusion, the orange juice intervention did not acutely increase nitrite plasma 
concentrations, decrease serum concentration of soluble gp91phox or inhibit platelet 
activation in healthy men at a mild to moderate risk of CVD at 5 h post intervention relative 
to the sugar and vitamin C matched control intervention. Further studies are required to 
determine the mechanisms by which flavanones exert beneficial CV effects and more 
platelet data are warranted to fully establish whether or not flavanones inhibit platelet 
function. 
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Chapter 6. Plasma concentrations of flavanone and 
phenolic acid metabolites 5 hours after a single oral 
dose of flavanones 
6.1 Introduction 
Evidence from epidemiological studies [48, 49] and human intervention trials [59, 60] 
suggests that consumption of flavanones and citrus fruits may have cardiovascular (CV) 
health benefits. Examination of the absorption, distribution, metabolism and excretion 
(ADME) of dietary flavanones is important to help us understand what forms of flavanone 
metabolites may act on which target tissues (e.g. the vascular endothelium and platelets) 
and, in turn, mediate potential beneficial CV effects. ADME of flavanone phase II 
metabolites has previously been examined, and relative urinary recovery of these 
metabolites ranged from only 1.5 to 14 % [71, 72, 78, 108]. Thus, it is understandable that 
dietary flavanones may also be subject to microbial degradation and bioavailable as 
phenolic acid metabolites. 
However, relatively little is known regarding ADME of flavanone-derived phenolic acid 
metabolites. Limited evidence from one orange juice intervention trial identified 5 phenolic 
acids as flavanone metabolites in 24 h urine at levels reaching 37 % of ingested 
flavanones relative to a flavanone-free control intervention [113]. Furthermore, Vallejo et 
al., [78] identified 7 circulating glucuronide conjugated phenolic acid metabolites and 
suggested that they were derived from oral intake of orange juice [78]. However, they did 
not include a flavanone-free control intervention and did not quantify plasma 
concentrations, and, therefore, it is unclear whether these putative phenolic acid 
metabolites originate from ingested flavanones or other sources such as the background 
diet [101, 266]. 
Moreover, little is known regarding the potential CV bioactivity of these absorbed 
flavanone and phenolic acid metabolites. In an acute flavanone RCT, a mean ± SEM 
plasma concentration of hesperetin of 0.86 ± 0.16 µM correlated with improved 
microvascular endothelial function suggesting that hesperetin metabolites may be partly 
mediating the observed beneficial CV effects [59]. However, this study enzymatically 
hydrolysed the glucuronides and sulfates from phase II metabolites of hesperetin and did, 
therefore, not quantify the unique circulating phenolic acid metabolites. 
The aim of the present study was to identify and quantify concentrations of a broad range 
of flavanone phase II metabolites and of previously reported and novel phenolic acid 
metabolites in 5 h post-intervention plasma samples from an acute crossover placebo-
controlled orange juice intervention in men at a mild to moderate risk of CVD. 
Relationships between plasma levels of flavanone metabolites and markers of CVD risk 
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(described in Chapter 3 and Chapter 4) were also explored to indicate which metabolites 
may be potential mediators of beneficial CV effects. 
6.2 Results 
Plasma samples collected at baseline and 5 h after participants received the control 
intervention and the orange juice intervention were analysed by HPLC-MS2 in sMRM 
analysis mode. Hesperetin, naringenin, 6 phase II metabolites of flavanones and 15 
phenolic acid metabolites were identified in plasma collected 5 h after participants 
received the orange juice intervention (Figure 6.1). 
Hesperetin, naringenin, naringenin-7-glucuronide and 11 phenolic acid metabolites were 
identified based on RT and having ≥ 3 sMRM transitions relative to a pure standard, whilst 
5 phase II metabolites of flavanones were putatively identified based on having ≥ 3 sMRM 
transitions (Table 3.3 & 5.3; Figure 6.1), which were previously reported and specific to 
phase II metabolites of flavanones [71, 72]. Moreover, 4 phenolic acids were putatively 
identified based on 3 to 5 sMRM transitions (i.e. 2 isomer phenolic acids and 2 phenolic 
acid glucuronides for which analytical standards were not available) (Figure 6.1; Table 
3.3). 
There were 13 further phenolic acids included in the original analysis (Appendix 4). 
However, 4 of these phenolic acids were below the limit of detection and plasma 
concentrations of the other 9 phenolic acids did not significantly differ between the orange 
juice and control interventions indicating they are not specific flavanone metabolites. 
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Figure 6.1 – Typical HPLC-ESI-MS
2
 trace of flavanone metabolites in plasma extracts collected 5 h after participants consumed the orange juice intervention 
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Table 6.1 – Chemical structure of identified flavanone and phenolic acid metabolites 
    
 
1
 Number refers to peak in Figure 5.3; 
2
 R = H, unless stated otherwise; 
3
 site of conjugation could 
not be ascertained as identification was based on known transitions where pure standards for 
isomers were not available or separation of isomers was chromatographically not possible 
5 h after consumption of the orange juice intervention, aglycones and phase II metabolites 
of flavanones were detected at mean plasma concentrations of 1.60 ± 1.33 μM, which was 
significantly increased relative to the control intervention and baseline (P < 0.01) (Figure 
6.2 A1 and Table 6.2). A negligible amount of flavanone aglycones and their phase II 
metabolites were detected in baseline and 5 h samples following the control intervention 
(Figure 6.2 A1). The plasma concentration of hesperetin-glucuronide was significantly 
elevated 5 h post control intervention relative to baseline, but only to a negligible extent 
(Figure 6.2 A1 and Table 6.2). Of the flavanone aglycones and their phase II metabolites, 
Chemical structure #1 Analyte name Configuration2
23
19 & 21
16 & 17
hesperetin
hesperetin-glucuronide3
hesperetin-diglucuronide3
R = H
R1, R2 or R3 = O-GlcA
R1&2, R1&3 or R2&3 = 
O-GlcA
22
18
20
naringenin
naringenin-7-glucuronide
naringenin-glucuronide3
R = H
R1 = O-GlcA
R2 or R3 = O-GlcA
6
3
2
hippuric acid
3-hydroxyhippuric acid
hydroxyhippuric acid3
R = H
R3 = OH
R1, R2, R4 or R5 = OH
12 ferulic acid-glucuronide3
isoferulic acid-glucuronide3
R1 = O-GlcA, R2 = CH3
R1 = CH3, R2 = O-GlcA
15
14
dihydroferulic acid
dihydroferulic acid-3-
glucuronide
R = OH
R = O-GlcA
8
10
4-hydroxyphenylacetic acid
3-hydroxyphenylacetic acid
R2 = OH
R1 = OH
13
5
11
4
9
1
vanillic acid
vanillic acid-3-glucuronide
isovanillic acid
isovanillic acid-3-glucuronide
4-hydroxy-benzoic acid
benzoic acid-4-glucuronide
R1 = OCH3, R
2 = OH
R1 = OCH3, R2 = O-GlcA
R1 = OH, R
2 = OCH3
R1 = O-GlcA, R2 = OCH3
R2 = OH
R2 = O-GlcA
O
R2 O
R3
R1
O
R2 O
O
CH3
R1
R3
NH
OH
O
O
R3
R2
R1
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R2
R1O
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hesperetin-glucuronides represented 64.4 % of the flavanones identified, followed by 
naringenin glucuronides (19.3 %), hesperetin-diglucuronides (18.9 %) and flavanone 
aglycones (0.8 %) (Figure 6.2 A2). 
Figure 6.2 – Plasma concentrations and relative proportions of flavanones and phenolic 
acid metabolites 
 
Mean (± SD) plasma concentrations of flavanone aglycones and their phase II metabolites (A) and total 
phenolic acid metabolites (B) quantified at baseline and 5 h after the control intervention (n = 14), orange juice 
intervention (n = 13) and flavanone extract intervention (n = 15; phenolic analysis was not performed). 
Individual metabolites and their relative proportions 5 h after the orange juice intervention (n = 13): (C): 1, 
hesperetin-glucuronide; 2, hesperetin-glucuronide; 2, hesperetin-glucuronide; 3, hesperetin-diglucuronide; 4, 
hesperetin-diglucuronide; 5, naringenin-7-glucuronide; 6, naringenin-glucuronide; 7, hesperetin; 8, naringenin; 
(D): 9, hippuric acid; 10, dihydroferulic acid; 11, dihydroferulic acid-3-glucuronide; 12, 4-hydroxyphenylacetic 
acid; 13, vanillic acid; 14, hydroxyhippuric acid; 15, iso/ferulic acid-glucuronide; 16, 3-hydroxyhippuric acid; 17, 
isovanillic acid; 18, 3-hydroxyphenylacetic acid; 19, vanillic acid-glucuronide; 20, isovanillic acid-glucuronide; 
21, iso/vanillic acid-glucuronide; 22, 4-hydroxy-benzoic acid; 23, benzoic acid-4-glucuronide; 5 h post 
intervention differences between the dietary interventions were established using a linear mixed model for 
crossover studies with baseline values on each experimental period as the covariate. Differences between the 
orange juice or supplement intervention and the control intervention were assessed by post-hoc analyses with 
Tukey adjustment and are indicated as follows; ****, P < 0.0001. 
A B
C
**** ****
D
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There was a high mean background concentration of phenolic acids present in baseline 
plasma, yet mean plasma concentrations of total phenolic acid metabolites were 
significantly elevated 5 h after the orange juice intervention compared to the control 
intervention (19.59 ± 7.46 μM and 5.69 ± 1.70 μM, respectively; P < 0.0001) and baseline 
(P < 0.001) (Figure 6.2 B1 and Table 6.3). Plasma concentrations of total phenolic acid 
metabolites was significantly decreased 5 h post control intervention relative to baseline 
(P < 0.05); in particular, hippuric acid and 3-hydroxyhippuric acid contributed significantly 
to this decrease, whereas some compounds such as isovanillic acid and 3-
hydroxyphenylacetic acid significantly increased (Table 6.3). Of the 15 identified phenolic 
acid metabolites, the ones found in the highest concentrations were hippuric acid 
contributing 54.2 % to total phenolic acid plasma concentration, followed by dihydroferulic 
acid (15.3 %), dihydroferulic acid-glucuronide (7.8 %) and 4-hydroxyphenylacetic acid (6.2 
%) (Figure 6.2 B2 and Table 6.3). 
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Table 6.2 – Plasma concentrations of flavanone aglycones and their phase II metabolites at baseline and 5 h after the 
dietary interventions 
1
 
 
 Mean ± SD (nM)  
 
Placebo 
 
Orange Juice 
 
Flavanone extract 
 
 
BL 5h BL 5h BL 5h P 
2
 
Total 12 ± 9 15 ± 7  12 ± 6 1601 ± 1331 ****  10 ± 11 61 ± 100 < 0.0001 
Hesperetin-glucuronide 13
a
 6 ± 4
c
  5
a
 756 ± 605 ****  ND 51 ± 77
h
 < 0.0001 
Hesperetin-glucuronide ND 6 ± 2
h
  5
a
 245 ± 223 ****  4
a
 25 ± 33
h
 < 0.0001 
Hesperetin-diglucuronide ND ND  ND 146 ± 121 ****  3
a
 11 ± 10
d
 < 0.0001 
Hesperetin-diglucuronide ND ND  ND 133 ± 137 ****  3
a
 4 ± 1
b
 < 0.0001 
Naringenin-7-glucuronide 4 ± 5 2 ± 2  4 ± 4 222 ± 247 ****  4 ± 6 4 ± 3 < 0.0001 
Naringenin-glucuronide 3 ± 2 2 ± 1  3 ± 1 82 ± 90 ****  5 ± 4 3 ± 2 < 0.0001 
Hesperetin 1 ± 0 1 ± 0  1 ± 0 9 ± 8 ****  NM NM < 0.01 
Naringenin 4 ± 2 4 ± 2  4 ± 2 9 ± 4 ****  NM NM < 0.05 
1 
The sample sizes for the dietary interventions were n = 14 (control), n = 13 (orange juice) and n = 15 (Flavanone extract). 
Some metabolites were detected only in a subset of the participants: a, n = 1; b, n = 3; c, n = 4; d, n = 5; e, n = 6; f, n = 7; 
g, n = 8; h, n = 9; i, n = 10; j, n = 12; k, n = 13)]. 
2
 Differences between the dietary interventions were established using a 
linear mixed model for crossover studies with baseline values on each experimental period as the covariate and 
considered significant at a P-value < 0.05. Differences between the orange juice or supplement intervention and the control 
intervention were assessed by post-hoc analyses with Tukey-Kramer adjustment and are indicated as follows; ****, P < 0.0001. If 
plasma concentration was ND, the concentration was replaced with the limit of detection for statistical analysis. ND; not 
detected. 
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Table 6.3 – Plasma concentrations of phenolics at baseline and 5 h after the dietary interventions 
1
 
 
 Mean ± SD (nM)  
 
Placebo 
 
Orange Juice 
 
 
BL 5h BL 5h P 
2
 
Total 10041 ± 6944 5689 ± 1702 *  7964 ± 4945 19590 ± 7464 *** < 0.0001 
Hippuric acid 7917 ± 6832 3127 ± 1298 *  6245 ± 4763 10100 ± 4097 ** < 0.0001 
Dihydroferulic acid 8 ± 4
g
 6
a
  14 ± 12
c
 2432 ± 2651 ** < 0.01 
Dihydroferulic acid-3-glucuronide ND ND  ND 1250 ± 1742 * < 0.05 
4-hydroxyphenylacetic acid 850 ± 594 853 ± 613  577 ± 299 1567 ± 812 *** < 0.01 
Vanillic acid 19 ± 6
k
 19 ± 6
k
  19 ± 8
j
 759 ± 777 ** < 0.01 
Iso/ferulic acid-glucuronide 27 ± 24
k
 114 ± 54 ***  27 ± 17 521 ± 163
i
 **** < 0.0001 
Hydroxyhippuric acid 129 ± 103 93 ± 78 **  110 ± 108 611 ± 382 *** < 0.001 
Isovanillic acid 48 ± 54
j
 205 ± 201*  43 ± 23 393 ± 218
i
 **** < 0.05 
3-hydroxyphenylacetic acid 686 ± 268
k
 848 ± 209
k 
*  639 ± 213 978 ± 206 **** < 0.05 
Isovanillic acid-glucuronide 12 ± 13
i
 165 ± 286
k **
  13 ± 9
f
 264 ± 256 ** < 0.05 
Vanillic acid-glucuronide 19 ± 24
e
 73 ± 53
i *
  6 ± 1
g
 199 ± 85 ** < 0.001 
3-hydroxyhippuric acid 224 ± 360 117 ± 215 *  179 ± 321 362 ± 337 ** < 0.001 
Iso/vanillic acid-glucuronide ND ND  ND 17 ± 16 ** < 0.01 
Benzoic acid-4-glucuronide 3 ± 4 2 ± 2  3 ± 3 7 ± 4 **** < 0.001 
4-hydroxy-benzoic acid 141 ± 109 121 ± 56  161 ± 91 159 ± 81 < 0.05 
1 
The sample sizes for the dietary interventions were n = 14 (control) and n = 13 (orange juice). The analysis was not performed for the 
flavanone extract intervention. Some metabolites were detected only in a subset of the participants: a, n = 1; b, n = 3; c, n = 4; d, n = 5; e, n = 6; 
f, n = 7; g, n = 8; h, n = 9; i, n = 10; j, n = 12; k, n = 13)]. 
2
5 h post intervention differences between the two dietary interventions were 
established using a linear mixed model for crossover studies with baseline values on each experimental period as the covariate and changes 
between baseline and 5 h post intervention were established using paired t-test. Significant changes of the statistical tests are indicated with * 
for P < 0.05, ** for P < 0.01, *** for P < 0.001 and **** for P < 0.0001. If plasma concentration was ND, the concentration was replaced with the 
limit of detection for statistical analysis. ND; not detected. 
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Cumulatively, phenolic acid metabolites reached a 10 fold higher plasma concentration 
than the flavanone aglycones and their phase II metabolites (15.96 μM versus 1.47 μM, 
respectively) 5 h after the orange juice intervention relative to baseline and the control 
intervention. There was a large inter-individual variability for the plasma concentration of 
flavanone and phenolic acid metabolites (5 h changes from baseline ranging from: 0.46 to 
5.29 µM and -1.2 to 30.8 µM, respectively) (Figure 6.3). 
Figure 6.3 – Inter-individual variability in plasma concentrations of flavanone and phenolic 
acid metabolites 5 h after the orange juice intervention relative to baseline
1 
 
1
 Increase in plasma concentrations of total flavanone aglycones and their phase II 
metabolites (A) and phenolic acid metabolites (B) for each participant. The blue and red 
lines highlight the participant with the highest and lowest change in plasma concentration 
of the metabolite, respectively. 
Plasma concentrations of 5 flavanone metabolites, 12 phenolic acid metabolites and their 
individual sums increased by ≥ 100 nM from baseline to 5 h post orange juice intervention 
(Table 6.2 & Table 6.3) and were, therefore, deemed as potentially physiologically 
important changes and included in correlation and regression analyses. Increased plasma 
concentrations of several metabolites were correlated (using Pearson’s correlations) with 
changes in specific markers of CVD risk (Appendix 5). For instance, increased total 
phenolic acid metabolites or 4-hydroxyphenylacetic acid levels from baseline to 5 h post 
orange juice intervention were negatively correlated with systolic BP or pulse wave 
velocity, respectively (where a decrease represents a biologically favourable change); 
conversely, increased levels of isovanillic acid-glucuronides were also positively 
correlated with heart rate (where an increase represents an unfavourable biological 
change). Yet, these relationships lost significance when using a multivariate regression 
model that included all 19 plasma metabolites. 
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6.3 Discussion 
The present study identified 23 plasma flavanone metabolites which were significantly 
elevated 5 h after an orange juice intervention (providing 320 mg hesperidin and 48 mg 
narirutin) compared to a flavanone-free control intervention, and these metabolites 
included 2 flavanone aglycones, 6 flavanone phase II metabolites, 9 additional previously 
unidentified phenolic acid metabolites and 6 phenolic acid metabolites that were 
previously reported in urine [113]. To the author’s knowledge, this was the first time 
phenolic acid metabolites have been quantified in plasma following consumption of a 
single dose of flavanones. 
The findings regarding flavanone aglycones and their phase II metabolites were similar to 
those reported in previous pharmacokinetic studies feeding orange juice [71, 72, 78, 107, 
108]. The mean plasma concentrations of total flavanone aglycones and their phase II 
metabolites 5 h after the orange juice intervention was in accordance with reported mean 
maximal plasma concentrations (i.e. 0.2 to 2.2 μM) [71, 72, 78, 107, 108], whilst only 
negligible amounts were detected at baseline and after the flavanone-free control 
intervention. These negligible amounts possibly originated from other dietary sources 
(other than citrus fruits) in the habitual and intervention diets, such as tomatoes or herbs 
containing small amounts of flavanones [100]. Consistent with previous studies [71, 78, 
108], the vast majority of the identified metabolites were glucuronide conjugates of the 
parent flavanones, whereas only trace amounts of flavanone aglycones were detected in 
plasma. The present study did not detect hesperetin-sulfate and hesperetin-sulfate-
glucuronide, two metabolites that were previously detected in urine [71, 72, 78] and only 
inconsistently in plasma by some studies [78, 108] but not by others [71]. Genetic 
polymorphisms in sulfotransferase enzymes between study populations could be a 
possible explanation for these discrepant findings [267]. Hesperetin was also observed to 
undergo phase I metabolism to the flavanone eriodictyol in an ex vivo pig caecum model 
[268]. However, neither eriodictyol aglycones nor its putative phase II metabolites (Figure 
3.6) were detected. Possible reasons may be that eriodictyol is a transient metabolite not 
reaching the human circulation but undergoing degradation to smaller phenolic acids or 
that the human microflora does not metabolise hesperetin to eriodictyol unlike the colonic 
microflora of pigs. 
Phenolic acids were present in the baseline diets and biological samples of individuals 
because they are ubiquitously present in plant based foods including fruit, vegetables, 
cereals, coffee and tea [266, 269] for which the present study could only control for to a 
limited extent. Moreover, certain phenolic acids such as hippuric acid may originate from 
endogenous metabolism [270]. Nevertheless, by using the control intervention to account 
for these influencing factors, plasma concentrations of 15 phenolic acids were significantly 
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elevated from baseline to 5 h after the orange juice intervention relative to the control 
intervention (Figure 6.2B), suggesting that these metabolites were derived from 
flavanones or phenolic acids in the orange juice intervention. These phenolic acids 
included 9 novel metabolites and 6 metabolites that were previously quantified in 24h 
urine by a controlled orange juice pharmacokinetic study of Roowi et al., [113] (Table 3.3, 
Table 6.3). Their study quantified 9 phenolic acids in 24 h urine samples and consistent to 
the data presented here, 24 h urinary excretion of dihydroferulic acid, 3-hydroxyhippuric 
acid and 3-hydroxyphenylacetic acid was significantly elevated after intake of orange juice 
compared to a control [113]. Furthermore, they identified 3-methoxy-4-
hydroxyphenylhydracrylic acid and 3-hydroxyphenylhydracrylic acid as flavanone 
metabolites [113]; however, the present study did not include these two metabolites 
because standards were not available for method development and, therefore, their 
presence and concentration in plasma remains unknown. Roowi et al., [113] did not 
observe increased 24 h urinary excretion of 4-hydroxy benzoic acid, hippuric acid and 4-
hydroxyphenyl acetic acid after intake of orange juice relative to control, whereas the 
present study observed significantly increased plasma concentrations of these 3 phenolic 
acids. Differences between analysed biofluids (i.e. urine versus plasma), assessment of a 
single timepoint versus a 24 h period and differences in the dietary restrictions before and 
during the experimental period may potentially explain these discrepant findings. 
Additionally, Vallejo et al., [78] identified a number of glucuronidated phenolic acid 
metabolites in plasma after intake of orange juice (i.e. phloretic acid-glucuronide, p-
courmaric acid-glucuronide, cinnamic acid-glucuronide, homovanillic acid-glucuronide, 
hydroxyl-benzoic acid-glucuronide and hippuric acid-glucuronide and hydroxyphenyl 
acetic acid-glucuronide). However, the data presented here suggest that p-courmaric 
acid-glucuronide may not be a flavanone metabolite (Appendix 4) and the other phenolic 
acids were not detected in plasma. Possible explanations for identification of different 
phenolic acid glucuronide metabolites could result of small differences in flavanone 
metabolism between the study participants or that the study of Vallejo et al., [78] did not 
have a comparative control intervention and therefore their reported metabolites may be 
attributed to a different dietary source than orange juice. Nevertheless, the present study 
identified similar flavanone metabolites to those that they identified such as isoferulic acid-
glucuronide, dihydroferulic acid-glucuronide and vanillic acid-glucuronide, or the same 
metabolites but not conjugated to a glucuronide, such as hippuric acid, 4-hydroxy-benzoic 
acid and hydroxyphenylacetic acid. Overall, in addition to these previous studies [78, 113], 
9 previously unidentified phenolic acid metabolites were identified and, to the author’s 
knowledge, phenolic acid metabolites (i.e. a total of 15) were quantified in plasma for the 
first time. 
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In comparison with plasma concentrations of flavanone aglycones and their phase II 
metabolites, phenolic acid metabolites reached 10 fold higher plasma concentrations. 
These findings suggest that phenolic acid metabolites contribute substantially to the 
circulating pool of flavanone metabolites and together with phase II metabolites of 
flavanones, dietary flavanones may be more bioavailable than previously thought [105, 
109]. In fact, the cumulative plasma concentrations of the 23 identified flavanone 
metabolites increased to a similar extent as did vitamin C (i.e. P = 0.70) 5 h after the 
orange juice intervention that provided 368 mg flavanones and 439 mg vitamin C relative 
to baseline and the control intervention. A large inter-individual variability in plasma 
concentrations changes from baseline of both flavanone phase II metabolites (i.e. range: 
0.46 to 5.29 µM) and phenolic acid metabolites (i.e. range: -1.2 to 30.8 µM) was observed 
5 h after the orange juice intervention relative to baseline and the control intervention. This 
is consistent with Vallejo et al., [78] who reported large differences in pharmacokinetics 
and urinary excretion of flavanone phase II metabolites between participants and at the 
same time they observed low within-participant variability and found no correlation with 
gender or BMI. These inter-individual differences in pharmacokinetics were observed not 
only for flavanones but for a wide range of dietary phytochemicals, and factors including 
the composition and activity of gut microflora, genetic variation in phase II enzymes (e.g. 
expression, stability and activity of glucuronsyltransferases and/or sulfotransferases) and 
intestinal transporters of each individual may determine to which extent they metabolise 
and absorb phytochemicals, including dietary flavanones [109, 267]. In turn, this may also 
translate to large inter-individual variability in how individuals might benefit from intake of 
dietary flavanones in relation to potential beneficial CV effects. 
Short-term (i.e. 3-4 week) intake of flavanones may reduce diastolic BP [59] and improve 
endothelial function [60] as recently reported in two human RCTs. However, little is known 
regarding which phase II metabolites of flavanones and phenolic acid metabolites are the 
responsible mediators of these beneficial CV effects. The present study observed no 
beneficial acute effects of the orange juice intervention on the assessed markers of CVD 
risk relative to the vitamin C matched control intervention (Chapter 3 and 4). Consistently, 
none of the multivariate regression analyses suggested a significant association between 
plasma concentrations of flavanone / phenolic metabolites and markers of CVD risk and 
only some significant correlations of an exploratory nature were found (Appendix 5) that 
would require further investigations. However, there is supportive evidence associating 
flavanones and phenolic acids with beneficial CV effects. In an acute flavanone RCT, 
improved endothelial function strongly correlated with plasma hesperetin concentrations 
(albeit they were using a method which enzymatically hydrolysed glucuronide and sulfate 
conjugates) [59], and multivariate regression analysis of an acute flavonoid intervention 
(with blueberry anthocyanins) suggested that differences in plasma concentrations of a 
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range of phenolic acid metabolites predict beneficial responses in endothelial function and 
NADPH oxidase activity [232]. Moreover, urinary excretion of hippuric acid has been 
inversely associated with BP in a large population-based study [271]. 
Despite the identification and quantification of some novel flavanone-derived circulating 
metabolites, this study has limitations. Even though a pooled (n = 13) plasma extract 
collected 5 h after the orange juice intervention was screened for presence of 158 
potential metabolites and identified 23 of them as flavanone metabolites (Figure 3.6), 
some flavanone metabolites might have been missed. Underlying reasons may include 
methods for two known flavanone metabolites (i.e. 3-methoxy-4-hydroxyphenyl hydracrylic 
acid and 3-hydroxyphenylhydracrylic [113]) were unavailable, and the used HPLC-MS2 
method, albeit sensitive for quantification of flavanone phase II metabolites, has a 
relatively high detection limit for certain phenolic acids due to their lower molecular weight 
or poor ionisation, and more metabolites might have been identified if gas 
chromatography-MS2 had been used. To the author’s knowledge, this is the first study that 
quantified plasma concentrations of 15 flavanone-derived phenolic acid metabolites; yet, 
concentrations were only assessed 5 h after an orange juice intervention and, therefore, a 
more complete time course (e.g. up to 24 h) and inclusion of urine and faecal sample 
analysis would be required to establish absorption, clearance kinetics and elimination 
routes of the identified circulating metabolites. 5 flavanone phase II metabolites and 4 
phenolic acid metabolites were only tentatively identified based on ≥3 sMRM transitions 
due to lack of availability of analytical standards, which would have been required to 
confirm a RT match. As a result, the site of glucuronide conjugation or the isomeric 
configuration could not be determined (Table 3.3). Whilst the used sMRM transitions of 
the phase II metabolites of flavanones match with those previously reported [71, 228], the 
use of synthesised standards or methods such as nuclear magnetic resonance 
spectroscopy would be necessary to confirm the exact structural identities of the putative 
phenolic acids. Although phenolic acid metabolites derived from flavanones of an orange 
juice intervention were identified relative to a flavanone-free control intervention, an 
intervention with isotopically labelled flavanones would provide more robust evidence and 
complete insights in regards to the metabolic fate of flavanones. Lastly, the phenolic acid 
content of the orange juice was not measured in-house but only estimated based on 
previously reported mean levels [208]. However, this estimate may not reflect the exact 
dose provided in the present orange juice intervention because phytochemical content of 
orange juice varies depending on geographic cultivation region, seasonal changes and 
processing [38]. 
In conclusion, the present study established that 5 h after an orange juice intervention 9 
novel and 14 previously identified flavanone and phenolic acid metabolites were 
significantly elevated in plasma relative to the control intervention. Future human studies 
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are required to establish the pharmacokinetics of these metabolites and their potential 
beneficial CV effects. 
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Chapter 7. General discussion and future research 
perspectives 
7.1 Overview 
A third of the UK’s mortality is attributed to cardiovascular disease (CVD) [1] and a diet 
rich in fruit and vegetables is a key factor in potentially reducing CVD risk [37]. Citrus fruits 
and flavanones may substantially contribute to these benefits given the large body of 
epidemiological evidence that suggests a high intake of either is inversely associated with 
CVD morbidity and mortality [43-51, 54, 236]. For example, in two large cohort studies 
using multi-variable adjusted models (including estimated vitamin C intakes), a diet rich in 
flavanones was associated with a significantly reduced risk of stroke [relative risk (RR): 
0.81 (95 % confidence interval (CI): 0.66 - 0.99)] [48] and coronary heart disease [RR: 
0.78 (95 % CI: 0.65 - 0.94)] [49].Furthermore, a number of supportive studies using animal 
models proposed that flavanones mediate beneficial cardiovascular (CV) effects by 
favourably altering lipid profile [165], vascular function [principally via enhanced 
bioavailability of nitric oxide (NO)] [60] and CV autonomic function [148] as well as through 
a reduction in blood pressure (BP) [93] and platelet reactivity [73]. However, scientific 
evidence that intake of dietary flavanones reduces CVD risk in humans has not yet been 
established. Thus, the aim of this work was to systematically review published human 
randomised controlled trials (RCT) that examined the effects of flavanones and citrus fruit 
on CVD risk markers, to identify the current state-of-the-art and the key research gaps in 
the literature (Chapter 2) and to address some of them by conducting an acute flavanone 
intervention RCT (Chapter 3-5) (Figure 7.1). 
In the systematic review (Chapter 2), ten human RCTs were identified that met the 
inclusion criteria (adopted from the methodology our group employed in a previous 
systematic review [128]) and examined the effects of flavanones and/or citrus fruits on a 
range of markers of CVD risk (Figure 7.1). A meta-analysis of six RCTs suggested that 
short-term (i.e. 3-8 weeks) daily intake of flavanones may reduce plasma total cholesterol 
(for individuals with elevated CVD risk (i.e. with metabolic syndrome or past history of 
CVD event) (-0.64 mM, 95 % CI: -1.04, -0.24; n = 87; 3 studies), but not in healthy adults 
(-0.01 mM, 95 % CI: -0.12, 0.10; n = 165; 3 studies). However, these findings have to be 
interpreted with caution because two studies in individuals with elevated CVD risk that 
found a highly significant reduction in blood lipids also had a high risk of bias. 
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Figure 7.1 – Overview of existing data regarding cardiovascular beneficial effects of 
dietary flavanones and summary of conducted acute trial 
 
Abbreviations: n, number of existing studies in the literature; CVD, cardiovascular disease; 
NADPH, nicotinamide adenine dinucleotide phosphate; n refers to numbers of studies that 
have been published in the scientific literature 
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concentration [59]. In summary, this systematic review suggests that flavanones may 
beneficially affect a range of markers of CVD risk; however, existing human RCT data are 
insufficient to provide evidence for a beneficial relationship between intake of flavanones 
and a reduction in CVD risk. In particular, optimal daily flavanone intakes, their potential 
health implications in various study populations and the potential importance of the food 
matrix in which flavanones are consumed (e.g. whole citrus fruit, citrus juices or purified 
supplements) remain to be established. Furthermore, potential effects of flavanones on 
other established markers of CVD risk markers including arterial stiffness [184], CV 
autonomic function [18] or platelet function [256] have not been examined and at present 
the mechanism by which flavonoids mediate beneficial CV effects are incompletely 
understood. Similarly, no acute human RCT to date has simultaneously assessed plasma 
concentrations of individual flavanone metabolites and looked at associations between 
these metabolites and changes in CVD risk markers. Even though previous studies have 
examined the bioavailability and pharmacokinetics of phase II metabolites of flavanones 
[71, 72, 78, 107, 108] and a few studies identified phenolic acid metabolites [78, 113] and 
quantified levels in urine but not in plasma [113]. 
Hence, an acute flavanone RCT was conducted in men at a mild to moderate CVD risk to 
address some of these existing research gaps (Chapter 3-5). An acute study design was 
chosen to identify which potential markers of CVD risk may be beneficially modulated by 
the intake of dietary flavanones. The aim was also to explore potential mechanisms of 
action underlying these modulations, and to correlate these bioactivity data with plasma 
concentrations of previously reported and novel flavanone metabolites. Even though it is 
acknowledged that a human RCT with a short-term or chronic flavanone intervention may 
have been more informative with regards to potential long-term health effects, results from 
this acute study may help inform the design of these longer term studies (e.g. selection of 
study population, flavanone dose and CVD risk maker endpoints). 
In regards to potential markers of CVD risk, data reported in Chapter 3 suggested that 
despite high concentrations of flavanone / phenolic metabolites in plasma 5 h after intake 
of orange juice (767 ml; providing 320 mg hesperidin and 48 mg narirutin), no parallel 
beneficial effects on BP, heart rate, central arterial stiffness, digital endothelial function 
and CV autonomic function were observed in healthy men at a mild to moderate risk of 
CVD relative to a sugar and vitamin C matched control intervention. Whilst no previous 
studies were found that examined potential effects of flavanones on arterial stiffness and 
CV autonomic function (Figure 7.1), the present null findings on digital endothelial function 
are inconsistent with the acute human RCT by Morand et al., [59] which suggested a 
beneficial effect of flavanones on microvascular endothelial function. Dissimilarities in the 
design of the present study and the study by Morand et al., [59] may explain these 
inconsistent findings; in particular that different methods and arterial sites were used to 
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measure endothelial function (i.e. in the digital artery using peripheral arterial tonometry 
and in the forearm microvascular using laser Doppler flow imaging and acetylcholine 
iontophoresis, respectively), that achieved flavanone plasma concentrations were unequal 
(i.e. 1.46 and 0.86 μM, respectively) and that the control interventions differed (i.e. 
matched or not matched for vitamin C, respectively). 
Similarly, data reported in Chapter 4 suggested that 5 h after intake of the orange juice 
intervention, no acute increase in plasma nitrite concentrations, reduction in serum 
concentration of soluble gp91phox or inhibition in platelet activation was observed in men at 
a mild to moderate risk of CVD relative to a sugar and vitamin C matched control 
intervention. The nitrite and platelet activation data, respectively, are consistent with the 
acute and short-term flavanone intervention human RCT by Morand et al., [59] that 
observed no increase in plasma total NO metabolites, and the uncontrolled human trial by 
Keevil et al., [259] that observed no effect of a one week orange juice or grapefruit juice 
intervention on platelet aggregation relative to baseline. Hence, current data indicate that 
an increase in NO bioavailability or inhibition of NADPH oxidase may not be the key 
mechanisms by which flavanones exert beneficial CV effects and also that platelet 
activation/aggregation may not be affected by intake of dietary flavanones. 
The aims addressed in Chapter 5 were to identify and quantify a range of novel and 
previously identified flavanone and phenolic acid metabolites in plasma samples of the 
acute human RCT and to examine, on an exploratory basis, whether their concentrations 
correlate with acute changes of assessed markers of CVD risk (Chapter 3 & 4). Out of 158 
considered potential metabolites, a total of 2 flavanone aglycones (albeit at low 
concentrations), 6 flavanone phase II metabolites and 15 phenolic acid metabolites were 
identified on the basis that their concentration was significantly elevated 5 h after the 
orange juice intervention compared to the flavanone-free control intervention. Comparing 
mean increases in plasma concentrations from baseline, phenolic acid metabolites 
reached 10 fold higher levels than the flavanone phase II metabolites (i.e. 15.96 μM and 
1.47 μM, respectively). Whilst the identified flavanone phase II metabolites have 
previously been detected at similar concentrations in plasma post orange juice 
consumption [71, 72, 78, 108], to the author’s knowledge, none of the 15 phenolic acid 
metabolites have previously been identified or quantified in plasma and 6 of them only in 
urine [113]. These novel data suggest that flavanones might reach higher plasma 
concentrations than previously thought [105, 109] and a great proportion are present as 
phenolic acid metabolites for which potential beneficial CV effects are currently poorly 
understood. Despite the overall null findings of the present acute human RCT, plasma 
concentrations of 7 certain flavanone and phenolic acid metabolites significantly 
correlated (using Pearson’s correlations) with changes in specific markers of CVD risk, 
and 5 of them were biologically favourable (Appendix 5). However, these correlations are 
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exploratory and may help in devising studies and hypothesis to test in future human 
RCTs. 
7.2 Future research perspectives for flavanone human 
randomised controlled trials 
As outlined in previous sections of this thesis, current research has not yet fully 
established the CV health implications of a diet rich in flavanones (Figure 7.2). 
Furthermore, only little is known about which CVD risk factors might be beneficially 
modulated, what the underlying cellular mechanisms of action are and how this potential 
bioactivity is affected by flavanone metabolism and absorption (Figure 7.2). 
In contrast to the flavanone subclass, the CV health implications of a diet rich in flavan-3-
ols and isoflavones have been more extensively examined. A large meta-analysis of 
human RCTs (n = 1297; 42 RCTs) provides scientific evidence that intake of flavan-3-ols 
and cocoa containing foods improves markers of CVD risk including a clinically significant 
improvement in brachial artery endothelial function, reductions in insulin resistance and 
DBP, but only marginal improvements in blood lipids and no inhibition of inflammation (as 
assessed by C reactive protein) [249]. Sensitivity analysis further suggested that effects 
on endothelial function were independent of the dose of flavan-3-ols ingested with doses 
below 50 mg/d still having a significant effect, whilst a dose above 50 mg/d is required to 
induce a reduction in DBP [249]. Furthermore, evidence from 10 human RCTs suggested 
that intake of flavan-3-ols and cocoa containing foods inhibit platelet function with 
consumption of 100 g dark chocolate having an effect comparable to 81 mg aspirin [164, 
272]. Similarly, three meta-analyses (n = 789-1281; 11-17 RCTs) provided data to suggest 
that intake of dietary isoflavones beneficially affects markers of CVD risk through clinically 
significant improvements in brachial artery endothelial function [273], reductions in total 
and low density lipoprotein cholesterol [274] and systolic BP (SBP) [275], but no change in 
triglycerides, high density lipoprotein cholesterol [274] or DBP [275]. Sensitivity analysis 
further revealed that there might be a synergistic or additive effect of isoflavones with soy 
protein (i.e. food matrix effect), that SBP lowering effects were more pronounced in 
studies intervening more than 3 months and cholesterol lowering effects were more 
pronounced in individuals with hypercholesterolemia. Thus, for dietary flavanones, further 
human RCTs with short-term to chronic interventions are required in addition to the 10 
existing RCTs previously identified in the conducted systematic review (Chapter 2). To 
enable future meta-analyses, RCTs should measure (consistently and in a standardised 
way) established independent markers of CVD risk, including the traditional modifiable CV 
risk markers (i.e. DBP and SBP and blood total, high and low density lipoprotein 
cholesterols) [276], brachial artery flow mediated dilatation as a marker of endothelial 
function [277], fasting circulating insulin as a marker of insulin resistance [278, 279], C 
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reactive protein as a marker of inflammation [280], and platelet aggregation as a marker of 
platelet function [201]. Collectively, these RCTs should aim to determine effects of 
flavanone types (e.g. naringenin or hesperetin), flavanone dose, food matrix of intake (e.g. 
supplement, whole citrus fruits or citrus juice), intake duration (i.e. acute to several 
months), baseline CVD risk of study populations (i.e. low up to high CVD risk and 
individuals who suffered CV event) and other characteristics of study populations (e.g. 
gender, gut microflora or genotype/phenotype) on markers of CVD risk. Importantly, RCTs 
should compare effects of a flavanone intervention against a closely matched control 
intervention and employ a design with minimal risk of bias [168]. In addition to RCTs 
examining established CVD risk markers that may provide data for future meta-analyses, 
potential effects of dietary intake of flavanones on other established CVD risk markers 
should also be explored. These may not only include digital endothelial function, BRS, 
central arterial stiffness and platelet activation tested in the present acute RCT (Chapter 3 
& 4) and microvascular endothelial function, inflammatory and metabolic biomarkers 
tested in previous RCTs [59, 60], but also previously unexplored or novel CVD risk 
markers such as carotid intima media thickness [281], endothelial microparticles [282] and 
endothelial progenitor cells [283]. 
Ultimately, long-term RCTs with a flavanone supplemented dietary intervention, an 
adequate control intervention and primary CV events as endpoints are required to fully 
determine the CV health implications of a diet rich in flavanones (Figure 7.2). These 
studies could be similar to a recently published large-scale human RCT (n = 7447; 4.8 y 
median follow up) that causally linked Mediterranean diets supplemented with olive oil or 
nuts with a significantly reduced risk of experiencing a CV event of 30 % or 28 %, 
respectively, relative to a control diet [284]. However, the conduct of such studies 
demands immense financial resources and multicentre involvement and, possibly 
therefore, no such data are currently available for flavonoid subclasses including 
flavanones. 
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Figure 7.2 – Overview of future research required to further our understanding regarding the potential CV health implications of a diet rich in flavanones 
 
Abbreviations: CV, cardiovascular; RCT, randomised controlled trial; CHD, coronary heart disease; BP, blood pressure; FMD, flow mediated dilatation; CRP, C-
reactive peptide; BRS, baroreflex sensitivity; CIMT, carotid intima media thickness; NO, nitric oxide; NADPH, nicotinamide adenine dinucleotide phosphate; ET-1, 
endothelin-1; RAAS, renin, angiotensin and aldosterone system 
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For those CVD risk markers that previous human RCTs suggested a beneficial change in 
response to flavanone intake (i.e. blood lipids (Chapter 2), DBP [59] and endothelial 
function [59, 60]), the potential underlying cellular mechanisms need to be examined 
(Figure 7.2). Modulations of hepatic lipid β-oxidation and fatty acid metabolism have been 
proposed by animal studies [165, 186] as the key cellular mechanisms underlying 
potential flavanone-induced blood lipid lowering effects. However, examining these 
proposed mechanisms in humans in vivo would possibly require unethical invasive 
methods and has, for example, not been addressed in any of the 11 RCTs of the 
isoflavone meta-analysis with blood lipid endpoints [274]. In contrast, a range of human in 
vivo biomarkers are available to examine possible mechanisms by which flavanones may 
induce DBP lowering and endothelial function improving effects. NO and superoxide-
generating NADPH oxidase are reported as the two key factors in the regulation of 
vascular homeostasis [17, 132]. However, the two existing RCTs to date (i.e. the present 
acute RCT (Chapter 4) and the RCT of Morand et al., [59]) suggested that flavanones do 
not increase NO production (as assessed by plasma nitrite and total NO metabolite 
concentrations, respectively) and the present acute RCT also found no decrease in 
NADPH oxidase gene expression (as assessed by serum concentration of gp91phox). 
Further human RCTs are thus required that confirm these findings; ideally, in study 
populations with low baseline NO production (e.g. smokers [285]) and assessing several 
in vivo biomarkers of vascular NO production and NADPH oxidase. For example, in 
addition to plasma nitrite concentrations and NADPH oxidase gene expression that were 
assessed (Chapter 4), urinary excretion of NO metabolites and plasma concentration of 
nitroso species have also been proven sensitive biomarkers to detect flavonoid-induced 
increases in NO production in previous RCTs [191], as has NAPDH oxidase activity in 
neutrophils to detect flavonoid-induced inhibition of NADPH oxidase [232]. Furthermore, 
other mechanisms, such as inhibitory effects on endothelin-1 [191] or the renin-
angiotensin-aldosterone system [286], modulation of eicosanoid synthesis (e.g. an 
increase in prostacyclin) [287] or an increase in hydrogen sulfides [134] could explain 
potential DBP lowering and endothelial function improving effects of flavanones and 
require further investigation through human RCTs. 
A more complete understanding of the absorption, distribution, metabolism and excretion 
(ADME) of dietary flavanones is also required to fully determine the potential CV health 
implications of a diet rich in flavanones (Figure 7.2). At present, the metabolic fate of 49 % 
of ingested flavanones is unknown as only 51 % have been recovered in urine as 
flavanone phase II metabolites and phenolic acid metabolites (i.e. 14.3 % [78] and 37 % 
[113], respectively). Furthermore, whilst the absorption and clearance kinetics of 
flavanone phase II metabolites have been well established and although 15 phenolic acid 
metabolites were detected in plasma collected 5 h after flavanone consumption (Chapter 
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5), the absorption and clearance kinetics of these phenolic acid metabolites remain to be 
established. Data presented in this thesis also showed that the plasma concentration of 
flavanone phase II metabolites was significantly elevated 5 h after intake of flavanones in 
orange juice, but only a negligible plasma concentration was detected when the same 
dose of flavanones was given in a supplement (Chapter 3). However, the underlying 
reason for this discrepancy remains unknown and potential effects of food matrix on 
ADME of flavanones require further examination. To address these research gaps, well-
controlled pharmacokinetic studies are warranted; that use comprehensive methods to 
detect a large number of flavanone phase II metabolites and phenolic acid metabolites; 
that quantify metabolite concentrations in plasma, urine and faecal samples over an 
adequate duration post flavanone consumption (i.e. at least 24 h); and that examine 
impact of food matrix on bioavailability of flavanones, in particular, when flavanones are 
ingested as a purified supplement. It is also critical that a well-controlled study uses 
isotopically labelled flavanones to verify with greater certainty that detected metabolites 
originate from flavanone intake and to determine the metabolic pathway of each 
metabolite; however, synthesis of these labelled compounds is labour- and costs-intensive 
[106]. Human studies are also limited in terms of knowing whether metabolites detected in 
plasma are also distributed into body tissue such as endothelial cells, blood cells/platelets 
or organs where they might potentially mediate beneficial CV effects. Although animal 
studies detected flavanones in tissues and organs [114] and suggested they can cross the 
blood brain barrier [288], these findings are difficult to be replicated in humans in vivo 
because they require the use of potentially C14 labelled flavanones which are expensive 
and challenging to synthesise. Given the bioavailability of phenolic acid metabolites over 
24 h [113], short- and long-term placebo-controlled human studies with a standardised low 
phenolic and flavonoid diet are also warranted to examine whether some of the 
metabolites may accumulate in the body. Ultimately, a complete understanding of which 
forms, to what extent and over which duration body tissues are exposed to metabolites 
originating from acute or regular intake of flavanones will be critical for the design and 
interpretation of human flavanone intervention RCTs with CVD risk marker endpoints 
[106]. 
Morand et al., [59] reported a significant association (using Pearson’s correlation) 
between plasma concentrations of hesperetin and improvements in microvascular 
endothelial function assessed 6 h after intake of flavanones, and the present data indicate 
exploratory associations between certain flavanone phase II metabolites or phenolic acid 
metabolites and changes in specific markers of CVD risk assessed 5 h after intake of 
flavanones (Chapter 5; Appendix 5). Although these data suggest that flavanone and 
phenolic acid metabolites may, at least in part, be mediators of beneficial CV effects; the 
overall picture is far from understood and data from the two existing acute RCTs comprise 
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some obvious limitations. Whilst Morand et al., [59] enzymatically removed glucuronides 
or sulfates from hesperetin metabolites before analysis and did not quantify phenolic acid 
metabolites, the present acute RCT found no overall effect in assessed markers of CVD 
risk relative to the control intervention and, therefore, the significant correlations were only 
of exploratory nature proposing hypothesis that require confirmation by future human 
RCTs (Chapter 5). Furthermore, both acute RCTs assessed plasma concentrations of 
flavanone metabolites and markers of CV assessments at a single timepoint (i.e. 6h and 
5h post flavanone consumption); however, flavanone-derived phenolic acid metabolites 
have been detected in urine up to 24h [113] suggesting that potential effects might also 
occur at later timepoints. Thus, acute RCTs are warranted that examine a time-course 
effect of acute flavanone intake (e.g. up to 24h) on markers of CVD risk and include a 
comprehensive quantification of flavanone phase II and phenolic acid metabolites to 
enable analysis of potential associations through simple correlations and/or multivariate 
regression analyses. These data may contribute critical information to improve our 
understanding of which metabolites are the key mediators of beneficial CV effects and at 
which timepoints or over which duration these effects may occur. 
Further studies using preclinical models are required to complement data from human 
RCTs. These studies should treat cultured endothelial cells in vitro or platelets ex vivo with 
physiologically relevant concentrations of flavanone phase II metabolites and/or phenolic 
acid metabolites and explore bioactivity of metabolites on a cellular to subcellular level to 
determine which metabolites may elicit beneficial CV effects and which signalling 
pathways might be modulated (via changes in gene expression or post-translational 
modifications of enzymes and signalling molecules). 
In conclusion, on the basis of the large body of epidemiological evidence suggesting that 
intake of flavanones is associated with improved heart health, the work conducted in this 
thesis contributed to the current literature by systematically reviewing existing human 
RCTs with a flavanone intervention and CVD risk marker endpoints and by conducting an 
acute RCT. Although this acute RCT established that 5 h after consumption of orange 
juice a number of flavanone / phenolic metabolites (including some previously identified as 
well as novel metabolites) were present in the circulation, assessed markers of CVD risk 
were not beneficially modulated in men at a mild to moderate risk of CVD. Thus, from this 
work it is clear that a number of further human RCTs are warranted to fully establish the 
health implications of a diet rich in flavanones and to comprehensively understand the 
CVD risk factors that are modulated, the cellular mechanisms underlying these 
modulations and the responsible key mediating circulating metabolites. 
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Appendix 1. Analysis of flavanones and vitamin C in orange juice and 
flavanone extract 
Appendix 2.1 Materials 
Orange juice from concentrate was provided by the Florida Department of Citrus (FDOC; 
Lake Alfred, Florida) and further 5 orange juices were purchased from 5 local 
supermarkets (i.e. Waitrose, Brakes, Aldi, Tesco and Cooperative). Flavanone extract was 
provided by Monteloeder (Alicante, Spain). HPLC grade methanol and acetonitrile were 
purchased from Fisher Scientific (Loughborough, UK), while hesperidin, narirutin, 
quercetin-3-rutinoside (rutin), taxifolin, L-ascorbic acid, hydrochloric acid and formic acid 
were purchased from Sigma-Aldrich (Poole, Dorset, UK). 
Appendix 2.2 Method 
In triplicate, 400 μL aliquots of orange juice were spiked with taxifolin (extraction efficiency 
standard; 50 μM end concentration) and subsequently extracted. Each aliquot was 
centrifuged (2500 rpm, 5 min, room temperature) to separate the soluble flavanones found 
in the supernatant from the insoluble flavanones found in the pellet. Whilst the 
supernatant was diluted in 400 μL acidified methanol (0.1 % hydrochloric acid), syringe 
filtered and spiked with rutin (calibration standard; 1 μM end concentration), flavanones 
from the pellet were extracted twice through reconstitution with 700 μL acidified methanol, 
sonication at 55C for 10 min and centrifugation (5000 rpm, 5 min, room temperature). 
Both pellet extracts were combined, syringe filtered and spiked with rutin (calibration 
standard; 1 μM end concentration). In triplicate, flavanone extract was reconstituted in 
methanol/MilliQ/formic acid (5:94.5:0.5 v/v/v) and ready for analysis. 
Samples were analysed on an Agilent 1200 series high performance liquid 
chromatography (HPLC) with a HPLC pump, a 250 to 600 nm diode array detector and an 
autosampler cooled to 4 °C. Separation was achieved on an Eclipse XDB-C18 (5 μM, 150 
x 4.6 mm) column kept at 37 °C, a flow rate of 1 ml/min and a sample injection volume of 
5μl. Whilst mobile phase A consisted of MilliQ/FA (99.5:0.5 v/v) and mobile phase B of 
methanol/FA (99.5:0.5 v/v), the course of the gradient indicated by mobile phase B was 5 
% B at 0 min, 35 % B at 6 min, 38 % B at 10 min, 100 % B at 11 min, 100 % B at 13 min, 
5 % B at 14 min and 5 % B at 16 min. The compounds of interest (i.e. hesperidin, narirutin 
and vitamin C) and calibration and extraction efficiency standards (i.e. rutin and taxifolin, 
respectively) were quantified in the samples based on a six point standard curve. Every 
10 injections, a sample consisting of diluted orange juice spiked with the compounds of 
interest was run as a quality control. 
In the orange juice and flavanone extract used for the study, potential flavanone and 
vitamin C degradation was verified through re-analysis after study completion. Statistical 
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differences were determined using pairwise two tailed T-test and considered significant at 
a P-value of less than 0.05. 
Appendix 2.3 Results 
Based on chromatography of analytical standards, the retention times (RT) and 
absorbance spectra (λ) for each compound have been identified. Whilst hesperidin, 
narirutin, taxifolin had a common λmax (i.e. 284 nm) and a RT of 10.2 min, 9.1 min and 7.6 
min, respectively, vitamin C had a λmax at 250 nm and RT of 1.5 min and rutin a λmax at 350 
nm and RT of 9.2 min (Appendix 4, Figure 1). The method had extraction efficiencies for 
the orange juice samples ranging from 97.3 to 109.1 % (Appendix 4 Table 1) and a mean 
intra-day variability of 3.4 % based on the calibration standard and the quality control 
samples. 
The 6 analysed orange juices from concentrate had a hesperidin content ranging from 
41.8 to 51.8 mg/100ml, a narirutin content ranging from 6.3 to 8.7 mg/100ml and a vitamin 
C content ranging from 39.5 to 57.6 mg/100ml (Appendix 4, Table 1). The soluble fraction 
was higher for narirutin (range: 55.8-70.7 %) compared to hesperidin (range 13.3-23.2 %). 
The flavanone extract consisted of 76.5 % hesperidin and 3.7 % narirutin, whereas no 
vitamin C was detected. 
Appendix 2 Table 1 – Flavanone and vitamin C content in orange juices from concentrate 
     
 
Narirutin Hesperidin vitamin C EE 
1
 
 
mg/100ml 
 % 
soluble
2 mg/100ml 
 % 
soluble
2 mg/100ml 
 % 
soluble
2
 
 % 
FDOC (pre-study) 6.3 55.8 % 41.8 23.2 % 57.3 67.2 % 107.7 
FDOC (post-study) 6.6 60.7 %* 45.74* 23.9 % 46.7** 65.9 % n/a 
Waitrose 7.4 64.0 % 42.3 13.3 % 39.5 42.4 % 109.1 
Aldi 7.4 67.2 % 46.6 17.2 % 57.5 29.5 % 98.1 
Tesco 6.4 70.7 % 42.2 18.6 % 48.0 33.8 % 97.3 
Cooperative 8.7 69.3 % 51.8 16.3 % 50.1 34.0 % 99.7 
Brakes 8.6 69.2 % 51.1 15.4 % 50.6 32.7 % 103.6 
1 
based on recovery of 50uM spiked taxifolin;
 2
 % of flavanones detected in the supernatant 
extract compared to the total flavanones detected in supernatant and pellet extracts; 
Abbreviations: EE, extraction efficiency; FDOC, Florida Department of Citrus; n/a, extraction 
efficiency was not established post-study; Statistical analysis: differences between pre- and 
post-study flavanone and vitamin C contents and solubility were determined using pairwise t-test 
(two-tailed) whereby significant differences are indicated with * for P<0.05, ** for P<0.01. 
Based on the post-study analysis of the FDOC orange juice and the flavanone extract, 
there was no flavanone degradation with even a marginal increase in hesperidin content 
and in narirutin solubility, which may be due to variability between the different tins of 
orange juice concentrate (Appendix 4, Table 1). On the other hand, vitamin C levels 
degraded in the FDOC orange juice. 
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Appendix 2 Figure 1 – Chromatograms of orange juice and flavanone extract analysis 
 
Chromatogramms of A) florida department of citrus (FDOC) supernatant extract, B) FDOC pellet 
extract and C) Monteloeder flavanone extract. Compounds were identified based on retention time 
(RT) and absorbance spectrum (λ): vitamin C (RT 1.6 min; λmax 250 nm)
1
, taxifolin (RT 7.7 min; λmax 
284 nm)
2
, narirutin (RT 9.1 min; λmax 284 nm)
3
, rutin (RT 9.2 min; λmax 350)
4
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Appendix 2. Food restrictions prior to experimental period 
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Appendix 3. Analysis of baroreflex sensitivity using finger arterial pressure data 
Appendix 4 Figure 1 – Raw signal of finger arterial pressure 
 
SBP; systolic blood pressure; PI, pulse interval 
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Appendix 4 Figure 2 – Tachogram and power spectra of pulse interval and systolic blood pressure signals1 
 
Abbreviations: PI, pulse interval; SBP, systolic blood pressure; AUC0.05 – 0.015 , area under the curve (i.e. power) in the low frequency band; αBRS, low 
frequency α-index indicating baroreflex sensitivity 
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Appendix 4 Figure 3 – Analysis of cross correlation baroreflex sensitivity 
 
A: Sequence of signals where an increase in systolic blood pressure is followed by a baroreflex induced increase in pulse interval. (Figure adapted from [215]) 
B: Cross-correlation baroreflex sensitivity (xBRS) is calculated as the regression slope between SBP and PI over a 10 seconds sliding windows and with a PI delay of 0 to 
5 seconds. Using the delay with the highest cross-correlation coefficient, the regression slope is accepted as a xBRS estimate if the correlation is significant at a P- value < 
0.01. (Figure adapted from [289]) 
Abbreviations: PI, pulse interval, SBP, systolic blood pressure 
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Appendix 4. Quantified phenolic acids that were not flavanone metabolites 
 
 
mean ± SEM (nM) 
 
   
5 h – baseline 
 Flavanone metabolite Baseline  Control Orange juice P-value
1 
Dihydroxy-benzoic acid 40 ± 7x  4 ± 3 -1 ± 7x 0.58 
4-hydroxybenyaldehyde 113 ± 8xx  39 ± 10 45 ± 11 0.62 
Salicyclic acid 876 ± 141  -586 ± 442 -229 ± 134 0.74 
Methoxybenzoic acid ND  ND 36 ± 0x 0.34 
Protocatechuic acid-4glucuronide 2 ± 0  17 ± 4x 18 ± 2x 0.80 
Protocatechuic acid-glucuronide 7 ± 1  -1 ± 0x -2 ± 1 0.56 
Methoxybenzoic acid-sulfate ND  8 ± 8 23 ± 13 0.62 
pCourmaric acid-glucuronide 28 ± 10  1 ± 2 -7 ± 2 <0.05 
Hydroxyhippuric acid-glucuronide 2 ± 0  17 ± 4x 18 ± 2x 0.80 
1
5 h post intervention differences between the two dietary interventions were established using a linear 
mixed model for crossover studies with baseline values on each experimental period as the covariate. The 
statistical analysis was performed in R 3.0.1 (R Foundation for Statistical Computing) and a change was 
considered significant when P < 0.05. 
 
Appendix 5. Significant Pearson’s correlations between markers of CVD 
risk and circulating flavanone metabolites of the acute orange juice 
intervention 
 
Marker of CVD risk 
(5h – BL)
 
flavanone metabolite  
(5h – BL)
 r 
a 
P 
Heart rate isovanillic acid-glucuronide 0.84 0.0003 
Systolic BP total phenolic acid metabolites -0.62
b
 0.03 
Pulse wave velocity 4-hydroxyphenylacetic acid -0.66
b
 0.02 
Cardiac baroreflex sensitivity vanillic acid-glucuronide 0.60
b
 0.03 
Plasma nitrite hydroxyhippuric acid 0.63
b
 0.02 
Serum soluble gp
91phox
 hesperetin-diglucuronide -0.73
b 
0.005 
Serum soluble gp
91phox
 isoferulic or ferulic acid-glucuronide 0.63 0.02 
a 
r, Pearson’s correlation coefficient (n = 13);
 b 
increased presence of flavanone metabolite 
has favourable effect on marker of CVD risk. 
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